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ABSTRACT 
 
Deregulation of platelet-derived growth factor receptor (PDGFR) signaling is a driving 
event in glioblastoma, promotes tumor progression epithelial to mesenchymal transition (EMT) 
in multiple cancers, modulates the tumor stroma to facilitate tumorigenesis and reduces tumor 
uptake of chemotherapeutics. Previous studies identified the 105 kDa isoform of ankyrin3 
(Ank105) as a binding partner of the PDGFR signaling machinery and demonstrated that 
expression of Ank105 promoted PDGFR degradation (Ignatiuk et al., 2006)(Ignatiuk et al., 
2006)(Ignatiuk et al., 2006). Receptor tyrosine kinases are targeted for degradation via 
endocytosis and ubiquitin-dependent trafficking to the lysosome. It was hypothesized that 
Ank105 promoted the constitutive degradation of the PDGFR and attenuation of PDGFR 
signaling by facilitating endocytosis of the PDGFR and targeting the PDGFR for lysosomal 
degradation via an ubiquitin-dependent mechanism. The studies in this thesis characterized the 
effects of Ank105 expression on PDGFR signaling and protein expression levels, determined the 
endocytic pathways involved in Ank105-mediated PDGFR degradation and studied the role of 
ubiquitin binding in Ank105 function. The most robust effect of Ank105 expression on the 
PDGFR was constitutive degradation as PDGFR protein expression levels in Ank105-expressing 
cells were significantly reduced compared to NIH 3T3 cells in the absence of PDGF ligand. Low 
constitutive PDGFR levels resulted in attenuated pro-proliferative AKT and mitogen-activated 
protein kinase (MAPK) signaling in response to ligand stimulation. To determine the endocytic 
requirements for Ank105-mediated constitutive PDGFR degradation, a constitutive PDGFR 
degradation assay was developed and the effects of several small molecule endocytosis inhibitors 
were evaluated. Additionally, the small molecule endocytosis inhibitors were validated by 
determining the effects of these inhibitors on low density lipoprotein (LDL) uptake and ligand-
induced PDGFR degradation in Ank105-expressing cells. Both LDL uptake and ligand induced 
PDGFR degradation are known to proceed by a clathrin and dynamin dependent mechanism of 
endocytosis. In Ank105-expressing cells, both LDL uptake and ligand incuded PDGFR 
degradation were dependent upon clathrin and dynamin function. Interestingly, constitutive 
PDGFR degradation in Ank105-expressing cells was not dependent upon CME, but required 
dynamin activity. Expression of Ank105 may promote clathrin-independent, dynamin-dependent, 
constitutive endocytosis of the PDGFR. Additionally, acute inhibition of either lysosomal or 
proteasomal degradation strongly impaired constitutive PDGFR degradation, whereas ligand-
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induced PDGFR degradation was less sensitive to protein degradation inhibitors, while LDL 
uptake was unaffected. It was unclear if PDGFR was degraded in the proteasome or if the 
proteasome was involved in sorting of PDGFR to the lysosome for degradation. Ubiquitination 
of receptors is required to target them for degradation. Ank105 was assayed for the ability to 
interact with ubiquitin and ubiquitinated proteins. Interestingly, Ank105 bound ubiquitin in vitro 
via the spectrin binding domain and co-immunoprecipitated with several ubiquitinated proteins, 
suggesting a role for Ank105 in the sorting of ubiquitinated proteins for degradation. 
Furthermore, Ank105 co-immunoprecipitated with a number of high and low molecular weight 
proteins in the absence of PDGF stimulation. Identification of Ank105 binding partners would 
provide further insight in the mechanism of Ank105-mediated constitutive PDGFR degradation. 
In summary, Ank105 promoted the attenuation of PDGFR signaling via alteration of constitutive 
PDGFR endocytosis and targeting of constitutive PDGFR for degradation, potentially through 
interaction with ubiquitin and ubiquitinated proteins. Reduction of constitutive PDGFR levels in 
cancers with PDGFR driver mutations, acquired PDGF responsiveness and stromal expression of 
PDGFR, could significantly reduce tumor proliferation, tumorigenesis and increase effectiveness 
of chemotherapeutics. 
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1.0 INTRODUCTION 
 
1.1 Platelet-derived growth factor receptor biology 
1.1.1 Structural and functional properties of platelet-derived growth factor receptor 
signaling 
 
1.1.1.1 Platelet-derived growth factor ligands 
 The platelet-derived growth factors (PDGF) are a family of soluble, protein based growth 
factors which exert their effects through the platelet derived growth factor receptors (PDGFR) 
(Kaplan et al., 1979). Several cell types express PDGF including fibroblasts, leydig cells, liver 
endothelial cells, pericytes, astrocytes, neurons, vascular smooth muscle cells, capillary 
endothelial cells and macrophages, as well as several others (Heldin and Westermark, 1999).  
PDGF has been classically described as two polypeptide chains, being A and B, each with an 
approximate molecular weight of 100 kDa. The A and B chains homo- and hetero-dimerize via 
disulfide bond formation between 8 conserved cysteine residues to form three distinct PDGF 
ligands; PDGF-AA, PDGF-BB and PDGF-AB (Heldin and Westermark, 1999). The A and B 
chains of PDGF show a high degree of similarity, sharing 60% amino acid sequence identity 
(Heldin and Westermark, 1999). Two additional isoforms of PDGF have been discovered which 
homo-dimerize to form PDGF-CC (Li et al., 2000) and PDGF-DD (LaRochelle et al., 2001). 
 
1.1.1.2 PDGFR family 
 Two PDGFR have been identified, designated α and β (Heldin and Westermark, 1999). 
The two PDGFR are members of the type III family of receptor tyrosine kinases (RTKs) (Heldin 
and Westermark, 1999) and are structurally related to the Kit/stem-cell factor receptor (Kit) 
(Yarden et al., 1987), colony-stimulating factor-1 receptor (Fms) (Coussens et al., 1986) and fetal 
liver kinase 2/ Fms-like tyrosine kinase 3 (FLK2/FLT3) (Rosnet et al., 1991). The chromosomal 
locations of the genes encoding these receptors are clustered. The gene encoding PDGFRα 
(PDGFRA) is located on chromosome 4q12 near the gene encoding Kit (Spritz et al., 1994) 
whereas the gene encoding PDGFRβ (PDGFRB) is located on chromosome 5q32 (Yarden et al., 
1986) near the gene encoding Fms (Roberts et al., 1988).  
The PDGFRA and PDGFRB genes encode protein products that when mature, and fully 
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glycosylated, are 170 and 180 kDa, respectively (Heldin and Westermark, 1999). The PDGFRα 
and PDGFRβ proteins are highly homologous and share a 46% amino acid sequence identity. 
The PDGF receptors contain three distinct regions that include an extracellular region, a 
transmembrane region and an intracellular region. The extracellular domain contains 5 
immunoglobulin-like (Ig) domains to mediate ligand binding (Alvarez et al., 2006). The 
transmembrane domain spans the plasma membrane once. The intracellular region consists of a 
conserved juxtamembrane domain, a split tyrosine kinase domain containing a non-catalytic 
inserted sequence without homology to other kinases and a C-terminal tail (Figure 1.1) which are 
both implicated in inhibition of PDGFR kinase activity (Heldin and Lennartsson, 2013).  
 
1.1.1.3 PDGFR activation and signaling 
 Activation of PDGFRs generates potent mitogenic and anti-apoptotic responses, as well 
as induces chemotaxis and actin rearrangement (Heldin and Lennartsson, 2013; Heldin and 
Westermark, 1999).  Binding of PDGFR to ligand facilitates dimerization of receptor molecules 
and activation of the receptor. Binding of all PDGF isoforms except PDGF-DD promotes homo-
dimerization of PDGFRα; whereas PDGFRβ homo-dimerization occurs upon binding of PDGF-
BB or PDGF-DD (Heldin and Lennartsson, 2013) (Figure 1.1). PDGF-CC only binds PDGFRα 
(Heldin and Lennartsson, 2013). In cell lines co-expressing PDGFRα and PDGFRβ, binding 
PDGF-BB or PDGF-AB can direct hetero-dimerization of PDGFRα and PDGFRβ (Heldin and 
Lennartsson, 2013) (Figure 1.1). These ligand binding patterns have been demonstrated in vitro, 
however only PDGF-CC and PDGF-AA binding to PDGFRα and PDGF-BB binding PDGFRβ 
have been demonstrated in vivo (Andrae et al., 2008). Ig-like domains 2 and 3 in the extracellular 
region of the PDGFR mediate ligand binding (Shim et al., 2010). Ig-like domains 4 and 5 
stabilize ligand-mediated receptor dimerization, orienting the PDGFR to facilitate trans-
autophosphorylation of tyrosine residues within the intracellular regions of the PDGFR (Yang et 
al., 2008).  The activation loop of the kinase domain is phosphorylated at Tyr849 and Tyr857 in 
PDGFRα and PDGFRβ, respectively (Baxter et al., 1998) (Figure 1.1). This phosphorylation 
event permits ATP and substrate access to the active site by changing the conformation of the 
activation loop, thereby fully activating tyrosine kinase activity (Baxter et al., 1998). 
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Figure 1.1: PDGFR ligand binding profiles and autophosphorylation sites 
Depiction of the specificity of PDGFRα (red), PDGFRαβ (red/blue) and PDGFRβ dimers (blue) 
for PDGF-AA (red), PDGF-BB (blue), PDGF-AB (red/blue), PDGF-CC (purple) and PDGF-DD 
(orange) ligand dimers. Tyrosine (Y) residues phosphorylated on activated receptors serve as 
binding sites for the recruitment and activation of downstream signaling pathways including 
phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma (PLC-γ), sarcoma kinase (Src), 
Ras GTPase activating protein (RasGAP), CT10 regulator of kinase (Crk) and growth factor 
receptor-bound protein 2 (Grb2). Phosphorylation sites in the activation loop of the split kinase 
domain at Y849 and Y857 of PDGFRα and PDGFRβ, respectively are depicted. 
 Dimerized PDGFRs trans-autophosphorylate multiple tyrosine residues within 
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cytoplasmic residues in the juxtamembrane domain, non-catalytic kinase insert and C-terminal 
tail of  the PDGFR that serve as docking sites for Src homology-2 (SH2) domain containing 
proteins to initiate several signaling cascades (Heldin and Lennartsson, 2013) (Figure 1.1). 
Signaling pathways potentiated from the activation of the PDGFR include phosphatidylinositol 
3-kinase (PI3K), phospholipase C gamma (PLC-γ), sarcoma kinase (Src), Ras GTPase activating 
protein (RasGAP), CT10 regulator of kinase (Crk), SHP-2 phosphatase, signal transducer and 
activator of transcription (STAT) and initiators of the mitogen activated protein kinase (MAPK) 
pathway (Figure 1.1; Figure 1.2) (Heldin and Lennartsson, 2013).  
Class 1A PI3K is a lipid kinase composed of a regulatory subunit, p85, and a catalytic 
subunit, p110. The p85 subunit stabilizes and inhibits the catalytic activity of p110 (Yu et al., 
1998). Upon activation of the PDGFR, PI3K is recruited to the receptor and binds 
phosphorylated Tyr731/742 and Tyr740/751 of PDGFRα and PDGFRβ, respectively, via its SH2 
domains (Heldin and Westermark, 1999) (Figure 1.1; Figure 1.2). Binding of PI3K to 
phosphorylated receptor relieves inhibition of p85 on p110 catalytic activity (Miled et al., 2007). 
PI3K catalyzes the phosphorylation of phosphatidylinositol 4,5-phosphate (PI4,5P2) at the D3 
position to produce phosphatidylinositol 3,4,5-phosphate (PI3,4,5P3) (Cantley, 2002) (Figure 
1.2). This lipid second messenger promotes the recruitment of proteins, containing PH domains 
to interact with plasma membrane PI3,4,5P3, and activation of several downstream signaling 
proteins including PDK1 Akt, p70 S6 kinase, JNK/SAPK, PKC as well as Rho family GTPases 
(Heldin and Westermark, 1999) (Figure 1.2). Additionally, p85 has been demonstrated to interact 
with proteins that regulate PDGFR endocytosis and degradation such as rab5 and the small 
isoforms of ankryin3 (Mellor et al., 2012).  
In the context of PDGF-mediated signaling, PI3K regulates the antiapoptotic and motility 
responses to PDGF stimulation (Heldin and Lennartsson, 2013) (Figure 1.2). Src mediated 
activation of the transcription factor Myc and MAPK/ERK signaling are responsible for the 
growth and proliferative effects of PDGF stimulation (Heldin and Westermark, 1999) (Figure 
1.2). Src binds Tyr572 of PDGFRα and Tyr579/581 of PDGFRβ (Heldin and Lennartsson, 2013) 
(Figure 1.1). Grb2, a component of the MAPK/ERK signaling pathway, binds PDGFRβ at 
Tyr716/775 (Heldin and Lennartsson, 2013) (Figure 1.1). PLC-γ binds PDGFRα at Tyr 988/1018 
and PDGFRβ at Tyr1009/1021 (Heldin and Lennartsson, 2013) (Figure 1.1). The PDGFRα and  
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Figure 1.2: Prominent PDGFR cellular signaling pathways: PI3K and MAPK  
PDGFR signaling generally inhibits apoptosis, induces cell motility and stimulates cell 
proliferation. Inhibition of apoptosis is initiated by PI3K mediated phosphorylation of 
phosphatidylinositol-4,5 bisphosphate (PI4,5P2) to phosphatidylinositol-3,4,5triphosphate 
(PI3,4,5P3) which promotes recruitment and activation Akt. The p85 subunit of PI3K regulates 
Rho family GTPases and cell motility. Cell proliferation is stimulated by Src and MAPK 
mediated activation of Myc, as well as other transcription factors. The MAPK pathway is 
activated via binding of a series of adaptor proteins to the PDGFR that promotes the eventual 
activation of MAPK. 
 
PDGFRβ receptors share very similar signaling profiles in response to ligand, however there are 
differences. PDGFRα exclusively binds Crk at Tyr762 (Heldin and Lennartsson, 2013), whereas 
PDGFRβ binds RasGAP (Tallquist and Kazlauskas, 2004) at Tyr771 (Heldin and Lennartsson, 
2013) (Figure 1.1). Indeed PDGFRα and PDGFRβ signaling can have different consequences at 
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the cellular level (Tallquist and Kazlauskas, 2004). While both receptor isoforms promote cell 
proliferation, only PDGFRβ inhibits apoptosis. Moreover activation of PDGFRβ stimulates 
chemotaxis whereas regulation of chemotaxis by PDGFRα is cell type dependent (Tallquist and 
Kazlauskas, 2004). 
 
1.1.2 Role of PDGFR signaling in vivo 
 Both PDGFRα (Soriano, 1997) and PDGFRβ (Soriano, 1994) are required during 
development as deletion of genes encoding either protein in mice results in lethality. Deletion of 
PDGFRα results in defects in supportive connective tissue, mesenchymal type cells. Defects are 
observed in lung aveolar smooth muscle, kidney, and dermal mesenchymal cells as well as in 
oligodendrocytes (Tallquist and Kazlauskas, 2004). PDGFRα is thought to stimulate the 
proliferation of these cell types and removal of these signals impairs proper development 
(Lindahl and Betsholtz, 1998). Indeed PDGFRα knockout mice have impaired lung function, 
cranial deformations, impaired muscle formation and die shortly after birth (Heldin and 
Westermark, 1999).  
Knockdown of PDGFRβ results in defects in the vascular smooth muscle cells of several 
organs including the kidney, eye, skin and brain (Lindahl et al., 1998; Lindahl et al., 1997b). 
Similar to PDGFRα, PDGFRβ signaling is thought to drive proliferation of these cell types and 
impairment of signaling impedes proper development (Tallquist and Kazlauskas, 2004). 
Knockdown of PDGFRβ impairs kidney function with reduced glomerular filtration rates and 
ablated development of kidney mesangial cells (Leveen et al., 1994; Soriano, 1994). 
Additionally, PDGFRβ knockout mice suffer from internal bleeding, causing death, due to 
impaired development of blood vessels in described cell types (Heldin and Westermark, 1999).  
Knockdown of PDGF-BB produces a similar phenotype to knockdown of PDGFRβ 
(Lindahl et al., 1997a), whereas knockdown of PDGF-AA produces a more mild phenotype than 
knockdown of PDGFRα (Bostrom et al., 1996), possible due to the ability of PDGFRα to signal 
via other isoforms of PDGF (Heldin and Westermark, 1999). In addition to roles during 
development, PDGFR signaling is also implicated in wound repair, neural maintenance and 
regeneration, angiogenesis and recruitment of pericytes to the vascular system as well as 
regulation of interstitial fluid pressure (Heldin and Westermark, 1999). 
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1.1.3 Role of PDGFR signaling in disease 
 
1.1.3.1 Role of PDGFR signaling in non-malignant disease 
Excessive PDGFR signaling can lead to non-malignant disease characterized by over-
production and deposition of connective tissue components such as collagen and 
glycosaminoglycans (Alvarez et al., 2006). Excess deposition of connective tissue components 
impairs proper organ function, resulting in disease. Atherosclerosis, rheumatoid arthritis, liver 
cirrhosis and fibrosis of the lungs and kidneys are linked to excess PDGFR signaling (Heldin and 
Westermark, 1999). In fibrotic disease, macrophages that have been activated by chronic 
inflammation secrete a number of inflammatory cytokines and growth factors, including several 
isoforms of PDGF. These cytokines and growth factors promote overexpression and activation of 
PDGFR on mesenchymal cells, driving their proliferation and production of connective tissue 
components (Bonner, 2004). Fibrosis of multiple organs was recapitulated in transgenic knock-in 
mice harboring a constitutively active PDGFRα gene (Olson and Soriano, 2009).  
The principal cause of heart attack and stroke is atherosclerosis (Ross, 1993). 
Atherosclerosis is characterized by excessive inflammatory and fibroproliferative response to 
damage to the vascular and arterial smooth muscle and PDGFR signaling is thought to be one of 
the mediators in the pathology of atherosclerosis (Alvarez et al., 2006). PDGF levels expressed 
in the arteries are increased after arterial damage (Ross, 1993). Indeed, other atherosclerosis 
associated cells express PDGF including activated macrophages, smooth muscle cells, 
endothelial cells and platelets (Alvarez et al., 2006). In a cholesterol induced model of 
atherosclerosis, atherosclerotic lesions were significantly reduced in rabbits fed a high 
cholesterol diet when treated with anti-PDGF-BB antibodies (Rutherford et al., 1997). 
Individuals with diabetes are at a statistically higher risk to develop atherosclerosis (Pyorala et 
al., 1987). Indeed, 70-75% of individuals afflicted with diabetes succumb to cardiovascular 
disease (Uusitupa et al., 1990). Diabetic mice treated with the tyrosine kinase inhibitor imatinib, 
targeting PDGFR activity, showed reduced formation of atherosclerotic lesions in the aorta and 
attenuated expression of both PDGF-BB and PDGFRβ, which are both elevated in diabetic mice 
(Lassila et al., 2004). 
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1.1.3.2 Role of PDGFR signaling in malignant disease 
 
1.1.3.2.1 Expression and autocrine signaling of PDGF and PDGFR in human cancers 
 The potential role of PDGFR signaling in malignant disease was first realized when it 
was discovered that simian sarcoma virus gene, sis, encoded PDGF-BB (Doolittle et al., 1983). 
The ability of the simian sarcoma virus to transform cells was abrogated by treatment with anti-
PDGF antibodies (Johnsson et al., 1985), suggesting a role of PDGFR signaling in cellular 
transformation. Several human cancers show up-regulation of either mRNA or protein expression 
of either the PDGFR or its ligand including several brain cancers, soft tissue sarcomas, breast 
cancer, multiple carcinomas and several forms of leukemia (Heldin and Westermark, 1999). An 
interesting feature of the available tumor expression data is that both the receptor and the ligand 
are often co-expressed in the tumor, suggesting an autocrine signaling mechanism. 
 The relationship between human glioblastomas and PDGFRα signaling has been well 
established. PDGFRα hyper-activity has been reported in roughly 30% of glial tumors (Brennan 
et al., 2009) and PDGFRα signaling may drive glial tumor progression to a more aggressive 
phenotype. PDGFRα positive staining cells are observable in all grades of the tumor and the 
staining density increases as tumor grade increases, indicating that PDGFRα expression 
increases with tumor aggressiveness (Hermanson et al., 1996). A similar pattern is evident with 
the expression of PDGF-AA as ligand is expressed at low levels, if at all, in low grade tumors 
and expressed at high levels in high grade tumors (Heldin and Westermark, 1999). Intensification 
of autocrine PDGFR signaling drives glial tumor progression (Heldin and Westermark, 1999). 
This pattern of ligand-receptor co-expression is also observable in sarcomas (Smits et al., 1992; 
Wang et al., 1994).   
Autocrine PDGFR signaling may be a driving event in glioblastoma tumorigenesis 
(Figure 1.3). Intracranial injection of simian sarcoma virus into marmosets (Heldin, 2004) or 
injection of a retrovirus containing the pdgfb gene in mice (Uhrbom et al., 1998) was sufficient 
to induce formation of glioblastoma. The prevailing mechanism of overexpression of mRNA and 
protein for both PDGF and PDGFR in glial tumors is unknown. Amplification of the PDGFRA 
gene has been occasionally observed in glial tumors, and this amplification promotes 
overexpression (Figure 1.3) (Fleming et al., 1992; Hermanson et al., 1996; Kumabe et al., 1992). 
A mutation of PDGFRα was identified where exons 8 and 9 of the extracellular domain of the  
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Figure 1.3: PDGF/PDGFR mutations expressed in human cancers 
Depiction of PDGF and PDGFR mutations expressed in several types of human cancers that 
promote tumor proliferation and progression. PDGFRα and PDGF-AA are amplified and 
overexpressed in glioblastomas. Gastrointestinal stromal tumors harbor several point mutations 
resulting in ligand independent constitutive activation including V561D, D842V and D846Y. 
Several myeloproliferative disorders express PDGFRβ fusion proteins such as ETV6-PDGFRβ, 
HIP1-PDGFRβ, H4/D1OS1-PDGFRβ, CEV14-PDGFRβ and Rabaptin5-PDGFRβ that result in 
ligand independent constitutive activation. Dermatofibrosarcoma protuberans expresses 
COLIA1-PDGF-BB fusion protein resulting in excess ligand and over-active signaling. Modified 
with permission (Andrae et al., 2008). 
 
receptor were deleted (PDGFRα-Δ8,9) and expression of this mutant resulted in transformation  
(Clarke and Dirks, 2003). Gastrointestinal stromal tumors also harbor mutations of PDGFRα that 
result in constitutive receptor activation and signaling. Mutations in the activation loop (D842V 
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and D846Y) and in the juxtamembrane domain (V561D) have been reported (Chompret et al., 
2004; Heinrich et al., 2003). These mutations are thought to alter PDGFRα conformation and 
promote ligand independent activity (Jones and Cross, 2004) (Figure 1.3). 
Myeloproliferative disorders such as acute myeloid leukemia (AML) chronic 
myelogenous leukemia (CML) and chronic myelomonocytic leukemia (CMML) can, albeit 
rarely, harbor chromosomal translocations that produce PDGFR fusion mutations which 
promotes constitutive PDGFR signaling (Alvarez et al., 2006) (Figure 1.3). Several PDGFR 
fusion mutants have been identified including ETV6-PDGFRβ, HIP1-PDGFRβ, H4/D1OS1-
PDGFRβ, CEV14-PDGFRβ and Rabaptin5-PDGFRβ (Alvarez et al., 2006; Jones and Cross, 
2004). These translocation mutations generally result in fusions between the intracellular 
domains of the PDGFR and the N-terminal regions of the fusion partner, replacing the 
extracellular domains of the PDGFR. The resulting fusion protein is insensitive to PDGF but is 
constitutively active (Jones and Cross, 2004). The N-terminal regions of the fusion partners 
promote dimerization that leads to constitutive activation of the PDGFR intracellular domains. 
Additionally, the expression of the fusion gene is under control of the regulatory elements of the 
fusion partner which can lead to higher expression levels of PDGFR-fusion protein than wild 
type PDGFR (Jones and Cross, 2004).  
Several of the PDGFR fusion mutants induce cellular transformation and disease. 
Expression of ETV6-PDGFRβ caused cellular transformation and impaired apoptosis in cell 
culture models via ligand independent activation of PDGFR signaling pathways (Carroll et al., 
1996; Jones and Cross, 2004; Jousset et al., 1997). Mouse bone marrow transplant models 
demonstrated that ETV6-PDGFRβ caused a myeloproliferative disease closely resembling 
CMML (Tomasson et al., 2000). Expression of Rabaptin5-PDGFRβ induced cellular 
transformation and caused myeloproliferative disease in mice that demonstrated sensitivity to 
imatinib treatment (Magnusson et al., 2001). Excitingly, treatment of patients harboring the 
Rabaptin5-PDGFRβ with imatinib resulted in remission (Apperley et al., 2002; Magnusson et 
al., 2002). In the rare soft tissue sarcoma dermatofibrosarcoma protuberans chromosomal 
translocation between the gene encoding PDGF-BB and collagen type Iα1 (COLIA1-PDGF-BB) 
have been reported (Kiuru-Kuhlefelt et al., 2001) (Figure 1.3). The COLIA1-PDGF-BB fusion 
protein is processed to PDGF-BB, resulting in autocrine stimulation of PDGFRβ receptors 
(Shimizu et al., 1999). A small group of patients with locally advanced dermatofibrosarcoma 
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protuberans were treated with imatinib; each of the patients responded to treatment, with 50% of 
the patients showing complete clinical response. One patient with metastatic 
dermatofibrosarcoma protuberans initially responded to imatinib treatment however, experienced 
disease progression after 7 months of therapy (McArthur et al., 2005). 
 Acquisition of constitutive PDGFR signaling can increase tumor invasiveness and 
promote metastasis. Tumors of epithelial origin are often unresponsive to PDGF stimulation 
(Heldin and Lennartsson, 2013). When epithelial tumors undergo epithelial to mesenchymal 
transition (EMT) profound alterations to gene expression occur and this transition is associated 
with increased invasiveness and metastasis (Thiery et al., 2009). Among gene expression patterns 
altered during EMT, PDGFRα and PDGFRβ expression was increased several fold (Jechlinger et 
al., 2003). Pharmacological inhibition of PDGFR signaling increased apoptosis and inhibited 
metastasis in mouse models of breast cancer (Jechlinger et al., 2006). PDGFRα and PDGFRβ 
expression positively correlated with tumor grade and invasiveness in human breast carcinoma 
(Jechlinger et al., 2006). Indeed, PDGFR was expressed in 39.2% of 181 human breast 
carcinoma samples tested and positively correlated with lymph node metastasis, HER-2 and Bcl-
2 expression (Carvalho et al., 2005). Attenuation of PDGFR signaling was also shown to inhibit 
metastasis of hepatocellular carcinoma (Gotzmann et al., 2006) and prostate cancer (Dolloff et 
al., 2005; Russell et al., 2009). Additionally PDGF has been shown to induce EMT in PDGF 
responsive liver and colon cancers (Yang et al., 2006) and thus promote tumor invasiveness and 
metastasis by inducing EMT (Figure 1.4). Indeed certain carcinomas may require PDGF 
signaling to maintain mesenchymal phenotype (Barr et al., 2008). 
 
1.1.3.2.2 Role of paracrine PDGFR signaling in the tumor micro-environment 
 PDGFR signaling can promote tumor invasiveness and metastasis through paracrine 
signaling between the cells of the carcinoma and its surrounding micro-environment. Several 
tumors including breast carcinoma, small-cell lung carcinoma and colorectal cancer express 
ligand while the stroma expresses receptor (Heldin and Westermark, 1999). The tumor stroma is 
composed of connective tissue components such as basement membrane and extracellular 
matrix, as well as several cell types including fibroblasts, vasculature and immune cells (Andrae 
et al., 2008). In normal, non-malignant, epithelial tissue the stroma plays a supportive role in 
regulating tissue homeostasis and is normally a barrier to tumor progression. Tumor cells 
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remodel the stroma to facilitate invasiveness, angiogenesis and metastasis (Bremnes et al., 2011; 
Zigrino et al., 2005).  
 
Figure 1.4: Role of PDGFR signaling in tumorigenesis 
1. Autocrine PDGFR signaling, via overexpression or constitutive activation, results in cell 
growth and proliferation and possible inhibition of apoptosis. PDGF and PDGFR expression 
correlate to tumor stage in glioblastoma and sarcoma cancers. 2. Epithelial to mesenchymal 
transition (EMT) may be initiated or sustained by PDGF-BB facilitating tumor progression to an 
invasive and metastatic phenotype. 3. PDGF-AA promotes the recruitment of cancer-associated 
fibroblasts (CAF). CAFs secrete a number of cytokines and growth factors promoting 
tumorigenesis. CAF secreted vascular endothelial growth factor (VEGF) initiates angiogenesis 
that facilitates tumor growth and proliferation. 4. PDGF stimulates CAFs to secrete and interact 
with components of the stromal extracellular matrix that increases interstitial fluid pressure 
(IFP). Increased IFP hinders tumor uptake of chemotherapeutics. 5. PDGF-BB recruits pericytes 
to and stabilizes new blood vessels. Excess PDGF can induce pericyte detachment and 
destabilize blood vessels promoting tumor progression. Modified with permission (Andrae et al., 
2008). 
 
One of the key events in stroma remodeling is the recruitment and activation of 
carcinoma associated fibroblasts (CAFs), which are distinct from normal fibroblasts (Figure 1.4). 
13 
CAFs show distinct genetic mutations and epigenetic regulation compared to normal fibroblasts 
(Bremnes et al., 2011) and express different cell surface markers. Indeed PDGFRα and PDGFRβ 
expression are CAF markers (Ostman, 2004). CAFs increase tumor growth, angiogenesis,  
invasiveness and metastatic potential (Bremnes et al., 2011) and are known to secrete several 
types of collagens, heparin sulfate proteoglycans, matrix metalloproteinases, cytokines and 
growth factors including vascular endothelial growth factor (VEGF) which is critical for 
angiogenesis  (Figure 1.4) (Bremnes et al., 2011). PDGF stimulates proliferation of CAFs and 
promotes their recruitment to sites of tumor growth (Bremnes et al., 2011). PDGF mediated 
recruitment of PDGFR expressing fibroblasts to tumor stroma has been demonstrated in several 
experimental models and this recruitment contributes to tumor growth. In a mouse cervical 
cancer model, PDGF recruited fibroblasts secreted several isoforms of fibroblast growth factor 
that stimulated tumor proliferation, and this proliferation was sensitive to imatinib even though 
the tumor itself did not express PDGFR (Pietras et al., 2008). Tumor cells devoid of VEGF 
expression show defects in initiation of angiogenesis (Andrae et al., 2008). VEGF knock out 
tumor cells that expressed PDGF-AA were transplanted into mice and promoted the recruitment 
of PDGFR positive fibroblasts. These PDGF recruited fibroblasts secreted VEGF and promoted 
angiogenesis (Dong et al., 2004). Indeed this mode of paracrine recruitment of fibroblasts may 
be relevant in human disease as recruitment of PDGFR positive fibroblasts via tumor produced 
PDGF has been demonstrated in human lung carcinoma (Tejada et al., 2006). 
PDGFR signaling can also affect tumor angiogenesis via regulation of pericytes (Figure 
1.4). PDGFRβ positive pericytes are recruited to newly formed blood vessels via PDGF-BB 
(Gerhardt and Semb, 2008). Pericytes adhere to the vascular endothelium and regulate the 
permeability and stability of blood vessels, preventing leakage of cells from the blood vessel 
(von Tell et al., 2006) (Figure 1.4). Indeed pericytes are required during angiogenesis for the 
stabilization and maturation of newly formed vasculature (Gerhardt and Semb, 2008). Given the 
importance of angiogenesis in promoting tumor growth, it is targeted as an anticancer therapy. 
VEGF is a critical component in the initiation of angiogenesis. Pharmacological inhibitors 
directed against the VEGF receptor show greater efficacy when combined with the PDGFR 
inhibitor imatinib in mouse models of pancreatic cancer, suggesting that destabilization of blood 
vessels by removal of pericytes, reduces tumor viability (Bergers et al., 2003). Other experiments 
in the same model system indicate that pericyte removal increases the permeability of blood 
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vessels and promotes tumor metastasis, as increased numbers of tumor cells were observed in the 
blood (Xian et al., 2006). Indeed many tumor types often display destabilized, leaky and 
inefficient vasculature generating gaps in the endothelial lining with poor pericyte coverage 
(Gerhardt and Semb, 2008). This type of vasculature promotes hypoxia that can drive tumor 
progression to an invasive and metastatic phenotype (Wilson, 2007). Thus pericyte removal from 
blood vessels via inhibition of PDGFR signaling may attenuate tumor growth but increase 
metastatic potential. Additionally, excess PDGF-BB may promote pericyte detachment (Andrae 
et al., 2008). 
PDGFR stroma signaling can also modulate tumor drug uptake via regulation of 
interstitial fluid pressure (IFP) (Figure 1.4). The interstitial space mediates exchange of nutrients, 
waste, oxygen and other small molecules between tissues and the vascular system (Heldin et al., 
2004). In normal tissue the IFP is slightly negative facilitating net movement of fluid into the 
interstitial space (Heldin et al., 2004). The IFP in many tumors including breast and colorectal 
carcinomas (Less et al., 1992) is elevated and leads to decreased interstitial transport from the 
vasculature in tumors (Heldin et al., 2004). High IFP reduces tumor uptake of 
chemotherapeutics, such as small molecule inhibitors and therapeutic antibodies thereby 
reducing therapeutic efficacy (Heldin et al., 2004) (Figure 1.4). Reduction of IFP was shown to 
increase interstitial transport of labeled small molecules and macromolecules (Brekken et al., 
2000; Rubin et al., 2000). Fibroblasts are thought to contribute to IFP by increasing tension in 
the extracellular matrix. Fibroblasts bind to collagen in the extracellular matrix via integrins. The 
fibroblast bound collagen molecules in turn interact with other components of the extracellular 
matrix including proteoglycans and hyaluronan. The net effect is to constrict the intersitium or 
stroma (Heldin et al., 2004). PDGF stimulation was found to enhance this process and increase 
IFP (Clark et al., 1989; Gullberg et al., 1990) (Figure 1.4).  
The tumor stroma is characterized by the presence of CAFs and increased constriction of 
the extracellular matrix (Heldin et al., 2004). As previously mentioned CAFs are highly sensitive 
to PDGF and actively secrete extracellular matrix components. Tumors with stromal expression 
of PDGFRβ including, lung, breast and colon carcinoma frequently demonstrate high IFP 
(Ostman and Heldin, 2001). Treatment with imatinib to inhibit PDGFRβ activity in a rat model 
of colon carcinoma decreased IFP and increased uptake of labeled small molecules (Pietras et al., 
2001). Decreasing IFP and increasing interstitial transport can improve efficacy of 
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chemotherapeutics. In a mouse model of thyroid carcinoma expressing stromal PDGFRβ, tumor 
uptake and efficacy of both taxol and 5-fluorouricil was increased when treated in combination 
with imatinib, whereas treatment with imatinib alone did not affect tumor growth. Indeed 
imatinib treatment corresponded to decreased IFP (Pietras et al., 2002). Additionally imatinib 
treatment increased tumor uptake and efficacy of cyclophosphamide in mouse models of lung 
and pancreatic carcinoma (Falcon et al., 2011). 
 
1.1.4 Summary of PDGFR signaling in biology 
 When activated by cognate ligand PDGFRα/β dimerize, prompting trans-
autophosphorylation on multiple cytoplasmic tyrosine residues that serve as docking sites for the 
recruitment and activation of SH2 domain containing signaling proteins (Figure 1.1). Signaling 
output from PI3K and MAPK/ERK pathways are prevalent, promoting cell survival and 
proliferation (Figure 1.2). PDGFRs are required for correct development of the lung, kidney, 
nervous system and vascular system. Knockout of either isoform of PDGFR is embryonic lethal. 
In adults PDGFR signaling is involved in wound healing. 
Hyperactivity of PDGFR signaling is implicated in both non-malignant and malignant 
human disease. In non-malignant disease PDGFR signaling is linked to fibrosis of multiple 
organs as well as to the pathogenesis of atherosclerosis. Diabetics have a statistically higher 
chance of developing cardiovascular disease. Diabetic mouse models show elevated expression 
levels of both PDGF and PDGFR. Inhibition of PDGFR signaling in non-malignant diseases, by 
therapeutic antibodies or small molecule inhibitors, reduced disease severity.  
Multiple cancers demonstrate overexpression of PDGF or PDGFR at the level of mRNA 
or protein. Aberrant expression of both receptor and ligand is associated with glioblastomas and 
sarcoma cancers (Figure 1.3), where expression levels correlate to disease progression. 
Expression of both point mutations and fusion mutations of PDGFR, granting ligand 
independency and constitutive activation, occur in gastrointestinal tumors and myeloproliferative 
disorders, respectively (Figure 1.3). PDGF fusion mutations, resulting in overexpression of 
ligand, also occur in rare skin cancers (Figure 1.3). Autocrine signaling resulting from 
PDGF/PDGFR overexpression or expression of oncogenic mutants promotes tumor proliferation, 
inhibition of apoptosis and disease progression (Figure 1.4). PDGFR signaling can also initiate 
and maintain EMT, which is associated with increased invasiveness and metastasis (Figure 1.4). 
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Inhibition of PDGFR signaling with small molecule inhibitors can attenuate tumor growth and in 
some cases results in clinical clearance.  
PDGFR signaling also contributes to tumorigenesis via paracrine regulation of the tumor 
micro-environment, or stroma (Figure 1.4). PDGF promotes the recruitment of CAFs stimulating 
their proliferation, secretion of extracellular matrix proteins and interaction with the extracellular 
matrix. Increased interaction with the extracellular matrix increases the interstitial fluid pressure 
of the stroma and impairs tumor uptake of chemotherapeutics (Figure 1.4). Inhibition of PDGFR 
signaling increased drug uptake and efficacy. CAFs promote angiogenesis via increasing 
secretion of VEGF. PDGF promotes recruitment of pericytes to newly formed blood vessels, 
increasing blood vessel stability (Figure 1.4). Inhibition of PDGFR signaling reduces pericyte 
coverage of blood vessels and impaired tumor growth; however, destabilization of blood vessels 
induces hypoxia and may increase metastatic potential.  
 
1.2 Endocytosis 
Receptor signaling is modulated by timely activation of endocytic pathways. Activated 
receptors at the plasma membrane are internalized via CME (CME) or non-clathrin endocytosis 
(NCE). Several distinct mechanisms of NCE exist including caveolar endocytosis, 
macropinocytosis, flotillin dependent endocytosis, lipid clustering, clathrin-independent 
carriers/GPI-enriched early endosomal compartments (CLIC/GEEC) endocytosis and circular 
dorsal membrane ruffling (Doherty and McMahon, 2009b) (Figure 1.5). While clathrin and 
caveolar endocytosis depend on the activity of dynamin for proper function, the majority of the 
NCE mechanisms of endocytosis identified function independently of dynamin activity (Doherty 
and McMahon, 2009b) (Figure 1.5). Many of the NCE mechanisms of endocytosis rely on actin 
dynamics and the presence of plasma membrane cholesterol for proper function (Doherty and 
McMahon, 2009b) (Figure 1.5).   
Of the mechanisms of endocytosis mentioned, CME, caveolar endocytosis and 
macropinocytosis have been implicated in the endocytosis of RTKs whereas lipid clustering and 
CLIC/GEEC endocytosis are implicated in the internalization of cytokine receptors and G-
protein coupled receptors, respectively (Doherty and McMahon, 2009b).These distinct 
mechanisms of endocytosis are thought to converge at the early endosome where cargo is either 
sorted for recycling back to the plasma membrane or trafficked to a degradative pathway (Le 
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Roy and Wrana, 2005; Mayor and Pagano, 2007) (Figure 1.5). 
 
Figure 1.5: Mechanisms of receptor internalization 
 A diagram of different pathways of receptor internalization is shown, as well as the 
dependencies of these pathways on the presence of the clathrin coat protein, the GTPase 
dynamin, plasma membrane cholesterol and the actin cytoskeleton for proper function. Each 
pathway is delineated by dashed grey lines. Solid black arrows indicate dependency while solid 
grey arrows indicate independence. CME, caveolar endocytosis and macropinocytosis are known 
to internalize receptor tyrosine kinases whereas lipid clustering and CLIC/GEEC endocytosis are 
implicated in the internalization of cytokine receptors and G-protein coupled receptors, 
respectively. The different pathways of internalization are thought to converge at the early 
endosome. 
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1.2.1 Mechanisms of receptor internalization 
 
1.2.1.1 Clathrin-mediated receptor internalization 
 
1.2.1.1.1 Formation of clathrin coated vesicles 
CME involves concentration of diverse cargo molecules into clathrin bound plasma 
membrane invaginations, termed clathrin-coated pits (CCPs). The clathrin lattice is composed 
repeating clathrin triskelions (Kirchhausen, 2000).  Each triskelion is a trimer of dimers formed 
from clathrin heavy (190 kDa) and light chain (25 kDa) subunits (Kirchhausen, 2000). Formation 
of CCPs progresses in stages. First clathrin and other protein factors assemble on the cytosolic 
leaflet of the plasma membrane. Secondly the CCP matures, where coat proteins and membrane 
components generate and retain curvature to form the budding vesicle (Kirchhausen, 2000). 
Lastly, scission releases the clathrin coated vesicle from the plasma membrane into the cytosol 
(Pucadyil and Schmid, 2009) (Figure 1.6). 
In the assembly stage various adaptor proteins are recruited to the plasma membrane 
through interactions with PI4,5P2, as well as by binding specific transmembrane cargo for 
incorporation into CCPs (Ungewickell and Hinrichsen, 2007) (Figure 1.6). The adaptor proteins 
then interact with clathrin, either directly or through accessory proteins, thereby linking clathrin 
to the designated cargo (Figure 1.6). The large number of potential adaptor proteins is thought to 
provide flexibility and diversity to the clathrin machinery, allowing for internalization of many 
different types of cargo and facilitating the specific needs of multiple cell types (Doherty and 
McMahon, 2009a). Several amino acid sequences have been identified in transmembrane cargo 
molecules that serve as internalization signals (Ungewickell and Hinrichsen, 2007). The PDGFR 
contains a 14 amino acid internalization sequence between residues 952-965 which is required 
for endocytosis (Mori et al., 1991). Of the numerous clathrin adaptor proteins identified adaptor 
protein-2 (AP-2), autosomal recessive hypercholesterolemia protein (ARH), β-arrestin, disabled-
2 (Dab2), epidermal growth factor receptor substrate 15 (Eps15), EPS-15-interacting protein 1 
(epsin), numb, adaptor protein 180/clathrin-assembly lymphoid myeloid leukaemia protein 
(AP180/CALM) and Huntingtin-interacting protein 1 related protein (HIP1/R) are among the 
best characterized. Each of these adaptor proteins is able to bind clathrin directly except Eps15 
(Ungewickell and Hinrichsen, 2007). AP-2 is thought to be particularly important as it forms an 
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interaction network with all endocytic proteins either by direct binding or binding through 
accessory proteins (Kirchhausen, 2000; Schmid et al., 2006). This AP-2 mediated interaction 
network reduces mobility of its components forming a gel-like micro-domain which facilitates 
clathrin assembly (Ungewickell and Hinrichsen, 2007). AP180/CALM simultaneously binds 
clathrin and PI4,5P2, thereby linking clathrin to the plasma membrane (Ford et al., 2001). 
To mature into a CCP, the clathrin lattice and underlying plasma membrane must generate 
and retain inward curvature. Polymerization of the clathrin lattice is energetically insufficient to 
generate membrane curvature (Nossal, 2001). Recruitment of proteins that penetrate the 
cytoplasmic leaflet of the plasma membrane is required to generate membrane curvature 
(Ungewickell and Hinrichsen, 2007). Proteins containing Bin–Amphiphysin–Rvs (BAR), epsin 
N-terminal homology (ENTH) and F-BAR domains are recruited to the plasma membrane via 
interaction with PI4,5P2, as well as interaction with AP-2 (Kirchhausen, 2000; Ungewickell and 
Hinrichsen, 2007). Insertion of amphipathic helices within these domains into the plasma 
membrane causes deformation and generates curvature (Farsad and De Camilli, 2003) (Daumke 
et al., 2014). The clathrin lattice is flexible and acts as a molecular ratchet by adjusting to 
changes in inward membrane curvature and preserving it (Ungewickell and Hinrichsen, 2007).  
Several methodologies exist to inhibit formation of the clathrin lattice and prevent 
clathrin-mediated internalization. Overexpression of the clathrin binding domain of AP180 is 
sufficient to inhibit CME by impairing the ability of the clathrin lattice to interact with the 
plasma membrane (Ford et al., 2001). Knockdown of the heavy chain of clathrin via RNA 
interference ablated endocytosis of EGFR and low density lipoprotein receptor (LDLR) (Motley 
et al., 2003) and inhibited transferrin uptake (Hinrichsen et al., 2003). Recently, small molecule 
inhibitors named pitstops have been developed and have been demonstrated to reversibly inhibit 
clathrin mediated uptake of EGF and transferrin, as well as block HIV virus entry (von Kleist et 
al., 2011). Pitstop inhibitors competitively bind the region of clathrin responsible for binding 
adaptor proteins and thereby prevent recruitment of clathrin to its adaptors (von Kleist et al., 
2011). 
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Figure 1.6: Internalization, endosomal sorting and degradation of receptor tyrosine kinases 
A diagram depicting the cellular fates of ligand stimulated receptor tyrosine kinases. 1. Clathrin-
coated pit (CCP) induction. Binding of ligand activates receptors prompting dimerization and 
trans-autophosphorylation of several cytoplasmic tyrosine residues, which creates binding sites 
for various endocytic adaptor proteins. Receptors are clustered and concentrated on the plasma 
membrane due to binding of endocytic adaptor proteins. These adaptors recruit clathrin and form 
a bridge between the receptor cargo and the clathrin lattice. The clathrin lattice and underlying 
membrane obtain curvature, generating a CCP. 2. Internalization. Scission of the clathrin-coated 
pit from the plasma membrane requires recruitment multiple proteins including dynamin, myosin 
and the actin cytoskeleton. Concerted action between dynamin and the actin cytoskeleton 
facilitates scission from the plasma membrane. Polymerization of dynamin constricts and 
tubulates the vesicle neck. Myosin motor protein associates with both dynamin and the clathrin 
lattice, generating force along the actin cytoskeleton and directing the vesicle toward the cell 
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interior. Directional lines of force are shown as light purple arrows. 3. Trafficking. The 
internalized vesicle is uncoated and its cargo may be ubiquitinated by E3 ubiquitin ligases. The 
vesicle is transported to the early endosome via the actin and microtubule cytoskeleton network. 
Fusion between the vesicle and the early endosome is regulated by Rab5. 4. Sorting. The 
majority of receptors are deactivated and recycled, whereas some receptors are targeted for 
degradation. 5a. Recycling. Ligand dissociates from the receptor and the receptor is 
dephosphorylated. The receptor is trafficked back to the plasma membrane in a Rab4-dependent 
manner where it can undergo additional rounds of activation and internalization. 5b. MVE 
biogenesis. Monoubiquitination of receptors delineate incorporation into multivesicular 
endosomes (MVE). Ubiquitinated receptors are recognized and concentrated on the late 
endosomal membrane by the ESCRT machinery. The endosomal membrane obtains inverse 
curvature and buds off into the lumen of the endosome via the concerted actions of Vps32 and 
Vps4. Cargo is de-ubiquitinated prior to inclusion in MVEs. 6. Degradation. Late endosomes 
containing MVEs are trafficked to the lysosome via rab7. The late endosome undergoes 
heterotypic fusion with the lysosome, generating a hybrid organelle where MVEs and their cargo 
are degraded. Inhibition of proteasomal activity impairs receptor degradation indicating a 
potential role of the proteasome in receptor degradation. 
 
1.2.1.1.2 Dynamin-mediated vesicle scission 
Completion of internalization requires fission of the budding vesicle from the plasma 
membrane (Figure 1.6). The large GTPase dynamin, 100 kDa, is recruited to budding vesicles 
after recruitment of AP-2 and clathrin (Ungewickell and Hinrichsen, 2007). Recruitment of 
dynamin to CCPs is dependent upon its activation state. Binding of GTP is required for the 
association of dynamin with the neck of the invaginating CCP (Chappie et al., 2009). Dynamin 
contains a C-terminal proline rich domain to interact with endocytic accessory proteins 
possessing SH3 domains and this interaction facilitates dynamin recruitment to invaginating 
CCPs (Shpetner et al., 1996). Dynamin contains a pleckstrin homology (PH) domain to facilitate 
interaction with the plasma membrane. Several amino acids of the PH domain protrude into the 
cytoplasmic leaflet that causes deformation of the budding vesicle neck (Ramachandran and 
Schmid, 2008). Assembly of dynamin on the vesicle neck stimulates its intrinsic GTPase activity 
and GTP hydrolysis results in disassembly from the budding vesicle neck (Chappie et al., 2009; 
Sever et al., 1999). Multiple rounds of GTP-mediated assembly and disassembly create a cycle 
of constriction and relaxation of the vesicle neck, promoting scission from the plasma membrane 
(Pucadyil and Schmid, 2009). Dynamin activity is inhibited by the expression of temperature 
sensitive mutants, the dominant negative mutant K44A and small molecule inhibitors such as 
dynasore (Macia et al., 2006a; Nankoe and Sever, 2006). Dynasore noncompetitively interferes 
with GTP hydrolysis without affecting the affinity of dynamin for GTP and treatment of cells 
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with dynasore is sufficient to prevent transferrin uptake, LDL uptake and EGFR endocytosis in 
response to ligand stimulation (Macia et al., 2006a). 
F-actin dynamics are implicated in several steps in CCP formation including lateral 
movement of clathrin-coated patches, membrane curvature and vesicle scission (Ungewickell 
and Hinrichsen, 2007) (Mooren et al., 2012) (Figure 1.6). Actin and other components of the 
actin cytoskeleton are associated with the budding CCP at the same time as dynamin 
(Ungewickell and Hinrichsen, 2007) (Mooren et al., 2012). The clathrin lattice is connected to 
the actin cytoskeleton via the endocytic adaptor protein HIP1/R (Le Clainche et al., 2007). In 
mouse fibroblasts treatment with either the actin polymerization inhibitor latrunculin A or the 
actin depolymerization inhibitor jasplakinolide blocked CME and resulted in the accumulation of 
CCPs still attached to the plasma membrane, indicating actin dynamics primarily affect vesicle 
scission (Yarar et al., 2005). Actin motor proteins myosin VI and myosin IE may provide the 
force required for vesicle scission (Ungewickell and Hinrichsen, 2007) (Mooren et al., 2012). 
Myosin VI binds the endocytic adaptor protein Dab2 and PI4,5P2, thereby linking itself to the 
CCP and the plasma membrane and generating force directing the vesicle inwards towards the 
cytoplasm (Spudich et al., 2007). Myosin IE binds dynamin via its SH3 domain and directs the 
dynamin ring towards the plasma membrane (Krendel et al., 2007). The pull of myosin VI on the 
vesicle toward the cytoplasm and the pull of myosin IE on the dynamin ring toward the plasma 
membrane in concert with the constriction and relaxation cycles of dynamin is thought to 
promote vesicle scission beneath the dynamin ring (Pucadyil and Schmid, 2009; Ungewickell 
and Hinrichsen, 2007) (Figure 1.6). Upon scission of the budding CCP, the clathrin coat is 
disassembled and the vesicle is trafficked to the endosomal system where its constituents are 
sorted (Figure 1.6). 
 
1.2.1.2 Caveolar endocytosis 
Caveolae are flask shaped plasma membrane invaginations that often from a network in 
conjunction with lipid rafts and occupy up to 40% of the plasma membrane in mammalian cells 
(Hommelgaard et al., 2005). Caveolae are enriched in caveolin-1 (22 kDa), which contribute to 
the spiked-like coat of caveolae (Doherty and McMahon, 2009b). Caveolin-1 forms highly 
ordered oligomers (Doherty and McMahon, 2009b) consisting of 14-16 caveolin-1 monomers 
(Sargiacomo et al., 1995). The ability of caveolin-1 to bind fatty acids and cholesterol is thought 
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to stabilize oligomerization (Monier et al., 1996). Oligomerization of caveolin-1 may induce 
membrane curvature (Parton et al., 2006). Extraction of plasma membrane cholesterol via 
methyl-β-cyclodextrin treatment flattens caveolae and attenuates caveolar endocytosis (Rothberg 
et al., 1992). Caveolin-1 binds the fatty acids portion of glycosphingolipid GM1 promoting 
association of caveolae with plasma membrane and detergent resistant lipid rafts (Hommelgaard 
et al., 2005). The role of caveolae in endocytosis is controversial. Study of the dynamics of 
caveolae reveals them to be highly immobile structures at the plasma membrane, demonstrating 
little turnover (Thomsen et al., 2002). Caveolae are rigidly linked to the actin cytoskeleton 
contributing to their observed immobility (Stahlhut and van Deurs, 2000). It is expected that 
mobility and a high turnover rate would be required for an endocytic pathway to efficiently 
process and internalize cargo (Hommelgaard et al., 2005).  
Two proposed mechanisms for caveolae internalization have emerged. In one mechanism 
a small proportion of caveolae that are not sufficiently stabilized are infrequently internalized, 
resulting in removal of a vesicle from the immobilized caveolar network (Hommelgaard et al., 
2005). In the second mechanism scission from the caveolar network occurs in coordination with 
Rho family GTPase-mediated remodeling of the actin cytoskeleton (Navarro et al., 2004). 
Additional studies on the dynamics of caveolae in live cells are required to further characterize 
caveolae-mediated internalization (Hommelgaard et al., 2005). Dynamin is implicated in the 
scission of caveolar vesicles (Mukherjee et al., 2006). Dynamin binds the budding neck of 
caveolae, colocalized with caveolin-1 and is required for the scission of caveolar vesicles 
(Henley et al., 1998; Oh et al., 1998). Inhibition of dynamin activity blocks caveolar-mediated 
uptake of cholera toxin subunit B (Henley et al., 1998; Oh et al., 1998). After scission the vesicle 
is transported to the early endosome and its cargo is sorted through the endosomal system. 
The traditional cargos for caveolar endocytosis are cholera toxin subunit B and SV40 
virus (Doherty and McMahon, 2009b). Other types of cargo including prion proteins (Peters et 
al., 2003) and several receptor tyrosine kinases have also been suggested to utilize this route of 
endocytosis (Mukherjee et al., 2006). Despite being canonically internalized by the clathrin 
machinery, RTKs including EGFR, PDGFR, vascular endothelia growth factor receptor 2 
(VEGFR-2) and transforming growth factor receptor β (TβRI/II) have been demonstrated to be 
internalized via caveolar endocytosis (Mukherjee et al., 2006). Caveolar endocytosis of TβRI/II 
may occur concurrently with CME (Di Guglielmo et al., 2003). VEGFR-2 endocytosis proceeds 
24 
preferentially via caveolae rather than by the clathrin machinery (Labrecque et al., 2003). In the 
case of PDGFR and EGFR high concentrations of ligand are thought to promote caveolar 
endocytosis (De Donatis et al., 2008; Sigismund et al., 2005). One study demonstrated that low 
concentrations of EGF resulted in predominantly CME of EGFR whereas high ligand 
concentrations promoted receptor internalization by a lipid raft dependent mechanism 
(Sigismund et al., 2005). Co-localization between EGFR and caveolae was increased 10 fold in 
the presence of high concentrations of ligand as compared to low concentrations (Sigismund et 
al., 2005). High concentration of ligand also promoted ubiquitination and increased degradation 
of the EGFR (Sigismund et al., 2005). Ubiquitination of the EGFR and expression of ubiquitin 
adaptor proteins Eps15 and epsin were required for internalization (Sigismund et al., 2005). This 
observation of internalization of EGFR via caveolar endocytosis in the presence of high 
concentrations of ligand is controversial. Studies by another group show inhibition of caveolar 
endocytosis does not greatly effect EGFR internalization in the presence of low or high 
concentrations of ligand whereas knockdown of clathrin heavy chain does (Kazazic et al., 2006). 
Moreover high concentrations of EGF do not promote co-localization of EGFR with caveolae 
and caveolae remained static structures in the presence of high concentrations of EGF (Kazazic 
et al., 2006). Akin to observations with EGFR, high concentrations of PDGF promote 
internalization of PDGFR via caveolar endocytosis (De Donatis et al., 2008). This modulation of 
PDGFR endocytosis also differentiated PDGFR signaling output. Internalization of PDGFR via 
caveolar endocytosis resulted in attenuation of cell migration and promotion of mitogenic 
signaling in response to high concentrations of PDGF (De Donatis et al., 2008). 
 
1.2.1.3 Internalization by macropinocytosis and membrane ruffling 
 Macropinocytosis is a distinct mechanism of endocytosis involving internalization of 
large portions of plasma membrane, macromolecules and extracellular fluid (Lim and Gleeson, 
2011). Macropinocytosis is induced by stimulation with a number of growth factors. Treatment 
of cells with either PDGF or EGF promotes extensive actin polymerization at the cell surface and 
formation of protrusions termed membrane ruffles (Jones, 2007). Indeed, even short term 
stimulation produced extensive ruffling visible across the entire cell (Jones, 2007). Occasionally 
these membrane protrusions fold back upon the plasma membrane or upon other membrane 
ruffles generating vesicles called macropinosomes that allows for internalization of large 
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volumes of extracellular fluid and plasma membrane lipids (Swanson, 2008).  
Rho family GTPases (Rac-1, Cdc42 and Rho) regulate actin polymerization and 
membrane ruffling (Kerr and Teasdale, 2009). Inhibition of the activity of these GTPases by 
small molecule inhibitors (West et al., 2000) or dominant negative mutation (Nobes and Marsh, 
2000; Schafer et al., 2000) attenuates internalization by macropinocytosis. Interestingly, 
inhibition of Rho family GTPases does not prevent membrane ruffling, yet blocks 
internalization, suggesting macropinocytosis is regulated at several steps (West et al., 2000). 
Treatment of cells with the ion exchanger protein inhibitor amiloride, or its derivatives, disrupts 
membrane ruffling and is sufficient to inhibit macropinocytosis without affecting other 
mechanisms of endocytosis (Kerr and Teasdale, 2009; West et al., 1989).  Membrane ruffles are 
enriched in lipid rafts which are known to contain receptor tyrosine kinases and several species 
of phosphoinositides (Le Roy and Wrana, 2005; Manes et al., 2003). Depletion of membrane 
cholesterol or inhibition of PI3K signaling both inhibit macropinocytosis (Grimmer et al., 2002).  
 Internalization by macropinocytosis results in the formation of large, irregular sized 
vesicles called macropinosomes (Lim and Gleeson, 2011). In contrast to clathrin-coated vesicles, 
macropinosomes are not encapsulated by a coat protein and their internalization is independent 
of dynamin activity (Kerr and Teasdale, 2009). Macropinosomes can be delineated from other 
endocytic structures via uptake of fluid phase markers including labeled dextran, horseradish 
peroxidase and Lucifer yellow (Lim and Gleeson, 2011). The fate of macropinosomes in the 
endocytic system may be cell type and/or context dependent. Macropinosomes reduce in size and 
acquire endocytic markers as they mature (Lim and Gleeson, 2011). In macrophages or in 
HEK293 cells stimulated with EGF, cargo in macropinosomes are targeted to the lysosomes 
(Kerr et al., 2006; Lim and Gleeson, 2011). At early time points of stimulation macropinosomes 
acquire staining of transferrin receptor which is indicative of the early endosomal system (Kerr et 
al., 2006). Transferrin receptor staining is subsequently lost, as the transferrin receptor is 
recycled, and Rab7 and lysosomal glycoprotein A staining is acquired, indicating trafficking to 
the late endosome and lysosome, respectively (Kerr et al., 2006; Racoosin and Swanson, 1993). 
In A431 cells, macropinosome cargo are not trafficked to the lysosome. Macropinosomes acquire 
transferrin and early endosomal antigen 1 (EEA1) staining and are eventually recycled back to 
the plasma membrane (Araki et al., 2006; Hamasaki et al., 2004). 
 While CME remains the predominant mechanism of internalization of RTKs, there are 
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several examples of situations promoting RTK internalization by macropinocytosis. 
Transformation of fibroblast cells via expression of oncogenic H-Ras (H-RasG12V) increases 
cellular PI3K signaling levels, possibly via interaction with the p110 subunit of PI3K (Schmees 
et al., 2012). Excessive PI3K signaling induces macropinocytic internalization of PDGFRβ as 
evident by PI3K dependent co-localization of PDGFRβ with fluorescently labeled dextran only 
in cells expressing H-RasG12V (Schmees et al., 2012). Indeed inhibition of PI3K activity 
abrogated PDGFRβ-dextran co-localization (Schmees et al., 2012). Internalization of PDGFRβ 
resulted in hyper-activation of the receptor and increased anchorage-independent proliferation of 
H-RasG12V transformed cells; anchorage-independent cell proliferation was sensitive to PDGFR 
inhibitors (Schmees et al., 2012). Expression of H-RasG12V in fibroblasts did not result in co-
localization between EGFR and dextran; however, in non-transformed fibroblasts co-stimulation 
of both EGFR and PDGFR resulted in macropinocytic uptake of both receptors as evident by 
EGFR-dextran and PDGFR-dextran co-localization (Schmees et al., 2012). Stimulation of either 
receptor individually did not result in dextran co-localization (Schmees et al., 2012). Indeed co-
stimulation of EGFR and PDGFR resulted in hyper-activation of each receptor and Akt 
(Schmees et al., 2012). Thus induction of macropinocytosis may be physiologically relevant as 
cells are likely to encounter co-stimulatory situations in vivo. Macropinocytic uptake of EGFR 
was also observed in cells with hyper-activated Rab5 (Balaji et al., 2012). Overexpression of 
Rin1, a Rab5 GTP exchange factor (GEF), was sufficient to induce macropinocytic uptake of 
EGFR and increased EGFR degradation (Balaji et al., 2012).  
 
1.2.2 Endocytic trafficking and receptor degradation 
 
1.2.2.1 Role of Rab proteins in endosomal trafficking 
Internalized vesicles and their cargo are sorted through the endosomal network by the 
action of Rab proteins. Rab proteins are the gatekeepers of membrane trafficking and provide 
specificity to the tethering events required for vesicle-endosome fusion (Stenmark, 2009; Zerial 
and McBride, 2001). Rab proteins are regulated by their GTP binding state (Mellor et al., 2012). 
GEFs facilitate exchange of GDP for GTP, thereby activating the Rab protein (Mellor et al., 
2012). Interaction with GTPase activating proteins (GAP) stimulates the intrinsic GTPase 
activity of Rab proteins, accelerating hydrolysis of GTP and deactivating the Rab protein 
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(Stenmark, 2009; Zerial and McBride, 2001). Internalized receptors are targeted to the early 
endosome by Rab5 (Mellor et al., 2012). Activated Rab proteins recruit tethering proteins that 
link the internalized vesicle to the early endosome and providing specificity to the soluble NSF 
attachment proteins (SNARE) proteins that mediated fusion of two endosomes (Zerial and 
McBride, 2001). Modulation of Rab5 and Rab4 GAP activity alters PDGFR activation and 
endocytosis, impairs receptor degradation and promotes cellular transformation (Chamberlain et 
al., 2004; Chamberlain et al., 2008; Chamberlain et al., 2010; Mellor et al., 2012). From the 
early endosome, internalized receptors can either be recycled back to the plasma membrane via 
Rab4 and are available for successive rounds of activation and signaling, or are incorporated into 
multivesicular endosomes and sorted for degradation in the lysosome via Rab7 (Zerial and 
McBride, 2001) (Figure 1.6). Rab proteins thus control receptor fate and signaling output 
through regulation of receptor trafficking to different compartments for recycling or degradation 
(Mellor et al., 2012). 
 
1.2.2.2 Receptor ubiquitination and sorting into multivesicular endosomes 
Incorporation of endosomal cargo including RTKs in multivesicular endosomes (MVEs) 
for lysosomal degradation requires ubiquitination of target cargo (Hicke, 2001) (Figure 1.6). 
Ubiquitin is a 76 amino protein which is post-translationally conjugated to target proteins. E3 
ubiquitin ligases mediate isopeptide bond formation between the carboxyl group of the C-
terminal glycine of ubiquitin and the ε-amino group of lysine residues in target proteins (Lu and 
Hunter, 2009).  Additional ubiquitin molecules can be linked sequentially to several lysine 
residues (lysine 6, 11, 27, 29, 33, 48 and 63) of the ubiquitin conjugated to target of interest 
(Tanno and Komada, 2013). As such, ubiquitin chains with different linkages can be generated 
(Tanno and Komada, 2013). 
Ligand binding of both EGFR and PDGFR induces autophosphorylation on cytoplasmic 
tyrosine residues creating docking sites for the E3 ubiquitin ligase Cbl promoting receptor 
ubiquitination (Mosesson et al., 2003) (Figure 1.6). Ubiquitination of receptors is not necessary 
for their internalization (Huang et al., 2007) but is required for sorting and incorporation into 
multivesicular endosomes (Hicke, 2001). Ubiquitinated cargo is recognized by several members 
of the endocytic machinery via a plethora of ubiquitin binding domains (Dikic et al., 2009). 
Ubiquitination serves as a molecular signal for several cellular responses including protein 
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degradation. Polyubiquitination delineates target proteins for degradation by the 26S proteasome 
(Ravid and Hochstrasser, 2008). In polyubiquitination, ubiquitin chains are formed where each 
successive ubiquitin molecule is linked via isopeptide bond to lysine residue 48 of the previous 
ubiquitin molecule (Lu and Hunter, 2009). Monoubiquitination and multiubiquitination, which is 
monoubiquitination at several lysine residues, targets activated receptor complexes for 
incorporation into MVEs and finally lysosomal degradation (Hicke, 2001). Polyubiquitination 
with lysine 63-linked chains are thought to be involved in a number of cell processes including 
endocytosis. Lysine 63 linked chains promote endosomal sorting and lysosomal degradation of 
target proteins and is thought to provide a more efficient signal than monoubiquitination (Tanno 
and Komada, 2013). Indeed, quantitative mass spectrometry analysis of ligand-activated EGFR 
demonstrated that over 50% of ubiquitin molecules conjugated to EGFR were in lysine 63 
linkages (Huang et al., 2006). Monoubiquitinated and lysine 63 polyubiquitinated cargo is 
thought to be sorted similarly by the endocytic machinery; however lysine 63 polyubiquitin 
chains are recognized with a higher affinity by ubiquitin binding proteins, thereby increasing the 
efficiency of the ubiquitin signal (Tanno and Komada, 2013). 
The endosomal sorting complex required for transport (ESCRT) machinery concentrates 
and packages ubiquitinated cargo into endosomal membrane invaginations (Raiborg and 
Stenmark, 2009). MVEs result from abscission of the budding vesicles into the lumen of the late 
endosome (Raiborg and Stenmark, 2009). The ESCRT machinery consists of four distinct multi-
protein complexes, functioning sequentially to facilitate MVE biogenesis. ESCRT-0, composed 
of HRS and STAM, concentrate endosomal ubiquitinated cargo via interaction with multiple 
ubiquitin interaction motifs (UIM) of HRS (Raiborg and Stenmark, 2009).  ESCRT-0 localizes to 
endosomal membranes through binding phosphatidylinositol-3 phosphate via the FYVE domain 
of HRS (Hanson et al., 2009; Raiborg and Stenmark, 2009). ESCRT-I is recruited by interaction 
with the PSAP motif of HRS (Raiborg and Stenmark, 2009). ESCRT-I is composed of four 
proteins, Tsg101 being the best characterized (Saksena et al., 2007). Tsg101 interacts with 
ubiquitinated cargo via an UEV domain and knockdown of tsg101 is sufficient to impair EGFR 
degradation (Saksena et al., 2007). ESCRT-I recruits ESCRT-II via its C-terminus (Raiborg and 
Stenmark, 2009). ESCRT-II is capable of binding ubiquitinated cargo, through interactions with 
a GLUE domain. A sequential ubiquitin hand-off model has been proposed for the different 
ESCRT complexes, but remains untested (Raiborg and Stenmark, 2009). ESCRTs 0-II function to 
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concentrate ubiquitinated cargo and recruit ESCRT-III to the site of membrane invagination 
(Raiborg and Stenmark, 2009). ESCRT-III, which does not bind ubiquitin, generates membrane 
curvature forming intraluminal invaginations, and catalyzes membrane abscission forming 
MVEs (Hanson et al., 2009; Raiborg and Stenmark, 2009). Cargo is deubiquitinated prior to 
inclusion in MVEs. ESCRT-III consists of numerous proteins (Raiborg and Stenmark, 2009; 
Saksena et al., 2009). Multiple molecules of highly charged Vps32 protein assemble into circular 
arrays on endosomal membranes and recruit the ATPase Vps4 (Raiborg and Stenmark, 2009; 
Saksena et al., 2009). Polymerization of Vps32 molecules are thought to drive constriction of the 
intra-luminal vesicle followed by abscission into the lumen of the endosome (Raiborg and 
Stenmark, 2009; Saksena et al., 2009). Vps4 catalyzes the de-polymerization of Vps32 and its 
subsequent recycling back to the cytosol (Raiborg and Stenmark, 2009; Saksena et al., 2009).  
Vesicles containing MVE, known as late endosomes, are delivered to the lysosome for 
degradation by a Rab7-dependent trafficking step (Raiborg and Stenmark, 2009; Zerial and 
McBride, 2001) (Figure 1.6). 
 
1.2.2.3 Mechanisms of protein degradation 
 
1.2.2.3.1 Lysosomal degradation 
 Lysosomes are dense membrane bound organelles and are the classical site of degradation 
of membrane proteins, extracellular proteins and macromolecules (Luzio et al., 2007). Indeed 
binding of ligand to PDGFR, EGFR and LDLR induces the internalization, endosomal 
trafficking, ubiquitin dependent sorting into MVEs and subsequent lysosomal degradation of a 
portion of activated receptors (Heldin and Westermark, 1999; Luzio et al., 2007). In the case of 
LDL-LDLR, the receptor and ligand dissociate and the receptor is recycled back to the plasma 
membrane while the ligand is degraded (Luzio et al., 2007).  
Lysosomes contain several proteases and lipases whose activity is dependent upon low 
pH to facilitate protein and macromolecule degradation (Luzio et al., 2007). Indeed lysosomes 
contain ATP-dependent proton pumps to maintain a pH of 4.6-5.0 (Luzio et al., 2007). Treatment 
of cells with weak bases such as chloroquine raises the pH of the lysosome, thereby inhibiting 
degradation (Luzio et al., 2007). Lysosomes can be distinguished from other organelles of the 
endosomal system by the lack of mannose-6-phosphate receptor staining (Luzio et al., 2007) and 
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can be detected by the presence of lysosomal-associated membrane protein 1 (LAMP-1) 
(Eskelinen et al., 2003). 
 Late endosome are trafficked to the lysosome along the microtubule cytoskeleton (Piper 
and Luzio, 2007). An intact microtubule cytoskeleton is required for efficient trafficking of cargo 
to the lysosome (Piper and Luzio, 2007). Activated Rab7 on late endosomal and lysosomal 
membranes initiates tethering and fusion events (Zerial and McBride, 2001). Transfer of cargo to 
the lysosome can occur either by complete heterotypic fusion of the late endosome and the 
lysosome or by kiss and run exchange of cargo and lipids (Bright et al., 2005). The two 
mechanisms are not mutually exclusive and kiss and run exchange often precedes heterotypic 
fusion (Bright et al., 2005). The resulting organelle is a hybrid between the lysosome and the late 
endosome and is the site of degradation of endosomal cargo (Luzio et al., 2007; Mullock et al., 
1998) (Figure 1.6). The lysosome is subsequently regenerated via a maturation process where the 
hybrid organelle losses endosomal markers and re-establishes the correct pH via the action of 
proton pumps (Bright et al., 2005; Luzio et al., 2007; Pryor et al., 2000). 
 
1.2.2.3.2 Proteasomal degradation 
 Degradation of the vast majority of intracellular proteins is regulated by the ubiquitin-
proteasome system. Target proteins must be recognized by the 26S proteasome, unfolded, 
translocated through the proteasome and degraded (Ravid and Hochstrasser, 2008). 
Polyubiquitination by E3 ubiquitin ligases marks target proteins for degradation by the 26S 
proteasome where they are proteolytically processed into oligopeptides. Ubiquitin is covalently 
conjugated to the ε-amino group of lysine residues on the target protein (Ravid and Hochstrasser, 
2008). Successive ubiquitin molecules are added to lysine 48 of the previous ubiquitin molecule, 
thus extending the chain. A minimum chain length of 4 ubiquitin molecules is required to target a 
protein for proteasomal degradation (Sorokin et al., 2009).  
The 26S proteasome is composed of two main subunits, the 20S proteasomal core particle 
and the 19S regulatory particle (Ravid and Hochstrasser, 2008). The 20S proteasomal core 
particle is composed of 4 heptameric rings consisting of α and β subunits that form a cylindrical 
barrel like structure (Coux et al., 1996). Eukaryotes have seven different isoforms of each α and 
β subunit (Sorokin et al., 2009). The β subunits each contain a catalytic threonine residue, 
conferring proteolytic activities similar to caspase, trypsin and chymotrypsin (Ravid and 
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Hochstrasser, 2008). Treatment of cells with the small molecule inhibitor MG132 disrupts the 
activity of the chymotrypsin-like catalytic site, and at higher concentrations, the activity of the 
caspase-like catalytic site (Goldberg, 2012). The 19S regulatory particle mediates recognition of 
polyubiquitinated substrates, unfolding of polypeptides and translocation into the 20S 
proteasomal core particle (Ravid and Hochstrasser, 2008). Prior to degradation, substrates are 
deubiquitinated to replenish the ubiquitin pool and facilitate the targeting and degradation of 
additional proteins (Ravid and Hochstrasser, 2008). 
 Although trafficking to the lysosome is the primary and accepted mechanism of RTK 
degradation in response to ligand stimulation, several lines of evidence point to a potential role 
of the 26S proteasome. Treatment of cells with small molecule inhibitors of either lysosomal 
degradation or proteasomal degradation blocks EGFR degradation in response to ligand 
(Ettenberg et al., 2001; Levkowitz et al., 1998; Lipkowitz, 2003). Several reports indicate that 
ligand induced degradation of the PDGFR is also proteasome dependent (Mori et al., 1992, 
1993; Mori et al., 1995b; Mori et al., 1995c) and that the PDGFR is polyubiquitinated in 
response to stimulation (Mori et al., 1995a; Mori et al., 1992). Additionally, the degradation of 
other RTKs including the growth hormone receptor may proceed via the proteasome (Strous et 
al., 1996; van Kerkhof et al., 2000).  
Several hypotheses have been proposed to account for the sensitivity of RTK degradation 
to proteasomal inhibitors. Inhibition of proteasomal degradation would result in accumulation of 
polyubiquitinated intracellular proteins and deplete the cellular pool of free ubiquitin required for 
lysosomal trafficking of RTKs (Swaminathan et al., 1999). Indeed depletion of free ubiquitin in 
yeast is sufficient to inhibit both proteasomal and lysosomal degradation (Swaminathan et al., 
1999). The EGFR however, is still ubiquitinated in response to growth factor stimulation in cells 
treated with proteasomal inhibitors (Longva et al., 2002). Several lines of evidence suggest that 
RTKs are not direct targets of proteasomal degradation and that proteasomal mechanisms are 
required for lysosomal degradation. Inhibition of proteasomal activity blocks EGFR 
internalization (Kesarwala et al., 2009) and trafficking through the endosomal system (Melikova 
et al., 2006), by preventing sorting of EGFR into multivesicular endosomes (Longva et al., 
2002). Others suggest a direct role of the proteasome where the RTK itself is degraded (Heldin 
and Westermark, 1999; Mori et al., 1992, 1993; Mori et al., 1995b; Mori et al., 1995c). 
 
32 
1.2.3 Ligand-independent receptor degradation 
 Although ligand-dependent endocytosis and lysosomal degradation is the canonical 
mechanism of receptor degradation, several examples of ligand-independent receptor 
endocytosis and degradation have been discovered. The mechanisms governing constitutive 
degradation are largely unknown, however; several themes are emerging, involving the 
modulation of endocytosis and sorting, ubiquitination and proteasomal and lysosomal 
degradation. Classic examples of receptors that undergo constitutive endocytosis are the 
transferrin receptor (TfR) and the LDLR, which are internalized in the absence of ligand and 
recycled back to the plasma membrane in a rab4 and rab 11-dependent manner via constitutive 
interaction with the clathrin adaptor AP-2 (Marmor and Yarden, 2004; Ullrich et al., 1996). The 
endocytosis machinery, in the case of TfR can be modulated to facilitate timely degradation of 
the TfR. Recent studies have demonstrated that rab12 mediated trafficking of TfR positive 
recycling endosomes to the lysosome for degradation in the absence of ligand (Matsui et al., 
2011). Indeed, this mechanism of TfR degradation was independent of conventional receptor 
degradation as knockdown of rab12 or its effector proteins did not affect EGFR degradation 
(Matsui et al., 2011).   
 PDGFRβ has been demonstrated to undergo constitutive degradation, independent of 
PDGFR phosphorylation and kinase activity, following cell detachment (Baron and Schwartz, 
2000).  Detachment from the extracellular matrix reduced PDGFRβ expression levels (Baron and 
Schwartz, 2000). PDGFRβ expression levels recovered when cells were plated on fibronectin 
(Baron and Schwartz, 2000). Increased PDGFR ubiquitination was observed following cell 
detachment and PDGFRβ degradation was blocked by treatment with proteasomal degradation 
inhibitors (Baron and Schwartz, 2000). 
The human growth hormone receptor (hGHR) is also targeted for ligand-independent, 
constitutive degradation and this degradation was blocked by the proteasomal degradation 
inhibitor MG132 (Mitchell et al., 2004). Indeed, the ratio of ubiquitinated hGHR to non-
ubiquitinated hGHR in MG132 treated cells was low, so it is unlikely that direct ubiquitination of 
hGHR drives constitutive hGHR degradation (Mitchell et al., 2004).  
TβRI/II undergo CME and rab4 and rab11-dependent endosomal recycling back to the 
plasma membrane both in the presence and absence of ligand (Mitchell et al., 2004). Indeed, the 
rate of internalization of TβRI/II was similar with or without ligand stimulation. TβRI/II 
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internalized in the absence of ligand is constitutively recycled, while TβRI/II internalized in the 
presence of ligand can be further sorted for degradation (Mitchell et al., 2004).  
Constitutive degradation of EGFR was demonstrated to rely on interaction with HRS 
protein of ESCRT-0 (Katz et al., 2002). Indeed, EGFR was polyubiquitinated and colocalized 
with HRS positive endosomes and the UIM of HRS was shown to be capable of interacting with 
polyubiquitinated proteins (Katz et al., 2002). The UIM of HRS was shown to recruit the E3 
ubiquitin ligase NEDD4, that resulted in the ubiquitination of HRS and this ubiquitination 
inhibited constitutive EGFR degradation (Katz et al., 2002). Indeed, blocking HRS 
ubiquitination promoted constitutive EGFR degradation (Katz et al., 2002).  The related receptor 
ErbB3 is constitutively internalized in the absence of ligand in a clathrin dependent manner, 
independent of ErbB3 phosphorylation state (Sak et al., 2012).  
 Interestingly, benzoquinone ansamycins class drugs such as geldanamycin, herbimycin A 
and their derivatives induce ligand-independent proteasomal degradation of a number of trans-
membrane proteins including EGFR and ErbB2 (Blagosklonny, 2002; Lipkowitz, 2003; 
Mimnaugh et al., 1996; Neckers, 2002; Sepp-Lorenzino et al., 1995; Tikhomirov and Carpenter, 
2000). Proteasomal degradation induced by benzoquinone ansamycins is independent of the 
kinase activity of the receptor (Citri et al., 2002; Xu et al., 2001), whereas lysosomal degradation 
requires kinase activity to generate phospho-tyrosine residues on the receptor to facilitate Cbl E3 
ubiquitin ligase binding, ubiquitination and subsequent trafficking through the endosomal system 
(Levkowitz et al., 1999). Benzoquinone ansamycins target chaperone proteins including Hsp90 
and Grp94 which stabilize RTKs (Blagosklonny, 2002; Neckers, 2002), causing the chaperone to 
adopt an alternate conformation which is indicative of protein instability (Blagosklonny, 2002; 
Neckers, 2002). The proteins interacting with the chaperone are ubiquitinated and degraded by 
the proteasome (Blagosklonny, 2002; Lipkowitz, 2003; Mimnaugh et al., 1996; Neckers, 2002; 
Tikhomirov and Carpenter, 2000; Xu et al., 2001). 
  
1.2.4 Summary of endocytosis 
 The signaling of activated RTKs is modulated by endocytosis and RTKs are internalized 
via several mechanisms. The classical and best-studied mechanism is internalization via clathrin 
coated pits. Numerous endocytic adaptor proteins, such as AP-2, interact with the plasma 
membrane and transmembrane cargo forming a scaffold for the assembly of the clathrin coat. 
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During maturation into a CCP, the clathrin lattice and underlying plasma membrane obtain 
inward curvature. Once mature, the vesicle absconds from the plasma membrane by the actions 
of dynamin and the actin cytoskeleton and the vesicle is trafficked to the early endosome in a 
Rab5 dependent manner (Figure 1.6). While CME is the predominant mechanism of 
internalization of RTKs, several examples of internalization by NCE mechanisms such as 
caveolar endocytosis and macropinocytosis have been discovered (Figure 1.5). Caveolar 
endocytosis involves internalization of cargo in vesicles coated with caveolin-1. Studies of 
mechanisms regulating vesicle formation and scission are limited; however, the activity of Rho 
family GTPases, dynamin-II and the actin cytoskeleton have been implicated in caveolar 
endocytosis (Figure 1.5). Macropinocytosis involves internalization of large portions of plasma 
membrane and extracellular fluid. Modulation of the actin cytoskeleton creates protrusions, or 
ruffles, of plasma membrane that fold back onto themselves, other ruffles or fold onto un-ruffled 
sections of the plasma membrane to generate internalized vesicles called macropinosomes. The 
formation of macropinosomes is independent of the activity of dynamin-II but requires the 
activity of Rho family GTPases, particularly Rac-1 (Figure 1.5). Both caveolar endocytosis and 
macropinocytosis are dependent upon the presence of cholesterol in the plasma membrane for 
activity (Figure 1.5). 
 Trafficking of internalized vesicles throughout the endosomal system is regulated by the 
GTP bound state of Rab proteins. Internalized vesicles are trafficked to the early endosome via 
Rab5. The presence of activated Rab5 on the membranes of the incoming vesicle and the 
endosome serve as binding sites for a number of effector proteins, including the tether EEA1 
which docks the vesicle with the endosome and initiates SNARE mediated vesicle fusion. From 
the early endosome internalized activated receptors can either be deactivated and recycled back 
to the plasma membrane via Rab4, or ubiquitinated and incorporated into MVEs and then 
trafficked to the lysosome via Rab7 for degradation (Figure 1.6). 
 Ubiquitination of receptors is mediated by E3 ubiquitin ligases that form an isopeptide 
bond between ubiquitin and surface exposed lysine residues on the target protein. 
Monoubiquitination of receptors targets them for incorporation into MVEs (Figure 1.6). 
Components of the ESCRT machinery, like Tsg101, recognize ubiquitinated cargo via several 
ubiquitin binding domains. The ESCRT machinery concentrates ubiquitinated cargo to the site of 
MVE formation on the late endosome. The endosomal membrane obtains inverse curvature and 
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buds off into the lumen of the endosome via the concerted actions of Vps32 and Vps4. Cargo is 
de-ubiquitinated prior to inclusion in MVEs. MVEs are trafficked to the lysosome in a Rab7 
dependent manner. The late endosome undergoes heterotypic fusion with the lysosome 
generating a hybrid organelle where MVEs and their cargo are degraded (Figure 1.6). 
Conjugation of polyubiquitin chains to substrates targets that substrate to the 26S proteasome for 
degradation. Although lysosomal degradation is the classical and accepted mechanism of RTK 
degradation, several lines of evidence point to a role for the proteasome. 
 
1.3 Ankyrin proteins 
Ankyrin proteins tether cytosolic domains of integral plasma membrane proteins to the 
cytoskeleton providing shape, structural support, and polarity to the cell (Bennett and Baines, 
2001). Three different ankyrin genes have been discovered ANK1, ANK2 and ANK3 that encode 
ankyrin1, ankyrin2 and ankyrin3, respectively (Bennett and Healy, 2008). Each ANK gene is 
expressed as several isoforms due to alternative splicing (Bennett and Healy, 2008) (Figure 1.7). 
Ankyrin proteins share common domain architecture including an N-terminal integral membrane 
protein binding domain consisting of 24 ankyrin repeat sequences, a central spectrin/fodrin 
binding domain, a death domain and a C-terminal regulatory domain (Bennett and Healy, 2008) 
(Figure 1.7).  
The N-terminal integral membrane protein binding domain and the death domain are 
highly conserved throughout the different ankyrin isoforms sharing 83% and 89% homology, 
respectively (Bennett and Healy, 2008). The spectrin binding domain and the regulatory domain 
are more variable sharing 78% and 53% homology, respectively (Bennett and Healy, 2008). 
Repeat sequences in the N-terminal domain mediate binding with numerous integral membrane 
proteins including cell adhesion molecules (such as L1CAMS, CD44  and E-Cadherin), ion 
channels (such as the anion exchanger, Na+/K+ ATPase, voltage-gated Na+ channels, Na+/Ca2+ 
exchanger, KCNQ2/3, Rh antigen, IP3 receptor and the ryanodine receptor) and other 
membrane-associated molecules (clathrin and tubulin) (Bennett and Healy, 2008).  
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Figure 1.7: Domain architecture and isoforms of ankyrin3 
A graphical representation of the general domain structure of ankyrin proteins and the different 
isoforms generated by alternative splicing of the ankyrin3 gene. All ankyrin proteins have the 
same common domain architecture consisting of an integral membrane protein binding domain 
(membrane) for interaction with numerous transmembrane proteins, a spectrin binding domain 
(spectrin) to facilitate interaction with the cytoskeleton, a death domain and a regulatory domain. 
Alternative splicing of the ANK3 gene results in expression of several isoforms of varying 
molecular weight, including two gene products lacking the integral membrane protein binding 
domain and possessing 6 unique N-terminal residues. 
 
The spectrin binding domain interacts with several isoforms of spectrin to link 
transmembrane proteins to the cytoskeleton (Bennett and Baines, 2001). The spectrin binding 
domain contains a 160 amino acid ZU5 motif which mediates interaction with spectrin (Mohler 
et al., 2004b). Mutation of conserved residues DAR999/1001 to alanine or A1024 to proline in 
ankyrin3 is sufficient to prevent spectrin binding (Kizhatil et al., 2007b). The role of the Death 
domain in ankyrin function is unknown; however it has been shown to bind Fas Ligand (FasL) 
(Bennett and Healy, 2008). The Regulatory domain has been show to bind Heat shock protein 40 
kDa (Hsp40) and obscurin (Bennett and Healy, 2008).  
Ankyrin proteins organize and cluster integral plasma membrane protein constituents into 
functional domains and disruption of ankyrin function is detrimental to cell physiology (Bennett 
and Healy, 2008). Ankyrin1 is expressed in human erythrocytes and provides structural support 
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allowing for the characteristic donut-like morphology of red blood cells (Bennett and Healy, 
2008). Defects in ankyrin1 are linked to hereditary spherocytosis where red blood cells assume a 
spherical morphology and are more prone to osmotic lysis and physical degradation as they pass 
through the vasculature, resulting in hemolytic anemia (Birkenmeier and Barker, 2004; 
Birkenmeier et al., 2003; Gallagher, 2005).  
Ankyrin2 is expressed in neural and cardiac tissues and links various transporters and 
adhesion molecules to the spectrin cytoskeleton (Bennett and Baines, 2001). While ankyrin2 
knockout mice die at birth, heterozygous mice suffer from defects in cardiac conduction, heart 
rate variability, sinus bradycardia and sudden death (Mohler and Bennett, 2005). In humans, loss 
of function mutation of ankyrin2 mapped to inherited type-4 long-QT cardiac arrhythmia, termed 
ankyrin-B syndrome (Mohler et al., 2007; Mohler et al., 2003).   
Ankyrin3 is widely expressed with highest expression levels in gut and kidney epithelium 
(Peters et al., 1995). Ankyrin3 is required for localization of voltage-gated sodium channels and 
L1CAM cell adhesion molecules at initial segments in Purkinje neurons (Jenkins and Bennett, 
2001), for both biogenesis (Kizhatil et al., 2007b) and maintenance (Kizhatil et al., 2007a) of 
lateral membranes in epithelial cells and is required for localization of photoreceptors in 
metazoans (Kizhatil et al., 2009).  
Interestingly, the cancer cell line encyclopedia (CCLE) showed that mRNA expression of 
the ANK3 gene is frequently deregulated in numerous cancer cell lines including those derived 
from tumors of the central nervous system, breast, kidney and stomach tissues 
(http://www.broadinstitute.org/ccle/home) (Barretina et al., 2012). Indeed, downregulation of 
ANK3 expression is frequently accompanied by overexpression of pro-oncogenic RTKs, while 
upregulation of ANK3 expression is accompanied by attenuated RTK expression.  In cancer cell 
lines derived from tumors of the central nervous system, including several glioblastomas 
attenuation of ANK3 expression frequently demonstrate upregulation of PDGFRa, PDGFRb and 
fibroblast growth factor receptor (FGFR) expression (U118MG, LN215, LNZ308, GB1, 
IOMMLEE, U138MG, U178, CCFSTTG1 and LN235 cells). Indeed, cancer cell lines derived 
from tumor of the central nervous system that demonstrated upregulation of ANK3 expression 
display downregulated expression of PDGFRa, PDGFRb and FGFR (SF767 and D283MED 
cells). In breast cancer cell lines, like central nervous system cancer cell lines, that display 
attenuated ANK3 expression also frequently demonstrate upregulated PDGFRa, PDGFRb and 
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FGFR expression (HS606T, MDAMB157, BT549, HS343T, HS742T, HS739T and HS579T). 
Breast cancer cell lines with upregulated expression of ANK3 frequently display attenuated 
expression of PDGFRa, PDGFRb and FGFR (HCC1428, YMB1, BT474, MDAMB415, 
HCC1419, BT483, EFM192A, MCF7, ZR7530, MDAMB175VII, AU565, SKBR3, 
MDAMB468 and HCC2157 cells). In the majority of kidney cancer cell lines, ANK3 expression 
is downregulated and these cell lines also demonstrate high expression of PDGFRb, FGFR and 
EGFR (UOK101, SLR24, VMRCRZ, SLR26, SLR23, UMRC6, HK2 and KMRC2 cells). In 
stomach cancer cell lines with downregulated ANK3 expression, the expression of PDGFRa and 
FGFR is frequently up regulated (ECC12, FU97, SNU1, SH10TC, LMSU, ECC10 and AZ521 
cells). Conversely, in stomach cancer cell lines with upregulated ANK3 expression PDGFRa and 
FGFR expression is frequently attenuated (RERFGC1B, HS764T, SNU16, MKN45, SNU520, 
TGCB11TKB, NUGC2, 2313287 and SNU216 cells). Additionally, downregulation of the ANK3 
gene was recently identified as part of an 11 gene signature, a prognostic indicator of metastasis 
and poor clinical outcome in multiple human cancers (Glinsky et al., 2005). Taken together, the 
expression data of ANK3 along with the reciprocal expression of pro-oncogenic RTKs in 
multiple cancer cell lines of different lineage suggests that ankyrin3 has a tumor suppressive role 
within the cell.  
 Previous studies from our laboratory implemented a phage display library to discover 
novel binding partners of the regulatory subunit of PI3K, p85 (King et al., 2000). Our laboratory 
has discovered a direct, phospho-tyrosine independent interaction between the SH2 domain of 
p85 and the 105 kDa isoform of ankyrin3 (Ignatiuk et al., 2006). Ankyrin3 is expressed as 
multiple isoforms (215, 200, 170 120, 105 kDa) due to two alternative transcriptional initiation 
sites within the ANK3 gene and alternative splicing (Peters et al., 1995) (Figure 1.7). The large 
isoforms of ankyrin3 differ from one another by the presence or absence of amino acid inserts A, 
B and C (Figure 1.7). The small isoforms (120, 105 kDa) of ankyrin3 are distinguished by the 
presence of 15 kDa insert C within the regulatory domain and also possess six unique N-terminal 
amino acids not present in large isoforms (Peters et al., 1995) (Figure 1.7).  The large isoforms of 
ankyrin3 are localized to the plasma membrane whereas small isoforms lacking the N-terminal 
repeat sequences responsible for integral membrane protein binding are localized to late 
endosomes/lysosomes (Hoock et al., 1997). Reciprocal interaction between Ank105 and p85 was 
confirmed via co-immunoprecipitation studies (Ignatiuk et al., 2006). Pulldown analysis using 
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purified proteins indicated that Ank105 bound the SH2 domains of p85 using both the spectrin 
binding domain and the regulatory domain (Ignatiuk et al., 2006).  
Overexpression of Ank105 prompted PDGFR inactivation and degradation in response to 
PDGF stimulation and attenuated the ability of fibroblasts to proliferate in the presence of PDGF 
(Ignatiuk et al., 2006). Ank105 overexpression attenuated the activation of PDGFR in response 
to PDGF stimulation, as evident by reduced phosphorylation of the receptor (Ignatiuk et al., 
2006). Indeed activation of downstream MAPK and PLC signaling pathways were also reduced 
(Ignatiuk et al., 2006). Co-immunofluorescence experiments showed colocalization between 
Ank105, p85, and PDGFR during endocytosis (Ignatiuk et al., 2006). Furthermore, Ank105 
colocalized with LAMP-1 but not with EEA1 (Ignatiuk et al., 2006). Treatment of cells with the 
lysosomal degradation inhibitor chloroquine prevented PDGFR degradation in response to ligand 
(Ignatiuk et al., 2006). These observations indicate that Ank105 enhances the degradation of the 
PDGFR and attenuates signaling pathways downstream of the receptor.  
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2.0 RATIONALE AND OBJECTIVES 
 
2.1 Hypothesis 
 Ank105 promotes the constitutive degradation of the PDGFR and attenuation of PDGFR 
signaling by facilitating endocytosis of the PDGFR and targeting the PDGFR for lysosomal 
degradation via an ubiquitin-dependent mechanism. 
 
2.2 Objectives 
 The objective of the thesis work was to determine the mechanistic requirements for 
Ank105-mediated constitutive PDGFR degradation. The effects of Ank105 expression on 
PDGFR expression and signaling were determined. PDGFR endocytosis in Ank105-expressing 
cells was characterized with small molecule inhibitors and RNA interference targeting proteins 
involved in endocytosis to evaluate the mechanism of Ank105-mediated constitutive PDGFR 
degradation. Additionally, to determine the requirements of known Ank105 binding partners for 
constitutive PDGFR degradation, Ank105 binding partners were targeted for knockdown via 
RNA interference. 
 
2.3 Specific objectives 
1. To characterize the effects of Ank105 expression on PDGFR expression levels, 
activation and downstream signaling, as well as to determine whether Ank105 expression alters 
the phosphorylation or ubiquitination of the PDGFR. The effects of Ank105 expression on the 
EGFR were also examined. 
2. To determine if Ank105 interacts with ubiquitin and ubiquitinated proteins and 
determine the region of Ank105 responsible for ubiquitin binding. Point mutations and deletion 
mutations were made to generate a mutant of Ank105 unable to interact with ubiquitin 
3. To determine the pathway of endocytosis required for Ank105-mediated constitutive 
degradation using a panel of small molecule inhibitors. The effects of the small molecule 
inhibitors on constitutive PDGFR degradation was compared to ligand induced PDGFR 
degradation and LDL uptake. The effects of knockdown of key proteins involved in endocytosis 
on constitutive PDGFR expression were determined via RNA interference. 
4. To determine the effects of knockdown of known Ank105 binding partners on 
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constitutive PDGFR expression via RNA interference and to identify novel binding partners of 
Ank105. 
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3.0 MATERIALS AND METHODS 
 
3.1 Materials 
 
3.1.1 Reagents and Supplies 
All chemicals were of analytical grade or higher and purchased from VWR, Sigma 
Aldrich, Invitrogen, Qiagen or Fisher Scientific unless otherwise stated. Antibodies were 
purchased from Santa Cruz Biotechnology, Cell Signaling Technology or LI-COR biosciences 
unless stated otherwise.  
 
3.2 Methods 
 
3.2.1 Molecular biology 
 All standard molecular biology protocols, such as restriction digestion, ligation and 
transformation of competent cells were performed as per Current Protocols in Molecular Biology 
(Ausubel et al., 2007) and Current Protocols in Protein Science (Coligan et al., 2007). All 
primers were obtained from Invitrogen. 
 
3.2.1.1 Generation of GST-tagged ubiquitin fusion plasmid 
 Ubiquitin-GST plasmid was provided generously by Stefan Jentsch (Max Planck Institute 
of Biochemistry, Munich, Germany). The isopropyl β-D-1-thiogalactopyranoside (IPTG) 
inducible bacterial expression vector pGEX6P1 (Amersham Pharmacia) is the backbone of the 
Ubiquitin-GST plasmid.  
 
3.2.1.2 Generation of HA-tagged Ank105 fusion plasmid   
 Ankyrin3 cDNA was provided generously by Samuel Lux (Dana Farber Cancer Institute, 
Boston, MA). The 105 kDA isoform of Ankyrin3 was assembled by PCR from full length 
Ankyrin3 cDNA (Ignatiuk et al., 2006). The mammalian expression vector pRc/CMV2 
(Invitrogen) was modified by the addition of three copies of the hemagluttinin (HA) epitope 
(YPYDVPDYA) upstream of the multiple cloning site (pHA3), encoding HA3-tagged fusion 
proteins (King et al., 2000).  Ank105 DNA was inserted in the pHA3 vector multiple cloning site 
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generating an N-terminal pHA3-Ank105 fusion plasmid (Ignatiuk et al., 2006) (Figure 3.1). 
 
 
Figure 3.1: Map of pHA3-Ank105 mammalian expression plasmid                      
Ank105 DNA containing 5´ BglII and 3´EcoRI restriction sites was inserted in the multiple 
cloning site of the pHA3 vector, generating a pHA3-Ank105 fusion plasmid. Mammalian 
expression is controlled by a CMV promoter and contains a bovine growth hormone (BGH) 
polyadenylation signal for optimal mRNA production. The vector also contains a neomycin 
resistance gene and an ampicillin resistance gene for mammalian and bacterial selection, 
respectively. Figure modified from the Invitrogen online resource website. 
(http://tools.invitrogen.com/content/sfs/manuals/prccmv 2_man.pdf) 
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3.2.1.3 Generation of HA-Ank105 mutant plasmids  
 
3.2.1.3.1 Generation of C-terminal Ank105 deletion plasmids 
 C-terminal residues of Ank105 were deleted in 50 amino acid increments via polymerase 
chain reaction (PCR) to remove a potential ubiquitin interaction motif between residues 816 to 
832 (Figure 4.5). Various amounts of pHA3-Ank105 DNA were incubated with 5´Ank105-
MALPS primer and the 3´ Ank105-ΔC primers (Table 3.1) along with other components required 
for the PCR (Table 3.2A). PCR was performed using PFU DNA polymerase (New England 
Biolabs) according to described PCR program (Table 3.2B). Successful reactions amplifying 
products of correct size were pooled and subjected to PCR clean up kit (Qiagen) using 
manufactures instructions. PCR products and empty pHA3 were each restricted with BglII (New 
England Biolabs) and EcoRI (New England Biolabs) to create appropriate DNA sticky ends. 
Restricted PCR products were cleaned up as described above and ligated into restricted pHA3 
vector using Quick Ligation Kit (New England Biolabs) according to manufacturer’s protocols 
and transformed into competent Escherichia coli (E. coli) TOP10 cells (Invitrogen). Single 
colonies of E. coli transformed with each Ank105 deletion plasmid were obtained via culture on 
Luria-Bertani (LB) broth (Sigma Aldrich) agar (Sigma Aldrich) (25mL) plates containing 
ampicillin (100 µg/mL) (Sigma Aldrich) at 37 °C overnight.  E. coli cells were then inoculated 
into LB broth (250 mL) containing ampicillin (100 µg/mL) and cultured overnight at 37 °C. 
Plasmid DNA for each was purified by Maxiprep Kit (Qiagen) according to manufacturer’s 
instruction. Plasmid inserts were verified via DNA sequencing. 
 
3.2.1.3.2 Generation of spectrin binding domain and regulatory domain plasmids 
 The spectrin binding and regulatory domains of Ank105 were generated via PCR prior to 
commencement of thesis studies (Ignatiuk et al., 2006). 
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Table 3.1: Ank105 mutagenesis primers 
List of primers used to generate deletion mutations and point mutations of Ank105. Primers are 
grouped and color coded based on type of mutation desired. BglII (AGA TCT) and EcoRI (GAA 
TTC) restriction sites are underlined. Primer nucleotides generating point mutations in Ank105 
are bolded. All primers were obtained from Invitrogen. 
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Table 3.2: PCR conditions for generation of C-terminal Ank105 deletion plasmids                                                                                                                                      
A. Concentration and volumes of each component of the PCR used to generate C-terminal 
Ank105 deletion fragments. B. PCR program used to generate C-terminal Ank105 deletion 
fragments. 
 
 
3.2.1.3.3 Generation of C-terminal spectrin domain deletion plasmids 
 C-terminal residues of Ank105 spectrin binding domain were incrementally deleted via 
PCR to identify the region of Ank105 mediating ubiquitin binding (Figure 4.7). Purified pHA3-
Ank105 DNA was incubated with 5´Ank105-MALPS primer and each of the 3´Ank105-SpecΔC 
primers (Table 3.1), along with other components required for the PCR (Table 3.3A). PCR was 
performed using PFU DNA polymerase according to described PCR program (Table 3.3B). A 
gradient PCR machine was used to perform the primer-DNA binding step of the PCR at several 
temperatures, allowing a large number of reactions with different primers to be carried out at the 
same time. Successful reactions amplifying products of correct size were pooled and subjected to 
PCR clean up kit) using manufactures instructions. PCR products and empty pHA3 were each 
restricted with BglII and EcoRI to create appropriate DNA sticky ends. Restricted PCR products 
were cleaned up as described above and ligated into restricted pHA3 vector using Quick Ligation 
Kit according to manufacturer’s protocols and transformed into competent E. coli TOP10 cells. 
Single colonies of E. coli transformed with each Ank105C-terminal spectrin domain deletion 
plasmid were obtained via culture on LB-agar (25mL) plates containing ampicillin (100 µg/mL) 
at 37 °C overnight.  E. coli cells were then inoculated into LB broth (250 mL) containing 
ampicillin (100 µg/mL) and cultured overnight at 37 °C. Plasmid DNA for each deletion was 
purified by Maxiprep Kit according to manufacturer’s instruction. Plasmid inserts were verified 
via DNA sequencing. 
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Table 3.3: PCR conditions for generation of C-terminal Ank105 spectrin binding domain 
deletion plasmids 
A. Concentration and volumes of each component of the PCR used to generate C-terminal 
Ank105 deletion fragments. B. PCR program used to generate C-terminal Ank105 deletion 
fragments. Gradient PCR machine used to perform primer-DNA binding step at a series of 
different temperatures. 
 
 
3.2.1.3.4 Generation of N-terminal Ank105 disordered region deletion plasmids 
Disordered regions of Ank105 were identified using the Russel-Linding Globprot2.3 
Software (Figure 4.7). N-terminal Ank105 deletion mutants were generated from disordered 
regions identified in the spectrin binding domain (Figure 4.8). Purified pHA3-Ank105 DNA was 
incubated with each of the 5´Ank105-ΔN primers (Table 3.1) and the 3´Ank105 primer, along 
with other components required for the PCR (Table 3.4A). The PCR was performed using KOD 
DNA polymerase (EMD Millipore) according to described PCR program (Table 3.4B). 
Successful reactions amplifying products of correct size were pooled and subjected to PCR clean 
up kit) using manufactures instructions. PCR products and empty pHA3 were each restricted with 
BglII and EcoRI to create appropriate DNA sticky ends. Restricted PCR products were cleaned 
up as described above and ligated into restricted pHA3 vector using Quick Ligation Kit according 
to manufacturer’s protocols and transformed into competent E. coli TOP10 cells. Single colonies 
of E. coli transformed with each pHA3-Ank105 N-terminal disordered region deletion plasmid 
were obtained via culture on LB-agar (25mL) plates containing ampicillin (100 µg/mL) at 37 °C 
overnight.  E. coli cells were then inoculated into LB broth (250 mL) containing ampicillin (100 
µg/mL) and cultured overnight at 37 °C. Plasmid DNA for each deletion was purified by 
Maxiprep Kit according to manufacturer’s instruction. Plasmid inserts were verified via DNA 
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sequencing. 
 
Table 3.4: PCR conditions for generation of N-terminal Ank105 deletion plasmids 
A. Concentration and volumes of each component of the PCR used to generate N-terminal 
Ank105 deletion fragments. B. PCR program used to generate N-terminal Ank105 deletion 
fragments. Gradient PCR machine used to perform primer-DNA binding step at a series of 
different temperatures. 
 
 
3.2.1.3.5 Site-directed mutagenesis of potential Ank105 ubiquitin interaction motif 
 To disrupt the ubiquitin binding function of a potential UIM within the C-terminal 
regulatory domain of Ank105 a conserved serine residue, essential for UIM function, was 
mutated to aspartic acid (Figure 4.5). This mutation was shown previously to disrupt UIM-
ubiquitin interaction (Fujiwara et al., 2004). Purified pHA3-Ank105 DNA was incubated with 
5´Ank105-S827D and 3´Ank105-S827D primers (Table 3.1), along with other components 
required for the PCR (Table 3.5A). PCR products were restricted with Dpn1 (New England 
Biolabs) according to manufacturer’s instruction to degrade remaining wild type template and 
then transformed into competent TOP10 E. coli cells. Single colonies of E. coli transformed with 
each pHA3-Ank105 UIM mutant plasmid were obtained via culture on LB-agar (25mL) plates 
containing ampicillin (100 µg/mL) at 37 °C overnight.  E. coli cells were then inoculated into LB 
broth (250 mL) containing ampicillin (100 µg/mL) and cultured overnight at 37 °C. Plasmid 
DNA for each Ank105 UIM mutant plasmid was purified by Maxiprep Kit according to 
manufacturer’s instruction. Plasmid inserts were verified via DNA sequencing. 
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Table 3.5: PCR conditions for generation of Ank105 S827D mutant 
A. Concentration and volumes of each component of the PCR used to generate Ank105S827D 
mutant. B. PCR program used to generate Ank105S827D mutant. 
 
 
3.2.1.3.6 Site-directed mutagenesis of residues of Ank105 required for spectrin binding 
 To disrupt the ability of Ank105 to interact with spectrin, two separate mutations, 
DAR124-26/AAA and A149P, were generated via PCR within the spectrin binding domain of 
Ank105. These two mutations were shown previously to disrupt Ankyrin3-spectrin interaction 
(Kizhatil et al., 2007a; Kizhatil et al., 2007b). Purified pHA3-Ank105 DNA was incubated with 
5´Ank105-DAR124-26/AAA primer and 3´Ank105-DAR124-26/AAA primer (Table 3.1), along 
with other components required for the PCR (Table 3.6A) to generate the Ank105-DAR124-
26/AAA mutation. To generate the Ank105-A149P mutation purified pHA3-Ank105 DNA was 
incubated with 5´Ank105-A149P primer and 3´Ank105-A149P primer (Table 3.1), along with 
other components required for the PCR (Table 3.6B). Both PCRs were performed according to 
the described PCR program (Table 3.6C). A gradient PCR machine was used to perform the 
primer-DNA annealing step of the PCR at several temperatures, allowing a large number of 
reactions with different primers to be carried out at the same time. PCR products were restricted 
with Dpn1 according to manufacturer’s instruction to degrade remaining wild type template and 
then transformed into competent TOP10 E. coli. E. coli cells Single colonies of E. coli 
transformed with each Ank105 UIM mutant plasmid were obtained via culture on LB-agar 
(25mL) plates containing ampicillin (100 µg/mL) at 37 °C overnight.  E. coli cells were then 
inoculated into LB broth (250 mL) containing ampicillin (100 µg/mL) and cultured overnight at 
37 °C. Plasmid DNA for each Ank105 spectrin binding mutant plasmid was purified by 
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Maxiprep Kit according to manufacturer’s instruction. Each point mutation within the spectrin 
binding domain was verified by DNA sequencing. Additionally, the remaining sequence of 
Ank105 in the spectrin binding mutant plasmids was verified by DNA sequencing to confirm that 
no addition mutation were erroneously introduced. 
 
Table 3.6: PCR conditions for generation of Ank105 spectrin binding mutants 
A. Concentration and volumes of each component of the PCR used to generate Ank105DAR124-
26/AAA mutant. B. Concentration and volumes of each component of the PCR used to generate 
Ank105A149P mutant. C. PCR program used to generate Ank105DAR124-26/AAA and 
Ank105A149P mutants. Gradient PCR machine used to perform primer-DNA annealing step at a 
series of different temperatures. 
 
 
3.2.1.4 qRT-PCR screening of knockdown cell lines 
 HA-Ank105-expressing cells and stable knockdown cell lines (3.2.2.4) were screened via 
qRT-PCR to quantify extent of target knockdown. mRNA was extracted from a confluent 6 cm2 
plate of each knockdown cell line using the RNeasy mini kit (Qiagen) according to 
manufacturer’s instruction. cDNA was generated from isolated mRNA using the RT2 First Strand 
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Kit (Qiagen) according to manufacturer’s protocol. Relative expression levels of genes silenced 
by shRNA in each stable knockdown cell line were quantified and normalized to β-Actin 
expression. Taqman Gene Expression Master Mix (Invitrogen) was incubated with cDNA 
generated from each of the stable knockdown cell lines and the corresponding primer/probe sets 
(Table 3.7) and qRT-PCR was performed using the Step One Plus Real-Time PCR System 
(Applied Biosystems), using a carboxyfluorescein (FAM) reporter (Applied Biosystems) 
according to manufacturer’s protocol. 
 
Table 3.7: qRT-PCR primer list 
Tabulation of primer/probe sets used to determine expression levels in knockdown cell lines. 
 
 
3.2.2 – Cell culture 
 
3.2.2.1 General growth conditions 
 All cell lines utilized during studies were cultured in standard cell culture media (Table 
3.8) and incubated at 37 °C with 5% CO2 (v/v). Cell lines stably expressing HA-Ank105 were 
cultured in this standard cell culture media with the addition of geneticin (G418) (400 µg/mL) to 
maintain stable expression. HA-Ank105 expressing cells stably transduced with shRNA plasmids 
were cultured in standard cell culture media with the addition of G418 (400 µg/mL) and 
puromycin (2 µg/mL) to maintain stable expression. All cell lines were passaged using trypsin 
buffer (Table 3.8). Stocks of each cell line were generated by suspending cells in freezing media 
(Table 3.8) and placing them for long-term storage in liquid nitrogen. 
 
 
 
 
52 
Table 3.8: Common buffers 
Buffers used to perform experiments in thesis are listed as well as the concentration/amount of 
their respective components. The solvent for all buffers when not directly listed is distilled H2O.  
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3.2.2.2 Transient transfection of mammalian cell lines 
 For transient transfection of DNA plasmids in mammalian cell lines, cells were seeded at 
1/3 confluency and cultured overnight in standard cell culture media at 37°C and 5% CO2 (v/v). 
The next day transfection media was prepared. For each 10 cm2 plate of cells transfected, 3 µg of 
the DNA plasmid of interest and 36 µL of lipofectamine (Invitrogen) were aliquoted into 1.5 mL 
optimem (Gibco) and incubated at room temperature for 15 minutes. To the transfection media, 
4.5 ml of DMEM per plate was added. Cells were washed once with 5 mL serum-free DMEM 
and then aspirated. Cells were cultured with 6 mL transfection media for 5 hours at 37 °C and 
5% CO2. Transfection media was aspirated and replaced with standard cell culture media. Cells 
were cultured to confluency at 37 °C and 5% CO2. 
 
3.2.2.3 Stable transfection of mammalian cell lines 
 For stable transfection of DNA plasmids in mammalian cell lines the same transfection 
protocol was followed as for transient transfection (3.2.2.2). When cells reach confluency they 
were passaged sparsely, seeding density of 1:50, in standard cell culture media with the addition 
of selection reagent to selectively eliminate untransfected cells from the population. G418 (400 
µg/mL) was added to select for stable expression of plasmids conferring neomycin resistance 
whereas puromycin (2 µg/mL) was added to select for stable expression of plasmids conferring 
puromycin resistance. Cells were cultured until single colonies are visually identified with light 
microscopy. Individual colonies were isolated and seeded into 24 well plates. Cells were 
expanded in standard cell culture media with the appropriate selection reagent at 37 °C and 5% 
CO2. Once the clones were sufficiently expanded, liquid nitrogen stocks were generated. Lysates 
were harvested and evaluated for expression of gene of interest by Western blot. 
 
3.2.2.4 Lentiviral transduction of mammalian cell lines 
 Expression of several endocytosis related proteins was selectively knocked down via 
transduction of HA-Ank105-expressing cells with lentivirus packaged with a pool of three 
shRNA plasmids directed against each specific target (Santa Cruz Biotechnology) (Table 3.9). 
Lentivirus was used as a delivery system for shRNA plasmids to overcome the inherently low 
transient transfection efficiency of NIH 3T3 cell lines. High expression levels of shRNA 
plasmids were hypothesized to increase the chances of obtaining clones with a high degree of  
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Table 3.9: Sequences of shRNAs used for knockdown of mammalian gene expression 
Tabulation of hairpin sequences of shRNA plasmids used for knockdown of mammalian gene 
expression. The shRNA plasmids are tranduced via lentivirus. Each commercially available 
lentivirus targeting each gene of interest are pooled. All lentivirus-shRNAs are species specific to 
mus musculus and were purchased from Santa Cruz Biotechnology. Catalogue numbers of each 
pooled lentivirus is provided. Sequences of each hairpin in the pool are provided and color coded 
to the target gene of interest. 
 
knockdown of the target of interest. Indeed, transduction of NIH 3T3 cells with lentivirus 
packaged with a GFP-expressing plasmid (Santa Cruz Biotechnology) demonstrated the 
transduction efficiency to be greater than 95% (Figure 3.2). HA-Ank105-expressing cells were 
seeded at a density of 4.2x104 cells per well in 12 well dishes. HA-Ank105-expressing cells were 
transduced with lentivirus packaged with a pool of three shRNA plasmids directed against 
endocytosis-related proteins (one of: clathrin, caveolin, p85, tsg101, rab7, spectrin β-II and 
dynamin II) (Santa Cruz Biotechnology) as well as control scrambled shRNA plasmids (Santa 
Cruz Biotechnology) with no specific target. Lentiviral transduction of NIH 3T3 cells stably 
expressing HA-Ank105 was performed according to the manufacturer’s instruction 
(http://datasheets.scbt.com/shrna_lv_protocol.pdf). Sequences of small hairpin RNAs used to 
target mammalian gene expression are provided (Table 3.9). Single, stable knockdown clones 
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were isolated with culture in standard cell culture media with the addition of G418 (400 µg/mL; 
for stable expression of pHA3-Ank105 plasmid) and puromycin (2 µg/mL; for stable expression 
of shRNA plasmid) as previously described. 
 
 
Figure 3.2: Lentiviral transduction of GFP reporter in NIH 3T3 cells 
NIH 3T3 cells were transduced with lentivirus encoding a GFP reporter. Cells were visualized 24 
hours post transduction with both light and fluorescent microscopy. 
 
3.2.3 SDS-PAGE and Western blot analysis 
 
3.2.3.1 Sample preparation 
 When denaturing lysis conditions were desirable, as for Western blot of cellular lysate to 
determine protein expression levels, cells were lysed in SDS sample buffer (Table 3.8). Cells 
were scraped in 150 µL SDS sample buffer per 10 cm2 plate. Lysates were collected and heated 
at 95 °C for 5 minutes. Samples were sonicated to reduce viscosity. Prior to SDS-PAGE and 
Western blot analysis, samples were normalized to total cellular protein content using Total 
Protein Micro Lowry Kit, Peterson’s modification (Sigma Aldrich) according to the 
manufacturer’s instructions. 
 
When non-denaturing lysis conditions were desirable, as for pulldown experiments, cells 
were lysed in PLC lysis buffer (Table 3.8). Cells were scraped in150 µL PLC lysis buffer (Table 
3.8) per 10 cm2 plate. Samples were centrifuged at 7000 g to pellet the triton insoluble fraction of 
the cell lysate. Supernatant was aliquoted and stored and the pellet was discarded. After 
experimentation with these samples, samples were mixed 1:1 with SDS sample buffer and heated 
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at 95 °C for 5 minutes prior to resolution by SDS-PAGE. 
 
3.2.3.2 SDS-PAGE 
 Protein content of cellular lysates was resolved via SDS-PAGE. Resolving gels were 
composed of 7.5-15% acrylamide (Table 3.8) in SDS-PAGE lower gel buffer (Table 3.8). 
Resolving gels were polymerized with the addition of 0.06% (w/v) ammonium persulfate and 
0.1% (v/v) N,N,N´,N´-tetra-methylethylenediamine (TEMED). Stacking gels were composed of 
4.5% acrylamide in upper gel buffer (Table 3.8) and poured on top of the resolving gel. A loading 
comb was inserted to created loading wells. Stacking gels were polymerized as described for 
resolving gels. Gels were placed in Mini-Protean-3 System (Biorad). Mini-Protean-3 buffer tank 
was filled with SDS-PAGE running buffer (Table 3.8) Samples, prepared as described previously, 
were loaded into wells. Prestained or unstained protein ladder (Fermentas) was also loaded as a 
reference for molecular weight. Samples were resolved at 225 V until the bromophenol blue dye 
from SDS sample buffer ran off the bottom of the gel.  
 
3.2.3.3 Coomassie blue staining 
 To visualize the protein content of SDS-PAGE resolved samples gels were covered with 
Coomassie blue stain (Table 3.8) and incubated at room temperature for 30 minutes on a nutator 
to allow incorporation of stain. Stain was discarded and gels were incubated with destain (Table 
3.8) until protein bands were visible. Gels were imaged using the Gel Doc XR+ System (Biorad) 
and analyzed using Quantity One Software (Biorad). 
 
3.2.3.4 Western blot analysis 
 Following SDS-PAGE gels were placed in transfer buffer (Table 3.8) for 15 minutes. 
Proteins were then transferred from gels to a nitrocellulose membrane using a semi-dry OWL 
separation system (VWR) at 500 mA for 15 minutes per gel. Nitrocellulose membranes were 
then placed into blocking buffer (Table 3.8) for 1 hour at room temperature. Nitrocellulose 
membranes were then incubated with 5 mL primary antibody (Table 3.10) in blocking buffer for 
1 hour at room temperature. Nitrocellulose membranes were washed 3 times for 5 minutes with 
copious amounts of PBS (Table 3.8). Following washing, nitrocellulose membranes were  
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Table 3.10: Antibody list and concentrations 
Antibodies and their respective working concentrations are listed. Antibodies are grouped and 
color coded according to functionality. 
 
incubated with 5 mL of secondary antibody (Table 3.10) in blocking buffer for 1 hour at room 
temperature. Next they were washed 3 times for 5 minutes with 50-75 mL PBS. For secondary 
antibodies conjugated to horseradish peroxidase, membranes were incubated with HRP substrate 
kit (Biorad) according to manufacturer’s instruction and imaged with the Molecular Imager® Gel 
Doc™ XR+  (Biorad) and Quantity One Software. For secondary antibodies conjugated to an 
infrared tag, membranes were imaged using the Odyssey Infrared Imaging System (LI-COR 
Biosciences) and analyzed using Odyssey Infrared Imaging System Application Software V3.0 
(LI-COR Biosciences). 
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3.2.3.4.1 Western screening of stable knockdown cell lines 
 HA-Ank105-expressing stable knockdown cells that demonstrated extensive knockdown 
of target mRNA levels as indicated by qRT-PCR screening (3.1.2.4) were further screened by 
Western blot to confirm knockdown of target at the protein level. Lysates were generated from 
one 10 cm2 plate of each knock down cell lines, as well as Ank105 parental and scrambled 
shRNA controls, under denaturing conditions (3.2.3.1), normalized to total protein content 
(3.2.3.1) and resolved by SDS-PAGE (3.2.3.2). Gels were transferred to nitrocellulose and 
protein expression was analyzed via Western blot (3.2.3.4) with anti-PDGFRβ (958), anti-
GAPDH and target specific antibodies (Table 3.10). 
 
3.2.4 Ligand stimulation of HA-Ank105-expressing cells 
 
3.2.4.1 PDGF stimulation of HA-Ank105-expressing cells 
The effects of Ank105 expression on PDGFR levels and signaling in NIH 3T3 cells 
stably expressing HA-Ank105 (Figure 4.1) were determined. Cells were cultured overnight in hi 
glucose DMEM with the addition of 0.5% FBS at 37 °C and 5% CO2. Cells were either lest 
unstimulated, or stimulated for 30 minutes with PDGF (50 ng/mL) in serum free hi glucose 
DMEM (2 mL). Cells were placed on ice and stimulation media was aspirated. Cells were 
washed with cold PBS (5 mL). Cells were lysed under denaturing conditions in SDS sample 
buffer (3.2.3.1), normalized to total protein content (3.2.3.1), resolved by SDS-PAGE (3.2.3.2) 
and analyzed by Western blot (3.2.3.4) with indicated antibodies (Table 3.10) (Figure 4.1). 
 
3.2.4.2 EGF stimulation of HA-Ank105-expressing cells 
The effects of HA-Ank105 expression on EGFR levels and signaling in HEK293 and 
HeLa cells transiently transfected with HA-Ank105 were determined (Figure 4.2). HEK293 and 
HeLa cells were each transiently transfected with HA-Ank105 (3.2.2.2). When cell confluency 
reached approximately 80%, cells were cultured overnight in hi glucose DMEM with the 
addition of 0.5% FBS at 37 °C and 5% CO2. Cells were either left unstimulated, or stimulated for 
indicated times (Figure 4.2) with EGF (80 nM) in serum free hi glucose DMEM (2 mL). Cells 
were placed on ice and stimulation media was aspirated. Cells were washed with cold PBS (5 
mL). Cells were lysed under denaturing conditions in SDS sample buffer (3.2.3.1), normalized to 
59 
total protein content (3.2.3.1), resolved by SDS-PAGE (3.2.3.2) and analyzed by Western blot 
(3.2.3.4) with indicated antibodies (Table 3.10) (Figure 4.2). 
 
3.2.5 Immunoprecipitation Studies 
 
3.2.5.1 Immunoprecipitation of PDGFR from NIH 3T3 cells 
The PDGFR was immunoprecipitated to determine the effects of HA-Ank105 expression 
on receptor activation and ubiquitination (Figure 4.3). HA-Ank105-expressing cells were 
cultured in standard cell culture media at 37 °C and 5% CO2.  When cell confluency reached 
approximately 80%, cells were cultured overnight in hi glucose DMEM with the addition of 
0.5% FBS at 37 °C and 5% CO2. Cells were stimulated for 0, 10 or 30 minutes with PDGF (50 
ng/mL) in serum free hi glucose DMEM (2 mL). Cells were placed on ice and stimulation media 
was aspirated. Cells were washed with cold PBS (5 mL). Lysates of HA-Ank105-expressing 
cells were generated under non-denaturing conditions in PLC lysis buffer (3.2.3.1) with protease 
inhibitor cocktail (1 tablet per 50 mL) (Roche) and normalized to total protein content (3.2.3.1). 
Lysate (1 mg) was pre-cleared with rabbit IgG conjugated to agarose (Table 3.10) (10 µg) with 
the addition of protein A Sepharose beads (30 µL) (Sigma Aldrich) to immunoprecipitate 
proteins that non-specifically interact with IgG and beads. Lysates were nutated for 1 hour at 
4 °C. Beads were pelleted by centrifugation and supernatant was saved for subsequent 
immunoprecipitations. To immunoprecipitate PDGFR, anti-PDGFR (958) antibody (10 µg) 
(Table 3.9) and protein A agarose beads (30 µL) were added to the supernatant. Samples were 
nutated at 4 °C for 90 minutes. Beads were pelleted by centrifugation and supernatant was 
aspirated. Beads were washed three times with HNTG wash buffer (1 mL) (Table 3.9). 
Immunoprecipitants were denatured (3.2.3.1), resolved by SDS-PAGE (3.2.3.2) and analyzed by 
Western blot (3.2.3.4) with indicated antibodies (Table 3.9) (Figure 4.3). 
 
3.2.5.2 Immunoprecipitation of HA-Ank105 from NIH 3T3 cells 
 To determine if Ank105 interacts with ubiquitinated proteins, Ank105 was 
immunoprecipitated from HA-Ank105 stable cell lines and immunoprecipitants were analyzed 
for ubiquitinated proteins which co-immunoprecipitate with HA-Ank105 (Figure 4.4). HA-
Ank105-expressing cells were cultured in standard cell culture media at 37 °C and 5% CO2.  
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When cell confluency reach approximately 80%, cells were cultured overnight in hi glucose 
DMEM with the addition of 0.5% FBS at 37 °C and 5% CO2. Cells were stimulated for 0, 3, 5 or 
10 minutes with PDGF (50 ng/mL) in serum free hi glucose DMEM (2 mL). Cells were placed 
on ice and stimulation media was aspirated. Cells were washed with cold PBS (5 mL). Lysates of 
HA-Ank105-expressing cells were generated under non-denaturing conditions in PLC lysis 
buffer (3.2.3.1) with protease inhibitor cocktail (1 tablet per 50 mL). The three plates of lysate (1 
mL total volume) were subjected to immunoprecipitation. Lysate was pre-cleared with mouse 
IgG conjugated to agarose (Table 3.9) (10 µg) with the addition of protein A Sepharose beads (30 
µL) to immunoprecipitate proteins that non-specifically interact with IgG and beads. Lysates 
were nutated for 1 hour at 4 °C. Beads were pelleted by centrifugation and supernatant collected. 
To immunoprecipitate HA-Ank105, anti-HA (F7) antibody conjugated to agarose (10 µg) (Table 
3.9) and protein A Sepharose beads (30 µL) were added to the supernatant. Samples were nutated 
at 4 °C overnight. Beads were pelleted by centrifugation and supernatant was aspirated. Beads 
were washed three times with HNTG was buffer (1 mL) (Table 3.9). Immunoprecipitants were 
denatured (3.2.3.1), resolved by SDS-PAGE (3.2.3.2) and analyzed by Western blot (3.2.3.4) 
with indicated antibodies (Table 3.9) (Figure 4.4). As a control, the immunoprecipitation 
procedure was also performed on untransfected NIH 3T3 cells; no ubiquitinated protein co-
immunoprecipitated (data not shown). 
 
3.2.5.3 Immunoprecipitation of HA-Ank105 from HEK293 cells 
 As a preliminary step to mass spectrometry, HA-Ank105 was immunoprecipitated from 
transiently transfected HEK293 cells to determine if a viable amount of Ank105 binding partners 
could be isolated for further analysis (Figure 4.25). HEK293 cells were transiently transfected 
with HA-Ank105 (3.2.2.2). When cells reached confluency, lysates were generated under non-
denaturing conditions in PLC lysis buffer (3.2.3.1) with protease inhibitor cocktail (1 tablet per 
50 mL). Amendment to lysis protocol: cellular debris was not immediately pelleted to increase 
solubilization of lysate. Five plates of lysate (1 mL total volume) were subjected to 
immunoprecipitation. Lysate was pre-cleared with mouse IgG conjugated to agarose (Table 3.9) 
(10 µg) with the addition of protein A Sepharose beads (30 µL) to immunoprecipitate proteins 
that non-specifically interacted with IgG and beads. Lysates were nutated for 1 hour at 4 °C. 
Beads and cellular debris were pelleted by two rounds of centrifugation at 14 x g. To 
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immunoprecipitate HA-Ank105, anti-HA antibody conjugated to agarose (10 µg) (Table 3.9) and 
protein A Sepharose beads (30 µL) were added to the supernatant. Samples were nutated at 4 °C 
for 2 hours. Beads were pelleted by centrifugation and supernatant was aspirated. Beads were 
washed five times with IP wash buffer (1 mL) (Table 3.9). Immunoprecipitants were denatured 
(3.2.3.1), resolved by SDS-PAGE (3.2.3.2) and analyzed by sypro ruby stain (Invitrogen) 
according to manufacturer’s protocol. Sypro ruby stain is an effective alternative to Coomassie 
staining as it rapid, sensitive, low background, UV detectable stain and allows for the detection 
of low abundance proteins (Berggren et al., 2000). As a control an IP was performed with non-
specific mouse IgG conjugated to agarose (Table 3.9) (10 µg) with the addition of protein A 
Sepharose beads (30 µL). In this manner, only proteins which specifically immunoprecipitate 
with anti-HA (F7) antibody are considered as HA-Ank105 binding partners. 
 
3.2.6 Pulldown of HA-Ank105 with an ubiquitin-GST fusion protein 
  
3.2.6.1 Induction and purification of ubiquitin-GST fusion protein 
Ubiquitin-GST fusion plasmid (3.2.1.1), under the control of an IPTG inducible 
promoter, was transformed into competent BL21 E. coli (Novagen) and inoculated into 50 mL 
LB Broth containing ampicillin (100 µg/mL). Proteins containing GST without ubiquitin were 
also prepared similarly. Cultures were incubated overnight at 37 °C in a shaking incubator. 
Cultures were inoculated into LB broth (1 L) containing ampicillin (100 µg/mL) and incubated at 
37 °C until the culture reached an optical density (600 nm) of 0.6 then induced with IPTG (0.1 
mM) and incubated overnight at room temperature in a shaking incubator. Cells were divided 
into aliquots (100 mL) and pelleted by centrifugation at 4200 x g for 20 minutes at 4 °C. 
Supernatant was discarded. Cells were resuspended in PBS (10 mL) containing protease inhibitor 
cocktail (1 tablet per 50 mL) and lysozyme (1 mg/mL) (Sigma Aldrich) and incubated 1 hour at 
4 °C to facilitate cell lysis. Lysate was sonicated three times for 30 seconds at setting 3 using a 
Model 250/450 Sonifier (Branson Ultrasonics). Triton X-100 (1% v/v) was added to lysate to 
facilitate solubilization. The triton x-100 insoluble fraction was pelleted by centrifugation at 
12,000 x g for 30 minutes at 4 °C. Supernatant was passed through a 0.8 micron cellulose acetate 
membrane filter (Nalgene). Glutathione Sepharose beads (Amersham Biosciences) were 
prepared in PBS (50% v/v) according to manufacturer’s instructions. Glutathione Sepharose 
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slurry (1 mL) was added to filtered lysate and incubated for 1 hour at 4°C. Beads were pelleted 
by centrifugation at 800 x g for 5 minutes at 4 °C. Beads were washed 3 times with cold PBS (50 
mL). Beads were suspended in PBS (50% v/v) and stored at 4°C. A sample of the beads was 
prepared under denaturing conditions (3.2.3.1) and resolved by SDS-PAGE (3.2.3.2). Protein 
expression was examined and concentrations were approximated against bovine serum albumin 
(BSA) standards using Coomassie blue staining (3.2.3.3). 
 
3.2.6.2 Generation of HA-Ank105 COS-1 lysates 
 pHA3-Ank105 (3.2.1.2), pHA3-Ank105 C-terminal deletion plasmids (3.2.1.3.1), pHA3-
Ank105 UIM mutant (3.2.1.3.5), pHA3-Ank105 spectrin domain, pHA3-Ank105 regulatory 
domain (3.2.1.3.2), pHA3-Ank105 spectrin domain C-terminal deletion plasmids (3.2.1.3.3) and 
pHA3-Ank105 N-terminal deletion plasmids (3.2.1.3.4) were individually transiently transfected 
(3.2.2.2) in COS-1 cells. Lysates were prepared under non-denaturing conditions (3.2.3.1) and 
stored at -20 °C. A sample of each lysate was denatured in SDS sample buffer (3.2.3.1), resolved 
by SDS-PAGE (3.2.3.2) and analyzed by Western blot (3.2.3.4) with anti-HA (F7) antibody 
(Table 3.9) for expression of each protein. Lysates were normalized according to the lowest 
expressing protein by diluting lysates with lysate from untransfected COS-1 cells. 
 
3.2.6.3 Ubiquitin-GST pulldown  
 Pulldown experiments with ubiquitin-GST fusion protein (3.2.6.1) were performed with 
lysates expressing HA-Ank105 and various HA-Ank105 mutants (3.2.6.2) to assay ubiquitin 
binding and determine the region of Ank105 required for interaction with ubiquitin. Each of the 
normalized lysates (200 µL) were precleared with GST bound to glutathione Sepharose beads 
(100 µg) and glutathione Sepharose beads (30 µL) for 1 hour at 4 °C on a nutator to remove 
proteins from the lysate which non-specifically interact with GST or glutathione sepharose 
beads. Beads were pelleted by centrifugation at 14,000 x g for 10 min at 4 °C. Supernatant was 
collected and beads discarded. GST glutathione Sepharose beads (10 µg) or ubiquitin-GST 
glutathione Sepharose beads (10 µg) along with unbound glutathione Sepharose beads (30 µL) 
was added to each the normalized, precleared lysate (200 µL). Pulldowns were nutated at 4 °C 
for 90 minutes. Beads were pelleted by centrifugation at 5000 x g for 2 minutes at 4°C. 
Supernatant was aspirated and beads were washed 3 times with IP wash buffer (1 mL) (Table 
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3.8). SDS sample buffer was added to each pulldown (3.2.3.1) resolved by SDS-PAGE (3.2.3.2) 
and analyzed by Western blot (3.2.3.4) with anti-HA (F7) antibody (Table 3.9) to detect HA-
Ank105 proteins that interact with ubiquitin. 
 
3.2.7 Evaluation of endocytosis in HA-Ank105-expressing cells using small molecule 
inhibitors 
 
3.2.7.1 Inducible constitutive PDGFR degradation assay 
 An inducible assay was developed to study constitutive PDGFR degradation in HA-
Ank105-expressing cells (Figure 4.9). Constitutive degradation is the change in baseline PDGFR 
protein expression levels in the absence of ligand stimulation.  HA-Ank105-expressing cells 
were cultured hi glucose DMEM (at pH 7.2) containing 1% FBS over night at 37 °C and 5% CO2 
to increase constitutive PDGFR levels. Media was replaced with standard cell culture media and 
cells were incubated for 0, 30 60 120 and 240 minutes at 37 °C and 5% CO2 to induce 
constitutive PDGFR degradation. Lysate was generated under denaturing conditions (3.2.3.1) and 
normalized to total protein content (3.2.3.1). Lysates were resolved by SDS-PAGE (3.2.3.2) and 
analyzed by Western blot (3.2.3.4) with anti-PDGFR (958) and anti-GAPDH antibodies (Table 
3.9). 
    
3.2.7.2 Preparation of small molecule inhibitors 
 Each inhibitor was resuspended in either DMSO or water depending on solubility 
requirements (Table 3.11). Inhibitors were aliquoted and stored at -20 °C. A literature search 
revealed appropriate working concentrations of each of the inhibitors in the small molecule 
endocytosis inhibitor panel. For inhibitors preventing proper vesicle coat formation, pitstop 
concentrations from 10-30 µM have been demonstrated to inhibit CME (Dutta et al., 2012). A 
chlorpromazine concentration of 20 µM has also been demonstrated to significantly inhibit CME 
(Marina-Garcia et al., 2009). Acute treatment of cells with 10 mM MβCD has been demonstrated 
to deplete plasma membrane cholesterol (Rodal et al., 1999).  To inhibit vesicle internalization, a 
concentration of 80 µM of dynasore impaired dynamin activity (Macia et al., 2006b). To inhibit 
cdc42 activity, a concentration of 10 µM is typically used, with no off target cellular effects 
observed with concentrations up to 100 µM (Martin-Granados et al., 2012; Surviladze Z, 2010). 
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Rac-1 activity was previously shown to be significantly inhibited with a 50 µM concentration of  
 
Table 3.11: Small molecule inhibitors of endocytosis 
Table lists small molecule inhibitors used in endocytosis studies along with their respective 
targets, molecular weights (M.W.) (g/mol), solvents in which they are soluble, catalogue 
numbers and suppliers. Inhibitors with similar function, such as blocking internalization, are 
grouped together and color coded. 
 
NCS 23766 (Gao et al., 2004). For cytoskeletal inhibitors, latrunculin A concentrations from 
0.01-1 µM have been demonstrated to inhibit actin dynamics (Krucker et al., 2000). 
Jasplakinolide concentrations from 0.05 to 5 µM have been demonstrated to inhibit actin 
polymerization (Bubb et al., 2000; Wang et al., 2002). Microtubule polymerization was inhibited 
at a concentration of 30 µM of nocodazole (Ausubel et al., 2007). Working concentrations of 
monensin range from 10-50 µM and disrupted proton gradients and endocytosis (Chen et al., 
2009; Ippoliti et al., 1998). Macropinocytosis was inhibited by 100 µM 5-(N-Ethyl-N-isopropyl)
amiloride (EIPA) (Gold et al., 2010; Meier et al., 2002), however a lower concentration of 40 
µM have been demonstrated to inhibit sodium channels, the target of EIPA (Praetorius et al., 
2000). Inhibition of Src family kinases with 4-Amino-5-(4-chlorophenyl)-7-(t-
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butyl)pyrazolo[3,4-d]pyrimidine (PP2) has been demonstrated in the literature at a variety of 
concentrations. Inhibition of Src family kinase signaling generated from PDGFR signaling was 
accomplished at concentrations ranging from 10-50 µM (Yang et al., 2010), whereas inhibition 
of Src family kinases in endocytosis is often accomplished at lower concentrations of 0.01-10 
µM (Balzac et al., 2005; Singh et al., 2006; Sorkina et al., 2002). For the inhibition studies 
performed in the thesis, concentration range of PP2 between 12.5-50 µM was employed (Table 
3.12) Inhibition of PI3K signaling with wortmannin was accomplished with concentrations 
ranging from 0.1-5 µM (Clarke et al., 2001; Kjeken et al., 2001). To inhibit proteasomal 
degradation, concentrations of carbobenzoxy-Leu-Leu-leucinal (MG132) ranging between 1-10 
µM are employed (Amanso et al., 2011; Ortiz-Lazareno et al., 2008). Lysosomal degradation is 
inhibited via chloroquine with concentrations ranging between 2-100 µM (Ignatiuk et al., 2006; 
Karch et al., 2012; Verschooten et al., 2012). While, the high range of chloroquine is listed as 
50µM (Table 3.12) it was found that a concentration of 100 µM was most effective at inhibiting 
PDGFR degradation (Ignatiuk et al., 2006) and was used in LDL uptake (Figure 4.15), as well as 
constitutive (Figure 4.13) and ligand induced (Figure 4.17) PDGFR degradation studies. For 
each inhibitor used to study constitutive PDGFR endocytosis a range of concentrations were 
tested (Table 3.12). In the majority of cases the medium concentration of inhibitor was sufficient 
to observe the effect of the inhibitor and the medium concentration was used in subsequent 
experiments.  
 
3.2.7.3 Disruption of constitutive endocytosis with small molecule inhibitors 
To determine the effects of inhibition of endocytosis on constitutive PDGFR degradation 
in HA-Ank105-expressing cells, a range of concentrations of each inhibitor used (Table 3.12) 
(Figure 4.12; Figure 4.13). One 10 cm2 plate of HA-Ank105-expressing cells per inhibitor 
treatment was cultured in standard cell culture media at 37 °C and 5% CO2 to 80% confluency. 
Cells were then cultured in hi glucose DMEM containing 1% FBS over night at 37 °C and 5% 
CO2 to increase constitutive PDGFR levels. Cells were then incubated with DMEM containing 
low, medium or high concentrations of each inhibitor (Table 3.12) for 30 minutes at 37 °C and 
5% CO2. This media was replaced with DMEM containing 10% FBS in the presence of each  
Table 3.12: Working concentrations of small molecule inhibitors of endocytosis 
Table lists small molecule inhibitors used in endocytosis studies along with their respective stock 
and working concentrations. Inhibitors with similar function, such as blocking internalization, 
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are grouped together and color coded. 
 
 
respective inhibitor at low medium or high concentrations. Cells were incubated for 240 minutes 
at 37 °C and 5% CO2 to induce constitutive PDGFR degradation, as determined previously 
(3.2.7.1). Control conditions where HA-Ank105-expressing cells were not cultured in 1% FBS 
(but cultured in 10% FBS), and HA-Ank105-expressing cells that were cultured overnight in 
media containing 1% FBS but were not stimulated in media containing 10% FBS were generated 
to provide a baseline of PDGFR expression levels in constitutive and serum-restricted 
conditions, respectively. Lysate was generated under denaturing conditions (3.2.3.1) and 
normalized to total protein content (3.2.3.1). Lysates were resolved by SDS-PAGE, transferred to 
a nitrocellulose membrane (3.2.3.2), and analyzed by Western blot (3.2.3.4) with anti-PDGFR 
(958) and anti-GAPDH antibodies (Table 3.10). Relative expression was quantified using 
Odyssey Infrared Imaging System Application Software V3.0 (LI-COR Biosciences) and 
replicate experiments were averaged. Statistical significance was determined for each inhibitor 
after 240 minutes of FBS incubation compared to untreated HA-Ank105-expressing cells after 
240 minutes of FBS incubation by t-test (Microsoft Excel). 
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3.2.7.4 Optimization of Dil-LDL detection in HA-Ank105-expressing cells 
 In order to validate observations made on the effects of endocytosis inhibitors on 
constitutive PDGFR degradation in HA-Ank105-expressing cells the effects of these inhibitors 
were determined for the endocytosis of LDL. Uptake of LDL has been extensively characterized 
and proceeds by a clathrin and dynamin dependent mechanism and is trafficked to the lysosome 
(Luzio et al., 2007). LDL endocytosis was studied by quantifying uptake of LDL labeled with the 
lipophilic fluorescent dye dialkylcarbocyanine (Dil-LDL) (Invitrogen) in HA-Ank105-
expressing cells. The reported excitation/emission maxima for Dil-LDL are 554 nm and 571 nm, 
respectively (Invitrogen). 
The excitation and emission wavelengths used to detect Dil-LDL were optimized to 
facilitate Dil-LDL detection under experimental conditions and with available equipment. A 
range of concentrations of Dil-LDL (0, 10, 25, 50 and 100 µg/mL) were prepared in DMEM 
media and aliquoted into a standard 96 well cell culture plate (BD Falcon) (50 µL per well). Each 
concentration of Dil-LDL was tested with 4 replicate wells. Spectral excitation analysis was 
performed at a range of excitation wavelengths (530, 535, 540, 545, 550 and 555 nm) and a fixed 
emission (580 nm) wavelength with an emission cut off filter (570 nm) using a Spectramax M5 
Multi-mode Microplate Reader (Molecular Devices) (Figure 3.3A). The excitation wavelength of 
550 nm was chosen because it demonstrated the next highest level of fluorescence as compared 
to the reported excitation maxima, but with significantly less background (Figure 3.3A). Next a 
spectral emission analysis was performed. The excitation wavelength was fixed (550 nm) and 
fluorescence was measured at a range of emission wavelengths (570, 575, 580, 585, 590, 595 and 
600 nm) with an emission cut of filter at 570 nm (Figure 3.3B). An emission wavelength of 580 
nm was chosen because it demonstrated the highest fluorescence signal with low background 
signal (Figure 3.3B).  
The experimental excitation (550 nm) and emission (580 nm) wavelengths for Dil-LDL 
in DMEM media were used to determine the optimal concentration of Dil-LDL in HA-Ank105-
expressing cells. HA-Ank105-expressing cells were seeded into standard 96 well cell culture 
plates at a density of 5x104 cells per well in standard cell culture media and cultured overnight at  
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Figure 3.3: Determination of optimal excitation and emission wavelengths for detection of 
Dil-LDL. 
Several concentrations of dialkylcarbocyanine-labeled LDL (Dil-LDL) were suspended in 
DMEM and aliquoted in 96 well cell culture plates. A. Spectral excitation and B. spectral 
emission analysis were performed using a Spectramax M5 Multi-mode Microplate Reader 
(Molecular Devices) to determine optimal experimental excitation and emission wavelengths for 
Dil-LDL. 
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37 °C and 5% CO2. Media was aspirated and replaced with DMEM containing 0.5% FBS to 
maximize uptake of LDL. Cells were cultured overnight at 37 °C and 5% CO2. Media was 
aspirated and HA-Ank105-expressing cells were incubated with increasing concentrations of Dil-
LDL (10, 25, 50 and 100 µg/mL) (50 µL per well) for indicated times (0, 30, 60, 120, 240, 300 
minutes). Each concentration of Dil-LDL and time point was tested with 4 replicate wells. Upon 
completion of incubation cells were placed on ice and washed gently 3 times with cold serum 
free DMEM (200 µL) to remove excess Dil-LDL. After the last wash step cells were placed in 
cold serum free DMEM (50 µL). LDL uptake was quantified as relative fluorescence signal 
intensity at excitation and emission wavelengths of 550 and 580 nm, respectively (Figure 3.4). 
The optimal concentration of Dil-LDL was determined to be 50 µg/mL, as the extent of uptake of 
Dil-LDL at a concentration of 50 µg/mL was similar to Dil-LDL at a concentration of 100 µg/mL 
(Figure 3.4).  
 
3.2.7.5 LDL uptake assay  
The effects of endocytosis inhibitors on LDL uptake in HA-Ank105-expressing cells 
were next determined (Figure 4.14; Figure 4.15). HA-Ank105-expressing cells were seeded into 
standard 96 well cell culture plates at a density of 5x104 cells per well in standard cell culture 
media and cultured overnight at 37 °C and 5% CO2. Media was aspirated and replaced with 
DMEM containing 0.5% FBS to maximize uptake of LDL. Cells were cultured overnight at 
37 °C and 5% CO2. Media was aspirated. Each of the small molecule endocytosis inhibitors were 
diluted to medium working concentration (Table 3.12) in DMEM and incubated with cells (50 
µL per well) for 30 minutes at 37 °C and 5% CO2 to allow equilibration of cells with each 
inhibitor prior to incubation with Dil-LDL. Media was aspirated. Both Dil-LDL (50 µg/mL) 
(3.2.7.4) and medium working concentrations of each small molecule endocytosis (Table 3.12) 
were suspended in DMEM and added to HA-Ank105-expressing cells (50 µL per well). 
Untreated HA-Ank105-expressing cells were incubated in DMEM (50 µL per well) containing 
only Dil-LDL (50 µg/mL). Cells were incubated at 37 °C and 5% CO2 for a range of times (0, 
30, 60, 120, 240, 300 minutes). Each condition was replicated in 4 wells to facilitate statistical 
analysis. Upon completion of incubation cells were placed on ice and washed gently 3 times with 
cold serum free DMEM (200 µL) to remove excess Dil-LDL. After the last wash step cells were 
placed in cold serum free DMEM (50 µL). LDL uptake was quantified as relative fluorescence 
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signal intensity at excitation and emission wavelengths of 550 and 580 nm, respectively. LDL 
uptake for each time point with each inhibitor was averaged and expressed as percent LDL 
uptake in untreated (no inhibitor) HA-Ank105-expressing cells after 300 minutes of incubation 
with Dil-LDL. Statistical significance was determined for each inhibitor after 300 minutes of 
Dil-LDL incubation compared to untreated HA-Ank105-expressing cells after 300 minutes of 
Dil-LDL incubation by t-test (Microsoft Excel). 
 
 
Figure 3.4: Optimization of Dil-LDL uptake in HA-Ank105-expressing cells. 
HA-Ank105-expressing cells were seeded onto 96 well plates (5x104 cells per well) and cultured 
overnight. Cells were then starved overnight in DMEM containing 0.5% FBS. Cells were 
incubated with increasing concentrations (0, 25, 50, 100 µg/mL) of dialkylcarbocyanine-labeled 
LDL (Dil-LDL) for indicated times (0, 30, 60, 120, 240, 300). Cells were washed and LDL 
uptake was quantified relative fluorescence intensity at excitation/emission spectra of 550/580 
nm. 
 
 
3.2.7.6 In-cell Western detection of PDGFR in HA-Ank105-expressing cells 
 To study the effects of small molecule endocytosis inhibitors on ligand-mediated PDGFR 
degradation in HA-Ank105-expressing cells an in-cell Western methodology was developed to 
facilitate rapid screening of each inhibitor. HA-Ank105-expressing cells were seeded onto a 96 
well plate at a density of 5x104 cells per well and cultured overnight in standard cell culture 
media (150 µL per well) at 37 °C and 5% CO2. Media was aspirated and cells were cultured in 
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DMEM containing 0.5% FBS overnight at 37 °C and 5% CO2 to maximize effects of ligand 
stimulation. Each of the small molecule endocytosis inhibitors were diluted to medium working 
concentration (Table 3.12) in DMEM and incubated with cells (100 µL per well) for 30 minutes 
at 37 °C and 5% CO2 to allow equilibration of cells with each inhibitor prior to stimulation with 
PDGF. Media was aspirated. Both PDGF (50 ng/mL) and medium working concentrations of 
each small molecule endocytosis (Table 3.12) were suspended in DMEM and added to HA-
Ank105-expressing cells (100 µL per well). Untreated HA-Ank105-expressing cells were 
incubated in DMEM (100 µL per well) containing only PDGF (50 ng/mL). Cells were incubated 
at 37 °C and 5% CO2 for a range of times (0, 30, 60, 120 and 240 minutes). Each condition was 
replicated in 4 wells to facilitate statistical analysis. Media was aspirated and cells were 
incubated in fixing buffer (Table 3.8) (200 µL per well) for 30 minutes at room temperature. 
Buffer was aspirated and replaced with PBS (Table 3.8) containing 0.5% (v/v) triton X-100 
(sigma) (200 µL per well) to permeabilize the cell membrane. Cells were incubated at room 
temperature for 30 minutes on a nutator. Buffer was aspirated. Cells were incubated with 
blocking buffer (Table 3.8) (200 µL per well) for 30 minutes at room temperature on a nutator. 
Buffer was aspirated. Blocking buffer containing anti-PDGFRβ (C82A3) primary antibody 
(Table 3.10) was added to cells (50 µL per well) and incubated at room temperature for 1 hour on 
a nutator. Primary antibody solution was aspirated and cells were washed gently 3 times with 
PBS (150 µL per well). Cells were incubated with blocking buffer (50 µL per well) containing 
anti-rabbit IgG 680RD secondary antibody (Table 3.10) at room temperature for 1 hour on a 
nutator. Secondary antibody solution was aspirated and cells were washed gently 3 times with 
PBS (150 µL per well). PBS (100 µL per well) was placed on cells and the plate was imaged 
using the Odyssey Infrared Imaging System (LI-COR Biosciences) using a focal offset of 4 mm 
to focus on the surface containing the cells (Figure 3.5) and quantified using Odyssey Infrared 
Imaging System Application software V3.0. 
 Serum starved HA-Ank105-expressing cells not stimulated with PDGF demonstrate the 
highest signal intensity (Figure 3.5). Upon ligand stimulation PDGFR is degraded with the most 
extensive degradation, and lowest signal intensity, occurring after 240 minutes of stimulation. 
Indeed the in-cell Western methodology can detect effects of endocytosis inhibitors on PDGFR 
degradation. In dynasore treated HA-Ank105-expressing cells, the signal intensity after 240 
minutes of ligand stimulation is similar to unstimulated cells (Figure 3.5). Relative PDGFR 
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expression was quantified using Odyssey Infrared Imaging System Application software V3.0 
(LiCOR Biosciences) and replicate experiments were averaged. Statistical significance was 
determined for each inhibitor after 240 minutes of PDGF stimulation compared to untreated HA-
Ank105-expressing cells after 240 minutes of PDGF stimulation by t-test (Microsoft Excel).  
 
 
Figure 3.5: In-cell detection of PDGFR in ligand stimulated HA-Ank105-expressing cells 
treated with various small molecule endocytosis inhibitors 
Serum starved HA-Ank105-expressing cells were treated with indicated inhibitors (Table 3.12) 
and then stimulated media containing PDGF (50 ng/mL) and inhibitor for a range of times (0, 30, 
60, 120 and 240 minutes) according to provided scheme. Cells were fixed, permeabilized and 
incubated with primary antibody (Table 3.10), followed by secondary antibody (Table 3.10) to 
detect PDGFR levels. 
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4.0 RESULTS 
 
4.1 Characterization of the effects of HA-Ank105 expression on PDGFR signaling and 
protein levels 
Our laboratory had identified Ank105 as a binding partner of the regulatory subunit of 
PI3K (Ignatiuk et al., 2006). Since PI3K is a downstream component of the PDGFR signaling 
cascade, the effects of Ank105 expression were examined in the context of PDGFR and PI3K 
signaling. It was shown that overexpression of Ank105 enhanced degradation of the PDGFR 
(Ignatiuk et al., 2006). Since this observation was made in a single stable clonal NIH 3T3 cell 
line, initial studies were carried out to determine if the level of Ank105 expression was 
proportional to PDGFR degradation. Cell lines showing a range in Ank105 expression were 
selected for analysis. Parental NIH 3T3 cells and cells stably expressing low, medium and high 
levels, respectively, of hemagluttinin tagged Ank105 (HA-Ank105) were stimulated for 30 
minutes with PDGF. Lysates were harvested, normalized to total protein content and analyzed via 
SDS-PAGE and Western blot analysis to evaluate HA-Ank105 expression, PDGFR expression, 
PDGFR activation, as well as activation of downstream signaling pathways, namely AKT and 
MAPK (Figure 4.1).  
Parental NIH 3T3 cells qualitatively show activation of the PDGFR, as indicated by 
phospho-tyrosine (pTyr) specific antibody detecting pTyr on the PDGFR after 30 minutes of 
ligand stimulation, as well as robust activation of downstream AKT and MAPK pathways. 
PDGFR protein levels are predictably reduced upon ligand stimulation, indicating a functional 
degradation pathway. The total levels of AKT and MAPK on the other hand did not change in 
response to stimulation. Qualitatively, expression of increasing levels of HA-Ank105 led to 
decreased constitutive (no stimulation) expression levels of PDGFR compared to parental cells. 
Stimulation of HA-Ank105-expressing cells with PDGF predictably reduced PDGFR levels 
further. Levels of activated PDGFR, AKT and MAPK after 30 minutes of PDGF stimulation 
were dramatically reduced in HA-Ank105-expressing cells as compared to parental cells, with 
the greatest impact being on the activation of PDGFR and MAPK. The total levels of AKT and 
MAPK proteins themselves remained consistent across the low, medium and high Ank105-
expressing cell lines. Ank105-mediated constitutive PDGFR degradation is dependent on the 
level of HA-Ank105 expression. The extent of reduction in constitutive PDGFR levels and 
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signaling activation in response to ligand tended to increase as HA-Ank105 expression 
increased. This trend was most evident when the activation of the PDGFR was examined as the 
high Ank105-expressing cell line appeared most attenuated when stimulated with ligand.  
 
Figure 4.1: HA-Ank105 expression reduced PDGFR signaling and receptor levels  
Untransfected control NIH 3T3 cells and cells stably expressing low, medium and high levels of 
HA-Ank105 were either left untreated (0 ng/mL) or treated for 30 minutes with PDGF (50 
ng/mL) for 30 minutes. Cell lysates (20 g) were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane. The nitrocellulose membranes were analyzed via Western blot to detect 
Ank105 expression (HA), PDGFR expression and activation (pTyr), Akt expression and 
activation (pAkt), as well as MAPK expression and activation (pMAPK). Western blots were 
developed using chemiluminescence and evaluated qualitatively. Results are representative of 
those from 3 independent experiments (N=3). 
 
One caveat is the cell line expressing the highest level of HA-Ank105 has higher levels of 
constitutive PDGFR than the cell line expressing medium levels of HA-Ank105. It may be 
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possible that at very high expression levels of Ank105, the endocytic cellular machinery became 
over saturated with Ank105 and excess Ank105 could sequester its binding partners, thereby 
impairing Ank105 function. Quantitatively determining the relative expression of each band 
proved challenging as Western blots were developed using chemiluminescence. Oversaturation 
of several bands made analysis by densitometry difficult. However, caveats aside, this 
experiment demonstrated the trend that expression of Ank105 in NIH 3T3 cells promoted 
PDGFR degradation and attenuated PDGFR signaling in response to ligand. Indeed, 
phosphorylation of Akt was detected in all Ank105 stable cell lines in the absence of PDGF 
stimulation, possibly due to overexposure of the Western blot. Since the cell line that expressed 
medium levels of Ank105 demonstrated the most significant effect on constitutive PDGFR 
protein levels, this cell line was used in all subsequent experiments unless indicated otherwise. 
 
4.2 Characterization of the effects of HA-Ank105 expression on EGFR protein expression 
levels 
 Since Ank105 promoted the degradation of PDGFR, we next determined whether HA-
Ank105 expression could promote the degradation of other related RTKs. The effect of HA-
Ank105 expression was determined for EGFR degradation. Increasing amounts of HA-Ank105 
were transiently transfected into HEK293 and HeLa cells. Both cell lines endogenously express 
EGFR. Cells were stimulated with EGF for indicated times. Lysates were harvested, normalized 
to total protein content and analyzed via SDS-PAGE and Western blot analysis to evaluate HA-
Ank105 expression, EGFR expression and EGFR activation, as approximated by Western blot 
detection of tyrosine phosphorylation at the expected molecular weight of EGFR (Figure 4.2). In 
HEK293 cells constitutive EGFR levels decreased as HA-Ank105 expression increased. The 
extent of EGFR activation was reduced in HA-Ank105-expressing HEK293 cells upon EGF 
stimulation as compared to untransfected control cells. Transfection of the spectrin binding 
domain of Ank105, lacking the regulatory domain, was sufficient to induce EGFR degradation; 
whereas, transfection of the regulatory domain, lacking the spectrin binding domain, did not 
affect EGFR degradation (data not shown). In HeLa cells, constitutive EGFR levels did not 
change in response to HA-Ank105 transfection. EGFR was activated to a similar extent upon 
EGF stimulation in HA-Ank105-expressing HeLa cells as untransfected control cells. HeLa cells 
also endogenously express PDGFR, albeit at much lower levels than NIH 3T3 cells. Expression 
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of HA-Ank105 in HeLa cells ablated PDGFR expression as compared to untransfected control 
cells. Thus HA-Ank105 expression differentially affects constitutive EGFR levels in HEK293 
cells versus HeLa cells. It may be that HEK293 cells express some additional factor, such as an 
adaptor protein, that sensitizes EGFR to Ank105-mediated degradation that is not expressed in 
HeLa cells; however this possibility was not explored further. 
 
Figure 4.2: HA-Ank105 expression differentially affects EGFR degradation in HEK293 and 
HeLa cells. 
A. HEK293T cells transiently transfected with increasing concentrations of HA-Ank105 (0, 1.5, 
3.0 µg DNA) were either left unstimulated (0 ng/mL) or stimulated with EGF (20 ng/mL) for 
indicated times. Cell lysates (50 g) were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane. The nitrocellulose membranes were analyzed via Western blot to detect 
Ank105 expression (HA), EGFR expression and EGFR activation (pTyr). Results are 
representative of those from 3 independent experiments (N=3). B. HeLa cells transiently 
transfected with increasing concentrations of HA-Ank105 (0, 1.5, 3.0 µg DNA) were stimulated 
with EGF (20 ng/mL) for indicated times. Lysates (50 μg) were analyzed with indicated 
antibodies Cell lysates (50 g) were resolved by SDS-PAGE and transferred to a nitrocellulose 
membrane. The nitrocellulose membranes were analyzed via Western blot to detect Ank105 
expression (HA), EGFR expression, EGFR activation (pTyr) and PDGFR expression. N=1. 
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4.3 Effects of HA-Ank105 expression on PDGFR ubiquitination and lysosomal degradation 
 Trafficking of activated receptor complexes to the lysosome for degradation requires 
monoubiquitination of receptor. Since Ank105 promoted degradation of the PDGFR, we 
examined PDGFR ubiquitination in HA-Ank105-expressing cells. NIH 3T3 cells and cells stably 
expressing HA-Ank105 were stimulated for a time course up to 30 minutes with PDGF. Lysates 
were generated and PDGFR was immunoprecipitated from each sample. Immunoprecipitants 
were resolved via SDS PAGE and examined via Western blot for PDGFR levels, PDGFR 
activation and PDGFR ubiquitination (Figure 4.3A). In NIH 3T3 cells, immunoprecipitated 
PDGFR is highly phosphorylated and ubiquitinated after 10 minutes of PDGF stimulation, which 
persists to 30 minutes of stimulation. PDGFR levels are only slightly reduced after 10 minutes of 
stimulation (Figure 4.3A). HA-Ank105-expressing cells again show a dramatic reduction in 
constitutive PDGFR levels as compared to parental cells and are hardly detectable after 30 
minutes of stimulation (Figure 4.3A). The PDGFR was ubiquitinated after 10 minutes of 
stimulation in HA-Ank105-expressing cells, but to a lesser extent than the parental cells. The 
level of PDGFR ubiquitination was dramatically reduced after 30 minutes of stimulation; 
whereas PDGFR ubiquitination in parental cells was robust after 30 minutes of stimulation 
(Figure 4.3A). The PDGFR was phosphorylated after 10 minutes of stimulation; however the 
level phosphorylation is markedly reduced after 30 minutes of stimulation. In contrast the 
parental cells demonstrate robust PDGFR phosphorylation after 30 minutes of stimulation 
(Figure 4.3A). Interestingly the PDGFR displays a different phosphorylation pattern in HA-
Ank105-expressing cells than in parental cells. The anti-phospho-tyrosine antibody detects 
higher molecular weight species in HA-Ank105-expressing cells, suggesting the PDGFR may be 
more highly phosphorylated upon stimulation in HA-Ank105-expressing cells than in parental 
cells (Figure 4.3A). Cells were not stimulated past 30 minutes in this experiment as 
phosphorylation and ubiquitination of the PDGFR in HA-Ank105-expressing cells occurred 
predominantly after 10 minutes of stimulation and the signal attenuated after 30 minutes. The 
lack of extensive smearing and laddering in the ubiquitination blots of immunoprecipitated 
PDGFR in both NIH 3T3 and HA-Ank105-expressing cell indicated that the PDGFR was likely 
monoubiquitinated (Figure 4.3A). Taken together these results indicate that HA-Ank105 
expression reduced PDGFR phosphorylation and ubiquitination in response to ligand 
stimulation, possibly by inducing constitutive degradation of PDGFR. 
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Figure 4.3: Ligand-induced ubiquitination of PDGFR is reduced in HA-Ank105-expressing 
cells while not requiring a functional lysosomal pathway for degradation. 
A. NIH 3T3 or HA-Ank105-expressing cells were either left unstimulated (0 ng/mL) or 
stimulated for indicated times with PDGF (50 ng/mL). PDGFR was immunoprecipitated from 
cell lysates, resolved via SDS PAGE, transferred to a nitrocellulose membrane and analyzed via 
Western blot for PDGFR levels, activation (pTyr) and ubiquitination (Ub). Results are 
representative of those from 3 independent experiments (N=3). B. NIH 3T3 cells and C. HA-
Ank105-expressing cells were either left untreated or treated for 4 hours with chloroquine (100 
µM) and stimulated for indicated times with PDGF (50 ng/mL). Lysates were normalized to total 
protein content (50 µg), resolved via SDS-PAGE, transferred to a nitrocellulose membrane and 
analyzed by Western blot for HA-Ank105 expression, PDGFR expression and PDGFR activation 
(pTyr). Results are representative of those from 3 independent experiments (N=3). 
 
Since activated, ubiquitinated receptors are sorted to the lysosome for degradation it was 
next determined whether HA-Ank105-expressing cells required a functional lysosomal pathway 
to target ligand stimulated PDGFR for degradation. NIH 3T3 cells and cells stably expressing 
HA-Ank105 were either untreated or treated for 4 hours with the lysosomal degradation inhibitor 
chloroquine (Figure 4.3B,C). Chloroquine is a tertiary amine that raises the pH of the lysosome, 
thereby inactivating low pH-dependent proteases required for protein degradation (Heldin et al., 
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1982). After treatment with chloroquine, cells were stimulated for a 120 minute time course with 
PDGF. Lysates were harvested, normalized to total protein content, resolved by SDS-PAGE and 
analyzed by Western blot for HA-Ank105 expression, PDGFR expression and PDGFR 
activation.  
In NIH 3T3 cells not treated with chloroquine the PDGFR is progressively degraded 
following PDGF stimulation, with the greatest extent of degradation after 120 minutes of 
stimulation (Figure 4.3B). The PDGFR is phosphorylated to the highest extent after 10 minutes 
of stimulation and tapers off as the time course progresses (Figure 4.3B). Treatment of NIH 3T3 
cells with chloroquine inhibits ligand induced PDGFR degradation. In chloroquine treated cells, 
the level of PDGFR present after 120 minutes of PDGF stimulation is similar to the constitutive 
level observed prior to stimulation (Figure 4.3B). With regards to receptor phosphorylation, the 
activation profile of PDGFR in chloroquine treated cells mirrors untreated cells, with the highest 
extent of phosphorylation occurring after 10 minutes of stimulation and tapering off at later time 
points (Figure 4.3B).  
In Ank105-expressing cells not treated with chloroquine, constitutive PDGFR expression 
levels are markedly reduced as compared to parental cells, as expected. Stimulation of HA-
Ank105-expressing cells with PDGF lead to further reduction in receptor levels (Figure 4.3C). 
When examined for receptor activation, HA-Ank105-expressing cells showed peak 
phosphorylation levels after 10 minutes of stimulation, which decreased at later time points. The 
level of phosphorylation in HA-Ank105-cells was significantly lower than parental cells (Figure 
4.3C). In chloroquine treated HA-Ank105-expressing cells there was a slight increase in 
constitutive PDGFR levels, however the level was still much lower than constitutive PDGFR in 
control cells (Figure 4.3C). Chloroquine treatment partially blocked PDGFR degradation in 
response to ligand in HA-Ank105-expressing cells whereas chloroquine treatment completely 
blocked ligand induced degradation in control NIH 3T3 cells. The PDGFR phosphorylation 
profile upon ligand stimulation in chloroquine treated HA-Ank105-expressing cells mirrored that 
of non-chloroquine treated HA-Ank105-expressing cells (Figure 4.3C). Thus inhibition of 
lysosomal degradation via chloroquine treatment completely inhibited ligand induced 
degradation in NIH 3T3 cells and partially inhibited degradation in HA-Ank105-expressing cells. 
Treatment of HA-Ank105-expressing cells with chloroquine partially recovered constitutive 
PDGFR levels. This data suggests that Ank105 may promote constitutive PDGFR degradation by 
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a lysosomal-mediated mechanism. Possible explanations for only a slight increase in constitutive 
PDGFR levels is that PDGFR in this cell model is under control of an endogenous promoter and 
4 hours of chloroquine treatment may be insufficient to increase PDGFR levels to those observed 
constitutively in NIH 3T3 cells. Treatment times longer than 4 hours have proved toxic. An 
alternative explanation is that Ank105 mediates the majority of its effect on PDGFR levels via 
proteasomal degradation. 
 
4.4 HA-Ank105 interacts with ubiquitin and ubiquitinated proteins 
 An overlying trend in the sorting of ubiquitinated cargo for lysosomal degradation is the 
ability of the sorting machinery is to recognize monoubiquitinated cargo by interacting with the 
ubiquitin tag itself. Additionally, these proteins are often ubiquitinated themselves. Since HA-
Ank105 promotes degradation of the PDGFR, the ability of HA-Ank105 to interact with 
monoubiquitin using a pulldown methodology was determined. pHA3-Ank105 was transiently 
transfected into COS-1 cells. COS-1 cells were chosen due to high transfection efficiency and 
high protein expression levels of transfected proteins. Lysates from COS-1 cells transiently 
overexpressing HA-Ank105 were incubated with either purified monoubiquitin-glutathione-S 
transferase (Ub-GST) fusion protein or glutathione-S transferase (GST) protein, both of which 
were bound to glutathione sepharose beads. Following incubation, beads were separated from 
lysate by several centrifugation and washing steps. Samples were then resolved by SDS-PAGE 
and analyzed via Western blot to detect the presence of HA-Ank105 (Figure 4.4A). If HA-
Ank105 specifically interacts with ubiquitin it will be bound to Ub-GST beads, but not to GST 
beads. Indeed, HA-Ank105 was readily detectable in an Ub-GST pulldown but not in a control 
GST pulldown (Figure 4.4B), indicating that HA-Ank105 interacted with monoubiquitin in vitro.  
Given that HA-Ank105 interacted with purified recombinant ubiquitin in an in vitro assay 
it was next determined whether HA-Ank105 was able to interact with ubiquitinated proteins in 
cells. NIH 3T3 cells stably expressing HA-Ank105 were stimulated for indicated times with 
PDGF and HA-Ank105 was immunoprecipitated from resulting lysates at each time point. 
Immunoprecipitants were resolved by SDS-PAGE and analyzed by Western blot for 
ubiquitinated proteins that co-immunoprecipitate with HA-Ank105. Western blot reveals that  
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Figure 4.4: HA-Ank105 interacts with ubiquitin in vitro and several ubiquitinated proteins 
in cells. 
A. Diagram of pulldown experiment. B. Lysates from untransfected COS-1 cells and cells 
transiently transfected with HA-Ank105 were incubated with either GST (100 µg) or ubiquitin-
GST (Ub-GST) (100 µg) immobilized on glutathione sepharose beads. Proteins bound to beads 
were resolved via SDS-PAGE and analyzed by Western blot for the presence of HA-Ank105. 
Results are representative of those from 3 independent experiments (N=3). C. NIH 3T3 cells 
stably expressing HA-Ank105 were starved overnight in DMEM containing 0.5% FBS and then 
stimulated for indicated times with PDGF (50 ng/mL). HA-Ank105 was immunoprecipitated 
with anti-HA antibody immobilized on protein G-sepharose beads. Immunoprecipitants were 
resolved by SDS-PAGE. Ubiquitinated proteins which co-immunoprecipitate with HA-Ank105 
were detected with an anti-ubiquitin antibody via Western blot. Ubiquitinated proteins are 
indicated with black arrows and the light and heavy antibody chains are indicated with red 
arrows. N=1. 
 
several ubiquitinated proteins co-immunoprecipitated with HA-Ank105 after 10 minutes of 
PDGF stimulation (Figure 4.4C). An intense band is visible between the 100 and 130 kDa 
molecular weight markers, a weight range that may correspond to HA-Ank105 (Figure 4.4C). 
Since the antibodies used for immunoprecipitation of HA-Ank105 and detection of ubiquitin had 
the same species origin, the heavy and light antibody chains are present in all time points tested 
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(Figure 4.4C). The Western blots in this this experiment were developed by chemiluminescence 
and as a result, the bands representing the heavy and light chains were overexposed. This 
overexposure was necessary to observe low abundance ubiquitinated proteins that co-
immunoprecipitated with HA-Ank105 (Figure 4.4). This data suggests that HA-Ank105 interacts 
with several ubiquitinated proteins under conditions that induce ligand-mediated PDGFR 
degradation and that HA-Ank015 may be ubiquitinated. 
 
4.5 HA-Ank105 interacts with ubiquitin via the spectrin binding domain 
 Since HA-Ank105 interacted with purified ubiquitin in vitro and several ubiquitinated 
proteins in cells it was next determined how HA-Ank105 interacted with ubiquitin. The primary 
sequence of Ank105 revealed a potential ubiquitin interaction motif (UIM) from amino acids 
1880 to 1894 within the regulatory domain. This potential UIM of Ank105 conformed well to the 
published consensus sequence (Fujiwara et al., 2004) and contained conserved alanine and serine 
residues (Figure 4.5A). UIMs fold into a single α-helix that interact with surface residues of 
ubiquitin (Fujiwara et al., 2004). In order to determine if this putative UIM facilitated Ank105-
ubiquitin interaction, a rational mutagenesis strategy was employed. The conserved serine 
residue 1891 (Figure 4.5B) was mutated to aspartic acid as this mutation was previously shown 
to abrogate UIM-ubiquitin binding (Fujiwara et al., 2004). As a complimentary methodology, 
deletion mutagenesis was also performed. Truncation mutants of HA-Ank105 were generated to 
progressively remove 50 amino acids at a time from the C-terminus of Ank105 until the putative, 
predicted, UIM was deleted (Figure 4.5B). Removal of 100 C-terminal amino acids was 
sufficient to delete the putative UIM. These proteins were evaluated for the ability to interact 
with ubiquitin via an Ub-GST pulldown experiment. Point mutation of the conserved serine 
residue to aspartic acid has been shown previously to prevent UIM-ubiquitin interaction 
(Fujiwara et al., 2004). The HA-Ank105-S1891D mutant retained the ability to interact with the 
Ub-GST fusion protein (Figure 4.5B,C). Indeed, HA-Ank105-C-terminal deletion mutants where 
the putative UIM was entirely removed also retained the ability to interact with ubiquitin. Thus, 
all mutants retained the ability to interact with ubiquitin (Figure 4.5B,C). Of note, the proteins 
showed some background binding to the GST control; however the band intensity of Ub-GST 
were consistently greater (Figure 4.5B,C). This data suggests that this putative UIM, which 
conformed well to the consensus sequence, does not mediate the Ank105-ubiquitin interaction  
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Figure 4.5: Mutation of proposed UIM of Ank105 does not prevent ubiquitin binding 
 A. Potential UIM within the C-terminal regulatory domain of Ank105 and its consensus 
sequence. The essential amino acids are highlighted. B. COS-1 cells were transiently transfected 
with indicated HA-Ank105 mutant proteins. Lysates were incubated with either GST (100 µg) or 
ubiquitin-GST (Ub-GST) (100 µg) immobilized on glutathione sepharose beads. Proteins bound 
to beads were resolved via SDS-PAGE, transferred to a nitrocellulose membrane and analyzed 
by Western blot for the presence of HA-Ank105 mutant proteins. Results are representative of 
those from 3 independent experiments (N=3). C. Quantification of Figure 4.5B. Only one blot 
was quantified as other replicates were developed using chemilumenescence. Yellow dots 
indicate conserved amino acids. Red dots indicate point mutations. 
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and raised the question as to which region of Ank105 confers the ability to bind ubiquitin. 
To determine the region of Ank105 responsible for mediating ubiquitin interaction the 
domains of Ank105, being the spectrin binding domain and the regulatory domain, were 
individually evaluated for the ability to bind ubiquitin using Ub-GST pulldown experiments 
(Figure 4.6). Both full length HA-Ank105 and the HA-spectrin-binding-domain, lacking the 
regulatory domain, interacted with the Ub-GST fusion protein (Figure 4.6A,B). The HA-
regulatory-domain, lacking the spectrin binding domain, was unable to interact with the Ub-GST 
fusion protein (Figure 4.6A,B). Even though the overall signal intensity is relatively weak and 
each of the GST control lanes contains background binding (Figure 4.6A), the signal intensity of 
the Ub-GST lanes are consistently higher than the GST lanes. This data suggests that the 
Ank105-ubiquitin interaction is mediated via spectrin binding domain and not the regulatory 
domain.  
Several C-terminal deletion spectrin binding domain mutants were generated to 
determine the region of the spectrin-binding domain responsible for the interaction with 
ubiquitin. Amino acids were progressively removed from the C-terminus of the spectrin-binding 
domain, deleting 250, 350, 400 and 450 C-terminal amino acids, respectively (Figure 4.7A). 
Once the deletion mutants were successfully generated, the resulting plasmids were transfected 
into COS-1 cells to evaluate and normalize expression levels for subsequent Ub-GST pulldown 
experiments. Unfortunately, all of the HA-spectrin-binding-domain-C-terminal-deletion mutants 
were not expressed when transfected into COS-1 cells, whereas full-length HA-Ank105 and full 
length HA-spectrin-binding-domain were expressed at the expected molecular weights (Figure 
4.7A). It was hypothesized that C-terminal deletion of amino acids at these particular positions 
(Figure 4.7A) in the spectrin binding domain compromised secondary and/or tertiary protein 
folding and this instability negatively impacted expression. 
The primary amino acid sequence of Ank105 was analyzed by Russell/Linding Globprot 
software to determine positions in the Ank105 sequence where amino acid deletions would be 
tolerated, allowing for transient protein expression of deletion proteins. The Russell Linding 
Globprot software distinguishes regions of a protein that have high polypeptide flexibility and a 
consistent lack of secondary structure from regions that have a high degree of order and 
packaged into globular units (Linding et al., 2003). In other words, the software identifies and 
distinguishes the globular/ordered regions of a protein from the disordered regions. The software 
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achieves this by analyzing the propensity of each amino acid residue in a primary sequence to be 
in an ordered or disordered state. The disorder propensities of each amino acid are summed and 
graphed versus residue number. Decreasing sums on the graph indicate regions of order whereas  
 
Figure 4.6: HA-Ank105 interacts with ubiquitin through the spectrin binding domain 
A. COS-1 cells were transiently transfected HA-Ank105 spectrin binding domain or regulatory 
domain proteins. Lysates were incubated with either GST (100 µg) or Ub-GST (100 µg) 
immobilized on glutathione sepharose beads. Proteins bound to beads were resolved via SDS-
PAGE, transferred to a nitrocellulose membrane and analyzed by Western blot for the presence of 
HA-Ank105 domain proteins. Results are representative of those from 3 independent 
experiments (N=3). Quantification and graphical representation of Figure 4.6A (mean +/- S.D). 
Data compared to Ub-GST HA-Ank105 pulldown. 
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Figure 4.7: Ank105 contains several regions of disorder 
A. Spectrin binding domain C-terminal deletion proteins were transiently transfected into COS-1 
cells. Lysates (50 µg) were resolved via SDS-PAGE and transferred to a nitrocellulose 
membrane. Expression of deletion proteins was analyzed by Western blot using an anti-
hemagluttinin antibody. N=1. B. The primary amino acid of An105 was analyzed by the 
Russell/Linding Globprot2.3 software http://globplot.embl.de/ to identify regions of order and 
disorder. Downwards trends in the disorder propensity sum versus residue graph indicate regions 
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with a high propensity for order whereas upwards trends identify regions with a high propensity 
for disorder (Linding et al., 2003). A domain map showing the spectrin binding domain and the 
regulatory domain compared to Ank105 residue is located directly below the graph. Disordered 
regions identified for generation of spectrin domain deletion mutants are indicated (amino acid 
residues 169, 359 and 385). 
  
increasing sums indicate regions of disorder (Linding et al., 2003) (Figure 4.7B). 
The Russell/Linding software identified several regions of disorder in the primary 
sequence of Ank105 (Figure 4.7B). Amino acids within several of these disordered regions were  
selected as candidates for deletion mutagenesis. It was hypothesized that generating deletion 
mutants within disordered regions would have less impact on the overall protein folding since 
these regions show a high degree of disorder. Several N-terminal deletion mutants of Ank105 
were generated in regions predicted to be disordered, truncating Ank105 at residues 169, 359 and 
385, respectively (Figure 4.8A). N-terminal deletion mutants are generated from full length HA-
Ank105 rather than the spectrin domain. By keeping the regulatory domain intact protein 
stability would be increased. Full length HA-Ank105 interacted with ubiquitin and the regulatory 
domain itself did not, thus the presence of the regulatory domain should not hinder screening of 
these mutants for ubiquitin binding. The N-terminal deletion mutants were transfected into COS-
1 cells and analyzed for protein expression. The HA-Ank105-NΔ169, HA-Ank105-NΔ359 and 
HA-Ank105-NΔ385 deletion mutants each were expressed at the expected molecular weights 
(Figure 4.8A).  
The N-terminal deletion mutants were evaluated for the ability to interact with ubiquitin 
via Ub-GST pulldown experiments. The HA-Ank105-NΔ385 deletion mutants interact with Ub-
GST fusion protein however the signal intensity was very low. The HA-spectrin-binding-domain 
was used as a positive control and bound Ub-GST, but with low signal intensity (Figure 4.8B). 
The HA-Ank105-NΔ169 and HA-Ank105-NΔ359 proteins did not appear to interact with Ub-
GST. The lack of interaction is odd considering the proteins with more significant amino acid 
deletions retained the ability to bind ubiquitin (Figure 4.8B). The absence of observable ubiquitin 
binding with the HA-Ank105-NΔ169 and HA-Ank105-NΔ359 mutant could be due to the low 
overall signal intensity or complications in protein expression, as the HA-Ank105-NΔ169 
protein is expressed as a doublet. Addition replicate experiments are required to improve signal 
intensity and determine the efficacy of HA-Ank105-NΔ169 ubiquitin binding, potentially using 
more input lysate to increase signal intensity. Assuming the HA-Ank105-NΔ385 proteins  
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Figure 4.8: HA-Ank105 N-terminal deletion proteins retain ubiquitin binding  
A. Domain map of HA-Ank105 N-terminal deletion proteins. B. HA-Ank105 N-terminal 
deletion proteins were transiently transfected into COS-1 cells. Lysates (50 µg) were resolved via 
SDS-PAGE and transferred to a nitrocellulose membrane. Expression of deletion proteins was 
analyzed by Western blot using an anti-hemagluttinin (HA) antibody. N=1. C. COS-1 cells were 
transiently transfected with indicated HA-Ank105-N-terminal deletion mutant proteins. Lysates 
were incubated with either GST (100 µg) or Ub-GST (100 µg) immobilized on glutathione 
sepharose beads. Proteins bound to beads were resolved via SDS-PAGE, transferred to a 
nitrocellulose membrane and analyzed by Western blot for the presence of HA-Ank105 mutants 
via Western blot with an anti-hemagluttinin (HA) antibody. N=1. D. Quantification and graphical 
representation of Figure 4.8C. Data compared to signal in Ub-GST HA-Spectrin domain 
pulldown. 
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interact with ubiquitin, the region of Ank105 mediating ubiquitin binding may be located 
between amino acids 360 and 588, which is the remainder of the spectrin binding domain. The 
Russell/Linding software predicts a small disordered region shortly after the 500th residue 
position of Ank105 (Figure 4.7B). Deletion mutagenesis in this region could generate proteins to 
more closely pinpoint the region of Ank105 mediating ubiquitin interaction. 
 
4.6 Inducible constitutive PDGFR degradation assay 
Ank105 promoted the constitutive degradation of PDGFR and EGFR, possibly by an 
endocytic mechanism involving Ank105 interaction with ubiquitinated proteins and targeting of 
receptors for degradation. Distinct mechanisms of endocytosis are distinguished by small 
molecule inhibitors (von Kleist and Haucke, 2012). Treatment of HA-Ank105-expressing cells 
with a panel of endocytosis inhibitors was used to determine the pathway by which Ank105 
functioned. As such, inhibition of an endocytosis pathway required for Ank105 function was 
expected to elevate PDGFR levels above levels in untreated HA-Ank105-expressing cells. One 
challenge of studying Ank105-mediated constitutive receptor degradation was that Ank105 
function is constitutive and occurred in the absence of ligand stimulation of the PDGFR. HA-
Ank105 expression under standard cell culture conditions (DMEM + 10% FBS + 5% CO2) was 
sufficient for Ank105 function; the receptor does not need to be stimulated to be degraded. Using 
small molecule inhibitors in a constitutively active system as in Ank105-expressing cells raised 
potential concerns. The PDGFR in HA-Ank105-expressing cells was under the control of an 
endogenous promoter and long inhibitor treatment times, potentially overnight, would be 
required to observe significant changes in PDGFR expression. Such long treatment times raised 
the possibility that changes observed in PDGFR expression may be due to off-target effects of 
the inhibitor. Thus a system permitting acute inhibitor treatment was desirable. 
It was observed that PDGFR expression levels were sensitive to the level of available 
nutrients in the culture media. When HA-Ank105-expressing cells were cultured in media 
contained low serum (1% FBS), the expression level of PDGFR was elevated approximately 2 
fold as compared to cells cultured with standard levels of serum (10% FBS) (Figure 4.9A). 
Given that serum restriction increased PDGFR levels HA-Ank105-expressing cells, it was next 
determined whether constitutive PDGFR degradation could be induced by incubation of low 
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serum treated cells in media containing normal levels of serum. HA-Ank105-expressing cells 
were cultured in low serum media (1% FBS) overnight to increase PDGFR levels. Overnight 
treatment with low serum increased PDGFR expression two fold as compared to cells cultured in 
normal serum levels (Figure 4.9B,C). The low serum treated cells were then re-incubated with 
media containing 10% FBS over time and induced PDGFR degradation (Figure 4.9B,C). After 4 
hours of incubation with 10% FBS containing media, the level of PDGFR expression was 
comparable to control HA-Ank105-expressing cells not incubated with low serum media (Figure 
4.9B,C). PDGFR levels did not decrease below control cells, as low serum treated cells 
incubated overnight with 10% FBS containing media expressed PDGFR at comparable levels 
(Figure 4.9B,C). An alternative explanation for the increase in PDGFR levels upon serum 
restriction is that serum contains a protein factor that promotes PDGFR degradation; however 
HA-Ank105-expressing cells cultured with the low protein content serum, Nuserum (Gibco), 
expressed PDGFR to similar levels as cells cultured in FBS (data not shown). Indeed, proteomic 
analysis of the growth factor content of several lots of FBS for different suppliers by mass 
spectrometry did not detect the presence of PDGF. Fibroblast growth factor (FGF), glial growth 
factor (GGF), transforming growth factor β-1 (TGF1) and insulin-like growth factor-II (IGFII) 
were readily and consistently detected in FBS (Zheng et al., 2006). Taken together this data 
suggests that restriction of nutrients and growth factors diverts PDGFR from Ank105-mediated 
degradation, presumably to prime the cell for maximum responsiveness to future nutrients and 
growth factors. When cells were re-exposed to sufficient levels of serum, PDGFR is shunted 
back to an Ank105-sensitive mechanism of degradation. 
Given that serum restriction elevated PDGFR levels in HA-Ank105-expressing cells and 
re-introduction of serum promoted constitutive PDGFR degradation, this model of inducible, 
constitutive PDGFR degradation was utilized to study the effects of small molecule inhibitors on 
constitutive PDGFR degradation. By using this inducible model of PDGFR degradation, the 
sensitivity issue of the PDGFR being under the control of an endogenous promoter was avoided. 
Furthermore, using this model allowed for acute inhibitor treatment and alleviated some of the 
potential concerns of off-target inhibitor effects with prolonged treatment times. To further 
address concerns of off-target effects of inhibitor treatment, the inhibitors used were validated by 
studying their effects on ligand induced PDGFR degradation and the endocytosis of LDL. The 
endocytosis of LDL follows a distinct and well characterized pathway, and will be discussed in 
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subsequent sections of the thesis. 
 
 
Figure 4.9: Generation of an inducible model of constitutive PDGFR degradation 
A. HA-Ank105-expressing cells were grown in DMEM containing 10% FBS or 1% FBS. 
Lysates were generated, normalized for total protein content, resolved by SDS-PAGE (100 µg), 
transferred to a nitrocellulose membrane and analyzed via Western blot for PDGFR and GAPDH 
expression. N=1. B. HA-Ank105-expressing cells were grown overnight in DMEM containing 
1% FBS to increase PDGFR levels and stimulated with DMEM containing 10% FBS for 
indicated times. Lysates for each time point were collected, normalized for total protein content, 
resolved by SDS-PAGE (100 µg), transferred to a nitrocellulose membrane and analyzed via 
Western blot for PDGFR and GAPDH expression. Expression was quantified as per 3.2.3.4. C. 
Quantification and graphical representation of Figure 4.9b (Mean +/- S.D.). Data compared to 
expression in Ank105 0min sample. Results are representative of those from 3 independent 
experiments (N=3) (** indicates P value <0.01). 
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4.7 Inhibition of endocytosis using small molecule inhibitors 
Several distinct mechanisms of endocytosis exist and may serve as routes promoting 
Ank105-mediated constitutive PDGFR degradation. CME, caveolar endocytosis and 
macropinocytosis are the most likely candidate pathways for constitutive PDGFR endocytosis 
since these pathways have been previously shown to internalize RTKs. The lipid clustering and 
CLIC/GEEC pathways are also candidates for constitutive PDGFR endocytosis; however cargo 
identified for these pathways is limited to IgE and GPI-anchored proteins, respectively. CME is 
by far the best-studied endocytic mechanism and has been extensively characterized in the 
endocytosis of RTKs. The clathrin-independent pathways of internalization are emerging in the 
literature and the range of cargo is largely unknown. Thus, it is prudent to inhibit each of these 
potential pathways.  
A ‘top-down’ strategy was employed to specifically inhibit each of these endocytosis 
mechanisms. The small molecule inhibitors chosen for these studies target several events in 
endocytosis such as coat formation, GTPases regulating internalization, endosomal pH, 
cytoskeleton dynamics, mechanisms of degradation, as well as kinases implicated in endocytic 
events (Table 4.1) (Figure 4.10). Pitstop-2 and chlorpromazine inhibit CME by preventing 
adaptor protein binding and inducing coat mis-assembly, respectively (Figure 4.10). Methyl-β-
cyclodextrin (MβCD) extracts membrane cholesterol and flattens caveolae, thereby preventing 
caveolar endocytosis (Figure 4.10). Next, small molecule inhibitors were selected to inhibit the 
internalization step of endocytosis. The small molecule dynasore inhibits dynamin GTPase 
activity, thereby blocking dynamin-mediated internalization (Figure 4.10). ML141 inhibits 
CLIC/GEEC endocytosis by attenuating the GTPase activity of Cdc42, while NCS 23766 
inhibits macropinocytosis by attenuating Rac-1 GTPase activity (Figure 4.10). Macropinocytosis 
can also be targeted by inhibiting the activity of proteins thought to be required for function. 
Inhibition of SRC family kinases by PP2, and sodium-proton exchange by EIPA block 
macropinocytosis (Figure 4.10).  
The actin cytoskeleton is implicated during the internalization step in all of the major 
pathways of endocytosis. Actin polymerization and depolymerization are inhibited by latrunculin 
A and jasplakinolide, respectively (Figure 4.10). Lysosomal degradation and proteasomal 
degradation are the two pathways of protein degradation in the cell. Although lysosomal 
degradation is the canonical endpoint of endocytosis, several lines of evidence suggest the  
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Table 4.1: Endocytosis inhibitor panel 
Small molecule inhibitors used to study Ank105-mediated constitutive PDGFR degradation, 
ligand induced PDGFR degradation and LDL uptake are tabulated and listed according to their 
respective targets. Inhibitors with similar function, such as blocking internalization, are grouped 
together and color coded. 
 
proteasome is involved in endocytosis-mediated protein degradation. Lysosomal degradation and 
proteasomal degradation are inhibited by chloroquine and MG132, respectively. Lastly, the 
cellular proton gradient and PI3K activity have been implicated broadly in many pathways of 
endocytosis. The proton gradient can be disrupted with monensin and PI3K activity can be 
inhibited by wortmannin (Figure 4.10). Several of the small molecule endocytosis inhibitors used 
to study Ank105-mediated constitutive PDGFR degradation are not specific to one endocytosis 
pathway, but rather affect several pathways at a common junction. Although the endocytosis 
pathways discussed are distinct, certain pathways use common mechanisms, such as 
internalization, to function. Several endocytosis pathways, including CME, caveolar endocytosis 
and lipid clustering require dynamin to drive internalization whereas others, including 
CLIC/GEEC and macropinocytosis, are independent of dynamin activity (Figure 4.11). MβCB 
can inhibit both CME and caveolar endocytosis; however caveolar endocytosis is thought to be  
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Figure 4.10: General endocytosis pathway and targets of small molecule inhibitors 
Depicts a general scheme of endocytosis common to major pathways, as well as delineates stages 
of endocytosis affected by various small molecule inhibitors. Cell surface receptors are 
incorporated into budding, protein coated vesicles (1.). Budding vesicles are internalized (2.), 
often requiring dynamin activity. Internalized vesicles are trafficked to the sorting endosome (3.) 
where they are sorted (4.) and either recycled back to the plasma membrane (5a.) or incorporated 
into multivesicular bodies (5b.) and subsequently trafficked for degradation (6.). 
 
more sensitive to plasma membrane cholesterol levels (Figure 4.11). Several inhibitors can be 
considered broad endocytosis inhibitors and affect multiple endocytosis pathways (Figure 4.11). 
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Thus by studying the effects of the endocytosis inhibitor panel on Ank105-mediated constitutive 
degradation, the pathway by which Ank105 functions was characterized. 
 
Figure 4.11: Pathway specificities of the small molecule endocytosis inhibitor panel 
Small molecule endocytosis inhibitors used to study Ank105-mediated constitutive PDGFR 
degradation, ligand induced PDGFR degradation and LDL uptake are organized according to 
which endocytosis pathways they affect. Text box size delineates endocytosis pathways affected. 
Endocytosis pathways are organized based upon the requirement of clathrin and/or dynamin for 
proper function. Modified from with permission from (von Kleist and Haucke, 2012). 
 
4.7.1 Ank105-mediated constitutive PDGFR degradation requires dynamin activity and 
functional lysosomal and proteasomal pathways 
PDGFR expression levels in HA-Ank105-expressing cells were increased by overnight 
culture in low serum media. Serum restricted cells were incubated with ranging concentrations of 
each small molecule endocytosis inhibitor (Table 4.1) for 30 minutes then incubated in media 
containing 10% FBS in the presence of inhibitor. Control conditions where HA-Ank105-
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expressing cells were cultured in either 10% FBS or 1% FBS overnight, not treated with inhibitor 
and not stimulated with 10% FBS were generated to provide a baseline of constitutive and serum 
restricted PDGFR protein expression levels. These control conditions were compared to serum 
restricted HA-Ank105-expressing cells treated with inhibitor and stimulated with 10% FBS. 
Lysates were collected, normalized to total protein content and analyzed for PDGFR protein 
expression. Western blot analysis of PDGFR expression again demonstrated that serum 
restriction in HA-Ank105-expressing cells increased PDGFR protein levels by approximately 2 
fold, and those levels return to base line after 4 hours of incubation with media containing 10% 
FBS (Figure 4.12A,B). Treatment of serum restricted cells with increasing concentrations 
chloroquine partially inhibited constitutive PDGFR degradation in response to incubation with 
media containing 10% FBS (Figure 4.12A,B). The PDGFR protein expression levels are similar 
between the medium (10 µM) and high (20 µM) concentrations of chloroquine indicating that the 
medium concentration elicits the maximum effect. It is possible that more robust response to 
chloroquine may be observed if the concentration is increased further as the difference between 
the medium and high concentrations is only 2 fold. Treatment of serum restricted cells with 
increasing concentrations of MG132 to inhibit proteasomal degradation completely blocked 
constitutive PDGFR degradation in response to incubation with media containing 10% FBS 
(Figure 4.12A,B). PDGFR expression levels were similar across all concentrations of MG132 
used (Figure 4.12B). The data indicates that both a functional lysosome and proteasome are 
required for constitutive PDGFR degradation. Lysosomal degradation and proteasomal 
degradation are associated with monoubiquitination and polyubiquitination, respectively.  It 
would prove interesting to evaluate the ubiquitination state of the receptor in degradation-
impaired HA-Ank105-expressing cells to gain insight to the mechanism of PDGFR degradation 
promoted by Ank105. 
Due to the large amount of data collected the remainder of the data from each of the other 
endocytosis inhibitors in the panel is summarized (Figure 4.12A,B). To simplify the comparison 
of the effects of these different inhibitors on Ank105-mediated constitutive PDGFR degradation 
the mid-range concentration for each inhibitor was used rather than comparing the effect of a 
range of inhibitor concentrations on constitutive PDGFR degradation. Indeed PDGFR expression 
levels were very similar amongst inhibitor concentrations in the same set, for instance, low, 
medium and high concentrations of MG132 display similar PDGFR expression levels (Figure  
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Figure 4.12: Proteasomal and lysosomal degradation inhibitors MG132 and chloroquine 
block constitutive PDGFR degradation  
A. HA-Ank105-expressing cells were cultured overnight in media containing 1% FBS to 
increase PDGFR levels. Control cells were cultured overnight in media containing 10% FBS. 
Cells were either left untreated treated with increasing concentrations of chloroquine (5 μM, 10 
μM and 20 μM) or MG132 (5 µM, 10 µM and 20 µM) for 30 minutes.  Cells were stimulated 
with media containing 10% FBS for 240 minutes. Control cells, one set which were cultured in 
media containing 10% FBS overnight and another set in media containing 1% FBS overnight, 
were not stimulated with media containing 10% FBS as to provide base line levels of constitutive 
and recovered PDGFR, respectively. Lysates for each time point were collected, normalized for 
total protein content, resolved via SDS-PAGE (100 µg), transferred to a nitrocellulose membrane 
and analyzed by Western blot for PDGFR and GAPDH expression. PDGFR protein expression 
was quantified as per 3.2.3.4. Results are representative of those from 3 independent experiments 
(N=3). B. Quantification and graphical representation of PDGFR expression data in Figure 
4.12A and additional replicate experiments (Mean +/- S.D.). Data was compared to expression in 
Ank105 240min sample.  
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4.12A,B). This pattern held true for the majority of inhibitors tested (data not shown). 
Chloroquine concentrations were increased to those used in previous acute treatment 
experiments (100 µM) (Figure 4.3B,C). 
PDGFR protein expression data from serum restricted cells treated with the medium 
concentration of each inhibitor was compiled (Figure 4.13) and organized according to 
mechanism of action of each inhibitor (Table 4.1). PDGFR protein expression levels for each 
inhibitor were compared to untreated control cells and analyzed for statistical significance. In 
examining PDGFR protein expression levels in samples treated with inhibitors preventing proper 
clathrin vesicle coat formation, it is evident that treatment with either pitstop (Pvalue 0.44) or 
chlorpromazine (Pvalue 0.45) did not affect constitutive PDGFR degradation (Figure 4.13). 
Inhibition of caveolar endocytosis via extraction of plasma membrane cholesterol with MβCD 
also did not affect constitutive PDGFR degradation (Pvalue 0.26) (Figure 4.13). This data 
suggests that inhibition of CME with chlorpromazine or pitstop did not affect Ank105-mediated 
constitutive degradation. Additionally, Ank105-mediated constitutive PDGFR degradation is 
independent of caveolar endocytosis. 
 The effect of internalization inhibitors on constitutive PDGFR degradation was next 
determined. Inhibition of dynamin activity with dynasore did not affect Ank105-mediated 
constitutive PDGFR degradation. PDGFR protein expression levels in dynasore treated cells 
were elevated as compared to untreated control cells (Pvalue 0.015) (Figure 4.13). This data 
indicates that constitutive PDGFR degradation is partially dependent upon dynamin function. 
Inhibition of Cdc42 regulated CLIC/GEEC pathway with ML141 did not affect Ank105-
mediated constitutive PDGFR degradation. PDGFR protein expression levels in ML141 treated 
cells were similar to untreated control cells (Pvalue 0.29) (Figure 4.13). This data indicates that 
constitutive PDGFR degradation is independent the CLIC/GEEC pathway. Targeting of 
macropinocytosis via inhibition of Rac-1 activity with NCS 27366 produced interesting results. 
Serum restricted cells treated with NCS 27366 showed a decrease in PDGFR protein expression 
as compared to untreated control cells (Pvalue 0.031) (Figure 4.13). This data suggests that 
disruption of macropinocytosis promoted constitutive PDGFR degradation, possibly by directing 
a greater proportion of PDGFR towards Ank105-mediated constitutive degradation. A potential 
caveat is that treatment of the macropinocytosis inhibitor EIPA did not affect PDGFR protein 
expression levels as compared to control cells (Pvalue 0.17) (Figure 4.13). It may be possible 
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that HA-Ank105-expressing cells are insensitive to EIPA treatment or greater concentrations may 
be required to produce an effect. Additionally, Src kinase activity is thought to be implicated in 
macropinocytosis (Doherty and McMahon, 2009b) and treatment of serum restricted cells with  
 
Figure 4.13: Ank105-mediated constitutive PDGFR degradation is blocked via inhibition of 
dynamin activity and cellular protein degradation 
HA-Ank105-expressing cells were grown overnight in media containing 1% FBS to increase 
PDGFR levels. Cells were treated with the small molecule endocytosis inhibitor panel for 30 
minutes then  stimulated with media containing 10% FBS for 240 minutes. Lysates for each time 
point were collected, normalized for total protein content, resolved via SDS-PAGE (100 µg), 
transferred to a nitrocellulose membrane and analyzed by Western blot for PDGFR protein 
expression. PDGFR expression levels were quantified and summarized for each inhibitor (Mean 
+/- S.D.). Data compared to expression in Ank105 240min sample and analyzed for statistical 
significance by t-test (* indicates Pvalue <0.05, ** indicates Pvalue <0.001). Results were 
compiled from 3 independent experiments (N=3).  
 
PP2 slightly inhibited PDGFR degradation (Pvalue 0.012) (Figure 4.13) which is the opposite 
effect as observed with NCS 27366. SRC family kinases are also implicated in other endocytosis 
pathways including caveolar endocytosis (Doherty and McMahon, 2009b) and flotillin-mediated 
endocytosis (Doherty and McMahon, 2009b). The role of implicated proteins such as Src is 
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likely to be cell type specific (Doherty and McMahon, 2009b). 
 The effects of cytoskeletal inhibitors on constitutive PDGFR degradation were 
determined. Treatment of serum restricted cells with actin polymerization inhibitor latrunculin A 
resulted in a statistically significant decrease in PDGFR protein expression as compared to 
untreated control cells (Pvalue 0.048) (Figure 4.13). Similarly, treatment of serum restricted cells 
with microtubule de-polymerization agent nocodazole also decreased PDGFR protein expression 
levels as compared to untreated control cells (Pvalue 0.011) (Figure 4.13) This data suggests that 
inhibition of polymerization of either actin or microtubules promotes Ank105-mediated 
constitutive PDGFR degradation. The effect of latrunculin A on constitutive PDGFR degradation 
is particularly surprising considering actin dynamics are thought to contribute extensively to 
many pathways of endocytosis.  
The effects of other broad endocytosis inhibitors, monensin and wortmannin, were also 
studied. Treatment of serum restricted cells with the proton gradient disruptor monensin inhibited 
constitutive PDGFR degradation. Indeed, monensin treated cells had elevated PDGFR protein 
levels as compared to control cells stimulated with 10% FBS containing media (Pvalue 0.034) 
(Figure 4.13), indicating an intact proton gradient may be required for Ank105 function. The data 
obtained with the inhibitor monensin did however demonstrate high degree of variance, as 
evident by the large values of standard deviation (Figure 4.13). Treatment with wortmannin to 
inhibit PI3K activity promoted Ank105 function. Serum restricted cells treated with wortmannin 
had significantly lower PDGFR protein levels than untreated control cells (Pvalue 0.00011) 
(Figure 4.13), indicating that inhibition of PI3K activity promotes Ank105 function. 
 The requirement of functional lysosomal and proteasomal pathways for Ank105-
mediated constitutive PDGFR degradation was also determined. Inhibition of lysosomal 
degradation with chloroquine blocked constitutive PDGFR degradation. Chloroquine treated 
cells had similar PDGFR protein levels as untreated control cells which were not stimulated with 
10% FBS containing media (Pvalue 0.00012) (Figure 4.13). Inhibition of proteasomal 
degradation with MG132 robustly inhibited constitutive PDGFR degradation. MG132 treated 
cells had similar PDGFR protein levels as untreated control cells which were not stimulated with 
10% FBS containing media (Pvalue 0.0063) (Figure 4.13). Taken together this data indicates that 
functional lysosomal and proteasomal degradation pathways are required for Ank105-mediated 
constitutive PDGFR degradation. 
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 Several of the treatment conditions, such as monensin, dynasore and MG132 has a large 
degree of error in measurement of PDGFR protein levels following incubation in media 
containing 10% FBS. One potential shortcoming of the constitutive PDGFR degradation assay is 
the low dynamic range of the assay as receptor levels are only 2 fold less in cells incubated with 
serum as serum restricted cells (Figure 4.13), whereas ligand-induced PDGFR degradation 
studies had a much higher dynamic range as the difference in PDGFR expression levels between 
stimulated and unstimulated cells was more substantial (Figure 4.17). The lower dynamic range 
of the constitutive PDGFR degradation assay combined with error in measurement between 
replicate sets could potentially reduce the statistical significance of the observed effects of the 
small molecule inhibitors on constitutive PDGFR degradation. Perhaps additional replicate 
experiments for these particular inhibitors would reduce error and improve statistical analysis. 
Additional experiments with alternative methodologies such as fluorescence activated cell 
sorting could be employed to also address these issues. 
 
4.7.2 LDL internalization proceeds by a clathrin and dynamin-dependent mechanism 
 In order to validate observations made with the effects of inhibitor treatment on 
constitutive PDGFR degradation, the effects of endocytosis inhibitor panel were determined for 
uptake of LDL. Endocytosis of LDL has been extensively studied and is known to proceed by a 
clathrin and dynamin dependent mechanism. HA-Ank105-expressing cells were incubated with 
chloroquine, dynasore and MG132 for 30 minutes. Cells were then incubated with 
dialkylcarbocyanine-labeled LDL (Dil-LDL) for indicated times; after several washing steps 
uptake of Dil-LDL was measured by fluorescence signal intensity (Figure 4.14). Untreated HA-
Ank105-expressing cells internalized LDL in a linear fashion over time, with the highest levels 
of internalized LDL after 300 minutes (Figure 4.14A,B). Treatments with chloroquine and 
MG132 did not appear to affect LDL uptake in HA-Ank105-expressing cells (Figure 4.14A,B). 
Indeed, cells treated with chloroquine and MG132 internalized LDL in a linear fashion with 
respect to time, similar to control cells. In addition, cells treated with chloroquine or MG132 
internalized LDL to the same extent as control cells (Figure 4.14A,B). Treatment with dynasore 
strongly inhibited LDL uptake in HA-Ank105-expressing cells. After 300 minutes of incubation 
with Dil-LDL, 90% of LDL uptake was inhibited (Figure 4.14A,B). 
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Figure 4.14: Dynasore treatment inhibits LDL uptake in HA-Ank105 expressing cells 
A. HA-Ank105-expressing cells were cultured overnight in media containing 0.5% FBS, treated 
with chloroquine (25 μM), dynasore (80 µM) or MG132 (10 µM) for 30 minutes then incubated 
with serum-free media containing Dil-LDL (50 µg/mL) in the presence of inhibitor for indicated 
times. Dil-LDL uptake was measured as fluorescence signal intensity (Ex: 540 nm; Em: 580 
nm). B. Quantification and graphical representation of LDL uptake of 300 minute time point 
(Mean +/- S.D.). Results were compiled from 3 independent experiments (N=3). 
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Due to the large amount of data collected the remainder of the data from each of the other 
endocytosis inhibitors in the panel is summarized (Figure 4.15). To simplify the comparison of 
the effects of these different inhibitors on Dil-LDL uptake, the 300 minute time point for each 
inhibitor was used rather than comparing the effects of each inhibitor over a range of times. In 
examining LDL uptake in samples treated with inhibitors preventing proper vesicle coat 
formation, it is evident that treatment with the clathrin endocytosis inhibitor pitstop-2 strongly 
inhibits LDL uptake (Figure 4.15). Treatment with pitstop-2 inhibited 75% of LDL uptake in 
HA-Ank105-expressing cells (Pvalue 0.00038) (Figure 4.15). Similarly, treatment with the 
clathrin endocytosis inhibitor chlorpromazine partially blocked LDL uptake by 40% (Pvalue 
0.0044) (Figure 4.15). Taken together, this data indicates that LDL internalization proceeds by a 
clathrin-dependent mechanism. Extraction of plasma membrane cholesterol with MβCD partially 
inhibited LDL uptake in HA-Ank105-expressing cells, reducing uptake by 15% (Pvalue 0.038) 
(Figure 4.15). This slight inhibition could be due to the effects of MβCD on caveolar endocytosis 
or CME. The data indicates that CME is the predominant mechanism of internalization of LDL 
in HA-Ank105-expressing cells. 
The effect of internalization inhibitors on constitutive PDGFR degradation was next 
determined. Inhibition of dynamin activity with dynasore ablated LDL uptake in HA-Ank105-
expressing cells. Indeed, dynasore treatment inhibits 90% of LDL uptake (Pvalue 7.65x10-18) 
(Figure 4.15), indicating that dynamin activity is essential for LDL internalization. Inhibition of 
the CLIC/GEEC pathway with Cdc42 inhibitor ML141 did not affect LDL uptake. Cells treated 
with ML141 internalized LDL to a similar extent as untreated cells (Pvalue 0.20) (Figure 4.15). 
Inhibition of macropinocytosis with Rac-1 inhibitor NCS 27366 also did not affect LDL uptake. 
Cells treated with NCS 27366 internalized LDL to an extent comparable to untreated HA-
Ank105-expressing cells (Pvalue 0.17) (Figure 4.15). Similarly, treatment with additional 
macropinocytosis inhibitors PP2 (Pvalue 0.17) and EIPA (Pvalue 0.27) also did not affect LDL 
uptake (Figure 4.15). The data indicates that LDL internalization in HA-Ank105-expressing cells 
proceeds by a dynamin-dependent mechanism and does not involve dynamin-independent 
pathways. 
The effects of cytoskeletal inhibitors on LDL uptake were next determined. Treatment 
either with the actin polymerization inhibitor latrunculin A did not affect LDL uptake in HA-
Ank105-expressing cells (Pvalue 0.37) (Figure 4.15). Treatment with the actin de-polymerization 
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inhibitor jasplakinolide slightly impaired LDL uptake compared to untreated cells (Pvalue 0.037) 
(Figure 4.15). Treatment of HA-Ank105-expressing cells with the microtubule polymerization 
inhibitor nocodazole also did not affect LDL internalization (Pvalue 0.30) (Figure 4.15). Taken 
together, the data suggests that the aspects of cytoskeletal dynamics tested are not extensively 
involved in LDL internalization in HA-Ank105-expressing cells. 
 
 
Figure 4.15: LDL uptake proceeds by a clathrin and dynamin-dependent mechanism in 
HA-Ank105-expressing cells 
HA-Ank105-expressing cells were treated with each inhibitor of the small molecule endocytosis 
inhibitor panel for 30 minutes then incubated with Dil-LDL (50 µg/mL) for 300 minutes in the 
presence of inhibitor. Excess inhibitor was washed away. Internalized LDL was quantified as 
fluorescent signal intensity (Ex: 540 nm; Em: 580 nm) (Mean +/- S.D.). Data for each inhibitor is 
compared to untreated cells and analyzed for statistical significance by t-test (* indicates Pvalue 
<0.05, ** indicates Pvalue <0.001). Results were compiled from 3 independent experiments 
(N=3).  
 
The effects of other broad endocytosis inhibitors, monensin and wortmannin, were also 
studied. Treatment of HA-Ank105-expressing cells with the proton gradient disruptor monensin 
did not inhibit LDL uptake (Figure 4.15). Monensin treated cells internalized LDL to a similar 
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extent as untreated control cells (Pvalue 0.15) (Figure 4.15), indicating cellular proton gradient is 
not required for LDL uptake. Likewise, inhibition of PI3K activity with wortmannin did not 
affect LDL uptake in HA-Ank105-expressing cells (Pvalue 0.26) (Figure 4.15). 
The requirement of functional lysosomal and proteasomal pathways for LDL uptake in 
HA-Ank105-expressing cells was also determined. Inhibition of lysosomal degradation with 
chloroquine did not affect LDL uptake as cells treated with chloroquine internalized LDL to the 
same extent as untreated cells (Pvalue 0.16) (Figure 4.15). Treatment with the proteasomal 
degradation inhibitor MG132 blocked LDL uptake by 10% as compared to untreated HA-
Ank105-expressing cells (Pvalue 0.003) (Figure 4.15). This data indicates that lysosomal 
degradation is not required for internalization of LDL in HA-Ank105-expressing cells. 
 
4.7.3 Ligand-induced PDGFR degradation proceeds by a clathrin and dynamin-dependent 
mechanism and requires plasma membrane cholesterol 
 Next the effects of the endocytosis inhibitor panel were determined for ligand-induced 
PDGFR degradation to elucidate differences between constitutive degradation promoted by 
Ank105 and the canonical mechanism of receptor degradation. HA-Ank105-expressing cells 
were starved overnight in media containing 0.5% FBS to maximize responsiveness to 
stimulation. Cells were then treated with each of the small molecule endocytosis inhibitor panel. 
Cells were then stimulated for indicated times with PDGF (50 ng/mL) in the presence of 
inhibitor. Cells were analyzed by in-cell Western to quantify PDGFR protein expression levels 
(Figure 4.16A). As an example, full time course data set is shown for chloroquine, dynasore and 
MG132. In untreated cells overnight starvation in media containing 0.5% FBS increases PDGFR 
protein levels (Figure 4.16A). PDGFR is degraded over time in response to PDGF stimulation 
with the highest extent of degradation occurring after 240 minutes of ligand stimulation. PDGFR 
is degraded slower in chloroquine treated cells as compared to untreated control cells, with 
higher PDGFR protein expression levels at each time point (Figure 4.16A). Treatment with 
chloroquine increases PDGFR protein expressions levels by approximately 20% after 240 
minutes of PDGF stimulation (Figure 4.16A,B). Treatment of HA-Ank105-expressing cells with 
dynasore inhibits ligand-induced PDGFR degradation. PDGFR expression levels are 
approximately 80% the level of unstimulated cells at each time point (Figure 4.16A,B). 
Treatment of HA-Ank105-expressing cells with MG132 impairs ligand-induced PDGFR  
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Figure 4.16: Ligand-induced PDGFR degradation is dynamin-dependent in HA-Ank105-
expressing cells 
A. HA-Ank105-expressing cells were cultured overnight in media containing 0.5% FBS to 
increase PDGFR levels and maximize responsiveness to stimulation. Cells were treated with 
chloroquine (25 μM), dynasore (80 µM) or MG132 (10 µM) for 30 minutes then stimulated with 
media containing PDGF (50 ng/mL) in the presence of inhibitor for indicated times. PDGFR 
protein expression was quantified by in-cell Western. B. Quantification and graphical 
representation (Mean +/- S.D.) of the 240 min time point of each treatment condition. Results 
were compiled from 3 independent experiments (N=3).  
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degradation. PDGFR is degraded slower in MG132 treated cells as compared to untreated control 
cells, with higher PDGFR protein expression levels at each time point (Figure 4.16A). Treatment 
with MG132 increases PDGFR protein expressions levels by approximately 30% after 240 
minutes of PDGF stimulation (Figure 4.16A,B). 
Due to the large amount of data collected the remainder of the data from each of the other 
endocytosis inhibitors in the panel is summarized (Figure 4.17). To simplify the comparison of 
the effects of these different inhibitors on ligand-induced PDGFR degradation, the 240 minute 
time point for each inhibitor is evaluated rather than the entire stimulation time course. In 
examining inhibitors affecting vesicle coat formation, chlorpromazine did not have an effect on 
ligand-induced degradation (Pvalue 0.97), however treatment of HA-Ank105-expressing cells 
with the CME inhibitor pitstop impaired ligand induced PDGFR degradation and increased 
PDGFR protein levels by approximately 2 fold as compared HA-Ank105-expressing cells not 
treated with inhibitor (Pvalue 8.5x10-4) (Figure 4.17). The data with the pitstop inhibitor strongly 
indicated that ligand induced PDGFR degradation in HA-Ank105-expressing cells occurs by a 
clathrin-dependent mechanism, possibly independent from the mechanism of action of 
chlorpromazine. Recall the different mechanisms of these two inhibitors; chloropromazine 
induces misassembly of the clathrin lattice on endosomes whereas pitstop prevents adaptor 
assembly. 
Extraction of plasma membrane cholesterol with MβCD partially inhibited ligand 
induced degradation (Figure 4.17). PDGFR protein expression levels in HA-Ank105-expressing 
cells treated with MβCD were approximately 2 fold higher after 240 minutes of ligand 
stimulation as compared to control cells (Pvalue 1.5x10-7) (Figure 4.17). This data suggests that 
ligand induced PDGFR degradation is sensitive to levels of plasma membrane cholesterol. Some 
proportion of ligand-induced internalization may proceed by caveolar endocytosis. MβCD 
treatment did not have an extensive effect on LDL uptake (Figure 4.15), a molecule known to be 
internalized by a clathrin-dependent mechanism, whereas MβCD treatment partially inhibited 
ligand-induced degradation. Additionally chlorpromazine treatment inhibited 40% of LDL 
uptake (Figure 4.15) but did not affect ligand induced degradation (Figure 4.17). 
The effect of internalization inhibitors on ligand-induced PDGFR degradation was next 
determined. Inhibition of dynamin activity with dynasore strongly inhibited PDGFR degradation 
in HA-Ank105-expressing cells. Indeed, dynasore treatment inhibits 90% of PDGFR degradation  
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Figure 4.17: Ligand-induced PDGFR degradation requires clathrin, dynamin activity and 
plasma membrane cholesterol 
HA-Ank105-expressing cells were cultured overnight in media containing 0.5% FBS to increase 
PDGFR levels and maximize responsiveness to stimulation. Cells were treated with each 
inhibitor of the small molecule endocytosis inhibitor panel for 30 minutes then stimulated with 
media containing PDGF (50 ng/mL) in the presence of inhibitor for indicated times. PDGFR 
protein expression was quantified by in-cell Western (Mean +/- S.D.). Data for each inhibitor is 
compared to untreated cells stimulated for 240 minutes with PDGF and analyzed for statistical 
significance by t-test (* indicates Pvalue <0.05, ** indicates Pvalue <0.001). Results were 
compiled from 3 independent experiments (N=3).  
 
(Pvalue 4.1x10-11) (Figure 4.17), indicating that dynamin activity is essential for ligand-induced 
PDGFR degradation. Inhibition of the CLIC/GEEC pathway with Cdc42 inhibitor ML141 did 
not affect ligand-induced PDGFR degradation. The PDGFR protein expression levels in ML141 
treated cells are only 5% higher than untreated control cells after 240 minutes of PDGF 
stimulation (Pvalue 0.043) (Figure 4.17). Inhibition of macropinocytosis with Rac-1 inhibitor 
NCS 27366 also slightly inhibited ligand-induced PDGFR degradation (Figure 4.17). The 
PDGFR protein expression levels in NCS 27366 treated cells are only 10% higher than untreated 
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control cells after 240 minutes of PDGF stimulation (Pvalue 0.00158) (Figure 4.17). Treatment 
of HA-Ank105-expressing cells with Src family kinase inhibitor PP2 partially inhibited ligand-
induced PDGFR degradation. PDGFR protein expression levels in PP2 treated cells are 20% 
higher than untreated control cells after 240 minutes of PDGF stimulation (Pvalue 2.1x10-7) 
(Figure 4.17). Treatment with EIPA however did not affect ligand-induced PDGFR degradation 
(Figure 4.17). Cell treated with EIPA had similar PDGFR expression levels as control cells after 
240 minutes of PDGF stimulation (Pvalue 0.37) (Figure 4.17). Taken together the data with 
internalization inhibitors suggest that ligand-induced PDGFR degradation proceeds 
predominantly by a dynamin-dependent mechanism. The CLIC/GEEC and macropinocytotic 
endocytosis mechanisms may play a sight role in ligand-induced PDGFR degradation. Treatment 
with PP2 inhibits ligand- induced degradation to a greater extent than NCS 27366, possibly due 
to the fact that SRC family kinases are implicated in endocytosis pathways other than 
macropinocytosis, such as caveolar endocytosis (Doherty and McMahon, 2009b). 
The effects of cytoskeletal inhibitors on LDL uptake were next determined. Treatment 
with the actin de-polymerization inhibitor jasplakinolide slightly inhibited ligand-induced 
PDGFR degradation (Figure 4.17). The PDGFR protein expression levels in jasplakinolide 
treated cells are 7% higher than in untreated control cells stimulated for 240 minutes with PDGF 
(Pvalue 0.008) (Figure 4.17). Treatment with the actin polymerization inhibitor latrunculin A did 
not affect ligand-induced degradation as latrunculin A treated cells had similar PDGFR protein 
expression levels as untreated cells (Pvalue 0.29) (Figure 4.17). Treatment with the microtubule 
polymerization inhibitor nocodazole slightly inhibited ligand-induced PDGFR degradation 
(Figure 4.17). Nocodazole treated cells expressed approximately 12% more PDGFR protein than 
untreated control cells stimulated with PDGF for 240 minutes (Pvalue 0.00024) (Figure 4.17). 
Taken together the data suggests that the actin cytoskeleton may have a minimal role in ligand-
induced PDGFR degradation, whereas the microtubule cytoskeleton may be more involved. 
The effects of other broad endocytosis inhibitors, monensin and wortmannin, were also studied. 
Treatment of HA-Ank105-expressing cells with the proton gradient disruptor monensin did not 
affect ligand-induced PDGFR degradation as the expression level of PDGFR protein in 
monensin treated cells are similar to untreated control cells (Pvalue 0.13) (Figure 4.17). 
Treatment with wortmannin slightly inhibited ligand-induced PDGFR degradation (Figure 4.17). 
Wortmannin treated cells expressed approximately 10% more PDGFR protein than untreated 
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control cells stimulated with PDGF for 240 minutes (Pvalue 0.003) (Figure 4.17). 
The requirement of functional lysosomal and proteasomal pathways for ligand-induced 
PDGFR degradation in HA-Ank105-expressing cells was also determined. Inhibition of 
lysosomal degradation with chloroquine and proteasomal degradation with MG132 both partially 
inhibited PDGFR degradation (Figure 4.17). Cells treated with chloroquine expressed 16% more 
PDGFR protein after 240 minutes of PDGF stimulation than untreated control cells (Pvalue 
0.00034) and cells treated with MG132 expressed 23% more PDGFR protein than untreated 
control cells (Pvalue 3.9x10-7) (Figure 4.17). 
 
4.8 shRNA-mediated knockdown of endocytosis proteins 
 To further define the endocytosis pathway by which Ank105-mediated constitutive 
PDGFR degradation occurs, proteins involved in several stages of endocytosis were targeted for 
knockdown via small hairpin RNA (shRNA) (Figure 4.18). Coat formation in clathrin-mediated 
and caveolar endocytosis was targeted for inhibition by transfection of HA-Ank105-expressing 
cells with shRNA plasmids directed against the heavy chain of clathrin and caveolin-1, 
respectively (Figure 4.18). The internalization step of endocytosis was targeted for inhibition 
with shRNA specific for dynamin-II (Figure 4.18). Multivesicular body biogenesis was targeted 
with shRNA directed against tsg101 (Figure 4.18). Trafficking to the lysosome was targeted via 
knockdown of rab7 (Figure 4.18). Known binding partners of Ank105 were also targeted for 
shRNA mediated knockdown including p85 and spectrin β-II (Figure 4.18). HA-Ank105-
expressing cells were also transfected with control shRNA plasmids, which are not specific for 
any known protein. If the proteins targeted for knockdown are required for Ank105-mediated 
constitutive PDGFR degradation, then reduction of expression would lead to an increase in 
PDGFR protein expression levels. Knockdown of proteins required for Ank105 function should 
revert the phenotype cause by HA-Ank105 overexpression. For each shRNA transduced into 
HA-Ank105-expressing cells, 24 clones were isolated under puromycin selection. Those clones 
surviving expansion were analyzed for mRNA expression of target knockdown genes. 
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Figure 4.18: General endocytosis pathway and targets of small hairpin RNAs 
Depicts a general scheme of endocytosis common to major pathways, as well as delineates stages 
of endocytosis targeted by various small hairpin RNAs (shRNA). Cell surface receptors are 
incorporated into budding, protein coated vesicles (1.). Budding vesicles are internalized (2.), 
often requiring dynamin activity. Internalized vesicles are trafficked to the sorting endosome (3.) 
where they are sorted (4.) and either recycled back to the plasma membrane (5a.) or incorporated 
into multivesicular bodies (5b.) and subsequently trafficked for degradation (6.). 
 
4.8.1 Inability to generate clathrin knockdown clones 
 HA-Ank105-expressing cells were lentivirally transduced with shRNA directed against 
the heavy chain of clathrin. Stable clathrin knockdown clones were generated under puromycin 
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selection (Figure 4.19). Clathrin heavy chain mRNA expression was evaluated by RT-PCR in  
 
Figure 4.19: Unsuccessful shRNA knockdown of clathrin heavy chain in Ank105-expressing 
cells 
HA-Ank105-expressing cells stably transduced with scrambled shRNA or shRNA specifically 
targeting clathrin heavy chain (clathrin HC) were generated. A. mRNA was purified, converted 
to cDNA and analyzed for clathrin HC expression via qRT-PCR and normalized to β-actin 
expression. (* indicates Pvalue <0.05; ** indicates Pvalue <0.001) Results were compiled from 3 
independent experiments (N=3). B. Lysates were resolved by SDS-PAGE (100 µg) and analyzed 
via Western blot for PDGFR, clathrin heavy chain and GAPDH expression. C. Quantification 
and graphical representation of Figure 4.19b. Data compared to expression in Ank105 Samples. 
N=1. 
 
stable knockdown cell lines and compared to HA-Ank105-expressing cells and HA-Ank105-
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expressing cells stably transduced with control scrambled shRNA (Figure 4.19A). The two 
clones obtained, Clathrin HC.13 and Clathrin HC.15, did not demonstrate knockdown in clathrin 
heavy chain expression (Figure 4.19A). Indeed, clathrin heavy chain mRNA expression was 
higher in clathrin HC.13 and clathrin HC.15 than HA-Ank105-expressing cells (Figure 4.19A). 
Clathrin heavy chain mRNA expression levels were slightly higher in cells transduced with 
control scrambled shRNA HA-Ank105-expressing cells (Figure 4.19A). Additionally, clathrin 
heavy chain protein expression levels were robust when examined by Western blot (Figure 
4.19B,C). Only two stable clathrin heavy chain knockdown cell lines were obtained, suggesting 
that clathrin heavy chain expression may be essential for viability in HA-Ank105-expressing 
cells. 
 
4.8.2 Knockdown of dynamin-II does not recover PDGFR protein levels in HA-Ank105-
expressing cells. 
 Two isoforms of dynamin are expressed. Dynamin-I is expressed in neuronal cells while 
dynamin-II is expressed ubiquitously (Altschuler et al., 1998). HA-Ank105-expressing cells 
were lentivirally transduced with shRNA directed against dynamin-II. Stable dynamin 
knockdown clones were generated under puromycin selection. Dynamin-II mRNA expression 
was evaluated by qRT-PCR in stable knockdown cell lines and compared to HA-Ank105-
expressing cells and HA-Ank105-expressing cells stably transduced with control scrambled 
shRNA (Figure 4.20A). Two cells lines were identified reduction in dynamin-II mRNA 
expression. The dynamin-II.15 cell line showed the greatest level of knockdown, with expression 
levels reduced 50% as compared to HA-Ank105-expressing cells (Pvalue 0.014) (Figure 4.20A). 
The dynamin-II.17 cell displayed expression levels reduced 40% as compared to control cells 
(Pvalue 0.022) (Figure 4.20A). Dynamin-II mRNA expression levels were similar between HA-
Ank105-expressing cells and cells transduced with control scrambled shRNA (Pvalue 0.08) 
(Figure 4.20A). Cell lines showing reduction in dynamin-II mRNA were examined by Western 
blot for PDGFR and dynamin protein expression (Figure 4.20B,C). Dynamin-II.15 (Pvalue 0.04) 
and dynamin-II.17 (Pvalue 0.04) cell lines also demonstrated reduction in dynamin protein 
expression levels (Figure 4.20B,C). Knockdown of dynamin-II in these cell lines did not increase 
PDGFR levels. PDGFR protein expression levels in dynamin-II.15 (Pvalue 0..07) and dynamin-  
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Figure 4.20: Knockdown of dynamin in Ank105-expressing cells does not impact 
constitutive PDGFR degradation 
HA-Ank105-expressing cells stably transduced with scrambled shRNA or shRNA specifically 
targeting dynamin-II were generated. A. mRNA was purified, converted to cDNA and analyzed 
for dynamin-II expression via qRT-PCR and normalized to β-actin expression. Results were 
compiled from 3 independent experiments (N=3). B. Lysates were resolved by SDS-PAGE (100 
µg), transferred to a nitrocellulose membrane and analyzed via Western blot for PDGFR, 
dynamin-II and GAPDH expression. C. Quantification of Figure 4.20b (Mean +/- S.D.). Data 
compared to expression in Ank105 samples via t-test. (* indicates Pvalue <0.05; ** indicates 
Pvalue <0.001). Results were compiled from 3 independent experiments (N=3). 
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II.17 (Pvalue 0.10) knockdown cell lines was similar to HA-Ank105-expressing cells (Figure 
4.20B,C). A caveat with this data there is a large degree of variance in quantification of PDGFR 
protein levels across these cells lines (Figure 4.20C). Additionally, dynamin protein expression 
levels in cells transduced with control scrambled shRNA are reduced as compared to HA-
Ank105-expressing cells (Figure 4.20B,C). This result is unexpected considering the two cell 
lines have similar dynamin-II mRNA expression levels (Figure 4.20A). It may be prudent to 
examine additional scrambled shRNA controls for dynamin-II mRNA and protein expression 
levels as well as perform additional replicates to decrease variance in the data. 
 
4.8.3 Knockdown of tsg101 does not recover PDGFR protein levels in HA-Ank105-
expressing cells. 
HA-Ank105-expressing cells were lentivirally transduced with shRNA directed against  
tsg101 to impair MVE formation. Stable tsg101 knockdown clones were generated under 
puromycin selection. Tsg101 mRNA expression was evaluated by RT-PCR in stable knockdown 
cell lines and compared to HA-Ank105-expressing cells and HA-Ank105-expressing cells stably 
transduced with control scrambled shRNA (Figure 4.21A). Several cell lines were identified 
showing a statistically significant reduction in tsg101 mRNA expression. The tsg101.3 cell line 
demonstrated the greatest extent of knockdown, with levels reduced 75% as compared to HA-
Ank105-expressing cells (Pvalue 1.79x10-5) (Figure 4.21A). Tsg101 mRNA expression levels in 
the other stable knockdown cell lines, tsg101.7 (Pvalue 7.10x10-5), tsg101.13 (Pvalue 2.31x10-5) 
and tsg101.14 (Pvalue 0.00067), were reduced approximately 50% as compared to HA-Ank105-
expressing cells (Figure 4.21A). Cells transduced with control scrambled shRNA had slightly 
elevated tsg101 mRNA expression levels as compared to HA-Ank105-expressing cells(Pvalue 
0.039) (Figure 4.21A). 
The cell lines showing knockdown of tsg101 mRNA expression were evaluated for 
PDGFR and GAPDH protein expression (Figure 4.21B,C). Tsg101.3 (Pvalue 0.16), tsg101.7 
(Pvalue 0.44) tsg101.13 (Pvalue 0.18) and tsg101.14 (Pvalue 0.40) knockdown cell lines all 
displayed PDGFR protein expression levels similar to HA-Ank105-expressing cells (Figure 
4.21B,C). PDGFR protein expression levels in cells transduced with control scrambled shRNA 
were similar to HA-Ank105-expressing cells (Pvalue 0.054) (Figure 4.21B,C). The tsg101 
knockdown cell lines were also evaluated for tsg101 protein expression levels. However, despite  
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Figure 4.21: shRNA knockdown of tsg101 in HA-Ank105-expressing cells does not recover 
constitutive PDGFR expression 
HA-Ank105-expressing cells stably transduced with scrambled shRNA or shRNA specifically 
targeting tsg101 were generated. A. mRNA was purified, converted to cDNA and analyzed for 
tsg101 expression via qRT-PCR and normalized to β-actin expression. Results were compiled 
from 3 independent experiments (N=3). B. Lysates were resolved by SDS-PAGE (100 µg) and 
analyzed via Western blot for PDGFR and GAPDH expression. C. Quantification and graphical 
representation of Figure 4.21b (Mean +/- S.D.). Data compared to expression in Ank105 samples 
by t-test. (* indicates Pvalue <0.05; ** indicates Pvalue <0.001). Results were compiled from 3 
independent experiments (N=3). 
 
testing several commercially available antibodies, suitable antibodies for Western blot detection 
117 
of tsg101 protein expression in HA-Ank105-expressing cells were not obtained. Assuming the 
reduction in tsg101 mRNA expression levels correspond to reduction in tsg101 protein levels, the 
data indicates that Ank105-mediated constitutive PDGFR degradation may be independent of 
tsg101 function since 75% knockdown of tsg101 mRNA levels does not increase constitutive 
PDGFR protein levels. Tsg101 has been shown to be required for sorting ligand activated EGFR 
into multivesicular bodies and subsequent degradation. An alternative explanation is that the 
level of knockdown achieved is insufficient to disrupt tsg101 function. 
 
4.8.4 Knockdown of rab7 in HA-Ank105-expressing cells reduces PDGFR protein 
expression levels 
Ha-Ank105-expressing cells were lentivirally transduced with shRNA directed against 
rab7. Stable rab7 knockdown clones were generated under puromycin selection. Rab7 mRNA 
expression was evaluated by RT-PCR in stable knockdown cell lines and compared to HA-  
Ank105-expressing cells and Ank105-expressing cells stably transduced with control scrambled 
shRNA (Figure 4.22A). Several cells lines were identified showing a statistically significant 
reduction in rab7 mRNA expression. Rab7 mRNA expression in the rab7.4 knockdown cell line 
was reduced 85% as compared to HA-Ank105-expressing cells (Pvalue 0.003) (Figure 4.22A). 
The rab7.11 cell line showed an 80% reduction in rab7 mRNA levels (Pvalue 0.0033) (Figure 
4.22A). The rab7.15 cells line displayed a 60% reduction in rab7 mRNA as compared to HA-
Ank105-expressing cells (Pvalue 0.006) (Figure 4.22A). The rab7.17 cell line had the greatest 
level of knockdown, expressing 87% less rab7 mRNA as HA-Ank105-expressing cells (Pvalue 
0.005) (Figure 4.22A). The rab7 mRNA expression levels in cells transduced with control 
scrambled shRNA were similar to HA-Ank105-expressing cells (Pvalue 0.19) (Figure 4.22A). 
The cell lines showing knockdown of rab7 mRNA expression were evaluated for PDGFR 
and GAPDH protein expression (Figure 4.22B,C). The majority of the rab7 knockdown cells 
lines showed reduction in PDGFR protein expression levels. The rab7.4 cell line had 25% 
reduced PDGFR protein expression levels as compared to HA-Ank105-expressing cells (Pvalue 
0.011) (Figure 4.22B,C). The PDGFR expression levels in the rab7.11 cell line were 55% less 
than HA-Ank105-expressing cells (Pvalue 0.004) (Figure 4.22B,C). Rab7.15 displayed the 
greatest reduction in PDGFR protein expression levels, being 65% less than HA-Ank105-  
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Figure 4.22: Knockdown of rab7 in HA-Ank105-expressing cells reduces PDGFR protein 
expression levels 
HA-Ank105-expressing cells stably transduced with scrambled shRNA or shRNA specifically 
targeting rab7 were generated. A. mRNA was purified, converted to cDNA and analyzed for rab7 
expression via qRT-PCR and normalized to β-actin expression. Results were compiled from 3 
independent experiments (N=3). B. Lysates were resolved by SDS-PAGE (100 µg), transferred 
to a nitrocellulose membrane and analyzed via Western blot for PDGFR and GAPDH expression. 
C. Quantification and graphical representation of Figure 4.22b (Mean +/- S.D.). Data compared 
to expression in Ank105 samples by t-test. (* indicates Pvalue <0.05; ** indicates Pvalue 
<0.001). Results were compiled from 3 independent experiments (N=3). 
 
expressing cells (Pvalue 0.0031) (Figure 4.22B,C). The trend with reduction of PDGFR levels 
does not follow the level of rab7 mRNA expression in knockdown cell lines. The cell lines with 
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the highest extent of rab7 mRNA knockdown do not necessarily show the greatest reduction in 
PDGFR protein expression. The cell line with the lowest PDGFR expression level, being 
rab7.15, has the highest rab7 mRNA expression levels of the knockdown cell lines characterized 
(Figure 4.22B,C). The cell line showing most extensive knockdown of rab7 mRNA, rab7.17, had 
PDGFR protein expression levels similar to HA-Ank105-expressing cells (Pvalue 0.10). PDGFR 
protein expression levels in cells transduced with control scrambled shRNA were 30% higher 
than Ank-105-expressing cells (Pvalue 0.001) (Figure 4.22B,C), highlighting the need to 
characterize these cell lines with additional scrambled shRNA controls. The rab7 knockdown cell 
lines were also evaluated for rab7 protein expression levels. However, despite testing several 
commercially available antibodies, I was unable to identify an antibody suitable for Western blot 
detection of rab7 protein expression in HA-Ank105-expressing cells. Assuming the reduction in 
rab7 mRNA expression levels correspond to reduction in rab7 protein levels, the data indicates 
that knockdown of rab7, in the majority of cell lines tested, promotes reduction in PDGFR 
protein expression. One potential explanation is that inhibition of lysosomal trafficking promotes 
alternative mechanisms of degradation, such as proteasomal degradation. Indeed Ank105-
mediated constitutive PDGFR degradation was completely inhibited by MG132 treatment 
(Figure 4.13). 
 
4.9 Contributions of Ank105 binding partners to constitutive PDGFR degradation 
 
4.9.1 Knockdown of βII-spectrin in HA-Ank105-expressing cells reduces PDGFR protein 
expression levels 
HA-Ank105-expressing cells were lentivirally transduced with shRNA directed against 
the Ank105 binding partner βII-spectrin. Stable βII-spectrin knockdown clones were generated 
under puromycin selection. βII-spectrin mRNA expression was evaluated by RT-PCR in stable 
knockdown cell lines and compared to HA-Ank105-expressing cells and HA-Ank105-expressing 
cells stably transduced with control scrambled shRNA (Figure 4.23A). Two cells lines were 
identified showing a statistically significant reduction in βII-spectrin mRNA expression. The βII-
spectrin.1 cell line had the greatest level of knockdown, expressing 85% less βII-spectrin mRNA 
as HA-Ank105-expressing cells (Pvalue 0.0008) (Figure 4.23A). The βII-spectrin.7 cell line 
expressed 65% less βII-spectrin mRNA than HA-Ank105-expressing cells (Pvalue 0.001)  
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Figure 4.23: Knockdown of βII-spectrin in HA-Ank105-expressing cells reduces PDGFR 
protein expression levels 
HA-Ank105-expressing cells stably transduced with scrambled shRNA or shRNA specifically 
targeting βII-spectrin were generated. A. mRNA was purified, converted to cDNA and analyzed 
for βII-spectrin expression via qRT-PCR and normalized to β-actin expression. Results were 
compiled from 3 independent experiments (N=3). B. Lysates were resolved by SDS-PAGE (100 
µg), transferred to a nitrocellulose membrane and analyzed via Western blot for PDGFR and 
GAPDH expression. C. Quantification and graphical representation of Figure 4.23b (Mean +/- 
S.D.). Data compared to expression in Ank105 samples by t-test. (* indicates Pvalue <0.05; ** 
indicates Pvalue <0.001). Results were compiled from 3 independent experiments (N=3). 
 
(Figure 4.23A). Cells transduced with control scrambled shRNA had similar βII-spectrin mRNA 
expression levels as HA-Ank105-expressing cells (Pvalue 0.05) (Figure 4.23A). The cell lines 
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showing knockdown of βII-spectrin mRNA expression were evaluated for PDGFR and GAPDH 
protein expression (Figure 4.23B,C). PDGFR protein expression levels were significantly 
reduced in the βII-spectrin.1 cell line, expressing 83% less PDGFR than HA-Ank105-expressing 
cells (Pvalue 0.0012) (Figure 4.23B,C). The βII-spectrin.7 cell line expressed 95% less PDGFR 
than HA-Ank105-expressing cells (Pvalue 0.011) (Figure 4.23B,C). PDGFR expression levels 
were similar in cells transduced with control scrambled shRNA as compared to HA-Ank105-
expressing cells (Pvalue 0.05) (Figure 4.23B,C). 
 
4.9.2 Knockdown of p85α in HA-Ank105-expressing cells does not affect PDGFR protein 
expression levels 
As p85α was identified by our laboratory as a binding partner of Ank105 (Ignatiuk et al., 
2006), the requirement of p85α expression for constitutive PDGFR degradation in Ank105-
expressing cells was determined by RNA interference. If p85α is indeed required to mediate 
Ank105 function, knockdown of p85α would be expected to elevate constitutive PDGFR 
expression levels. HA-Ank105-expressing cells were lentivirally transduced with shRNA 
directed against the Ank105 binding partner p85α. Stable p85α knockdown mixed populations 
were generated under puromycin selection. A control mixed population was also generated via 
transduction of HA-Ank105-expressing cells with scrambled shRNA, followed by selection in 
puromycin. Lysates from HA-Ank105-expressing cells, control scrambled shRNA mixed 
population and p85α knockdown mixed population cell lines were evaluated for PDGFR, p85α 
and GAPDH protein expression via Western blot (Figure 4.24A,B). PDGFR protein expression 
levels were similar in HA-Ank105-expressing, control scrambled shRNA mixed population 
(Pvalue 0.42) and p85α knockdown mixed population cell lines (Pvalue 0.10), while only the 
p85α knockdown mixed population cell line demonstrated reduction in p85α protein expression 
levels (Figure 4.24A,B). Indeed, p85α protein expression was attenuated by 80% in the p85α 
knockdown mixed population cell line (Pvalue 0.007) as compared to HA-Ank105-expressing 
and the control scrambled shRNA mixed population cell line (Pvalue 0.31) (Figure 4.24A,B). 
These results indicate that p85α is not required for Ank105-mediated constitutive PDGFR 
degradation. Even though p85α was demonstrated to be a binding partner of Ank105 via both 
binding studies with purified proteins and co-immunoprecipitation studies in cells (Ignatiuk et 
al., 2006), the interaction of Ank105 and p85α may be involved in other cellular pathways other  
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Figure 4.24: Knockdown of p85α in HA-Ank105-expressing cells does not affect PDGFR 
protein expression levels 
Mixed populations were generated by transducing HA-Ank105-expressing cells with scrambled 
shRNA or shRNA specifically targeting p85α, followed by selection in puromycin. A. Lysates for 
HA-Ank105-expressing cells (Ank105), control scrambled mixed populations (control) and p85α 
knockdown mixed populations (p85 KD) were collected, normalized to total protein content, 
resolved by SDS-PAGE (50 µg), transferred to a nitrocellulose membrane and analyzed by 
Western blot for PDGFR, p85α and GAPDH protein expression. Results are representative of 
those from 3 independent experiments (N=3). B. Quantification of Figure 4.24A. PDGFR and 
p85α protein expression levels were compared to those from HA-Ank105-expressing cells. Data 
analyzed for statistical significance via t-test (* indicates Pvalue <0.05). Results were compiled  
from 3 independent experiments. 
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than Ank105-mediated constitutive PDGFR degradation. Since PI3K is a regulator of cell 
motility (Qian et al., 2003), it may be possible that Ank105-p85α interaction promotes cell 
motility as HA-Ank105-expressing cells migrate at a significantly faster rate than NIH 3T3 cells 
when seeded on glass cover slips (data not shown), however this possibility was not tested 
further. Indeed Ank105-p85α interaction occurred reciprocally in the absence of PDGF 
stimulation (Ignatiuk et al., 2006). 
 
4.10 HA-Ank105 interacts with several unidentified proteins under non-stimulated 
conditions 
 Since knockdown of known Ank105 binding partners, being βII-spectrin and p85α, did 
not elevate PDGFR expression levels, identification of novel binding partners of Ank105 could 
provide insight into the mechanism of Ank105-mediated constitutive PDGFR degradation. HA-
Ank105 plasmid DNA was transiently transfected into HEK293 cells to generate high protein 
expression levels of HA-Ank105. Indeed, HEK293 cells are a suitable model to pursue Ank105 
binding partners as transient expression of HA-Ank105 in HEK293 cells induces constitutive 
degradation of the EGFR. Cells were not stimulated with growth factor in order to facilitate 
isolation and identification of proteins that interact with Ank105 under constitutive conditions. 
HA-Ank105 was immunoprecipitated from lysate prepared under non-denaturing conditions 
using anti-HA antibody. As controls, lysates from untransfected HEK293 cells and HEK293 cells 
transiently transfected with HA-Ank105 were subjected to immunoprecipitation using anti-HA 
and non-specific IgG antibodies, respectively, to identify those proteins which specifically 
interact with HA-Ank105. Samples were denatured, resolved by SDS-PAGE and proteins were 
visualized by sypro ruby staining and UV light. HA-Ank105 interacted with a number of high 
(Figure 4.25A) and low (Figure 4.25B) molecular weight proteins. Immunoprecipitated HA-
Ank105, as well as the light and heavy antibody chains was also observed (Figure 4.25A,B). Our 
laboratory is actively collaborating with the laboratory of Dr. Mohan Babu (University of 
Regina) to determine the identity of proteins that interact with Ank105 via mass spectrometry, 
both in HEK293 cells and in NIH 3T3 cells stably expressing HA-Ank105. 
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Figure 4.25: HA-Ank105 interacted with several proteins under constitutive conditions in 
HEK 293 cells 
HA-Ank105 was transiently transfected in HEK293 cells. HA-Ank105 was immunoprecipitated 
from lysate prepared under non-denaturing conditions using and anti-HA antibody (10 µg). As 
controls, lysates from untransfected HEK293 cells and HEK293 cells transiently transfected with 
HA-Ank105 were subjected to immunoprecipitation using anti-HA (10 µg) and non-specific IgG 
antibodies (10 µg), respectively. Samples were denatured, resolved by SDS-PAGE and visualized 
via sypro ruby staining and UV light. A. Sypro ruby stained image of immunoprecipitants 
resolved by SDS-PAGE in a 7.5% poly-acrylamide gel. B. Sypro ruby stained image of 
immunoprecipitants resolved by SDS-PAGE in a 12% poly-acrylamide gel. Red arrows indicate 
unidentified proteins that co-immunoprecipitated with HA-Ank105. Blue arrows indicate 
antibody chains and HA-Ank105. 
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5.0 DISCUSSION 
 
5.1 Effects of Ank105 expression on PDGFR and EGFR degradation 
 Previous work using a phage display library identified Ank105 as a binding partner of 
p85 (King et al., 2000). Ank105 interacts with the SH2 domains of p85 in a phosphotyrosine-
independent manner via residues located in both the spectrin binding domain and regulatory 
domain (Ignatiuk et al., 2006). Interaction between p85 and Ank105 was confirmed in cells via 
reciprocal co-immunoprecipitation (Ignatiuk et al., 2006). Besides its well documented role in 
PI3K/PTEN signaling (Chagpar et al., 2010; Mellor et al., 2012), p85 stimulates the intrinsic 
GTPase activity of Rab5 thereby modulating the endocytosis of the PDGFR (Chamberlain et al., 
2008; Chamberlain et al., 2010; Mellor et al., 2012). Binding of p85 and Ank105 suggests that 
Ank105 may have a role in the regulation of PI3K signaling and PDGFR endocytosis. The 
effects of HA-Ank105 overexpression were studied in NIH 3T3 cells which endogenously 
express high levels of PDGFR. Overexpression of HA-Ank105 prompted PDGFR inactivation 
and degradation in response to PDGF stimulation and reduced the ability of fibroblasts to 
proliferate in the presence of PDGF (Ignatiuk et al., 2006). HA-Ank105 overexpression 
attenuated the activation of PDGFR in response to PDGF stimulation, as evident by reduced 
phosphorylation of the receptor (Ignatiuk et al., 2006). Indeed activation downstream Shc and 
PLC signaling pathways were also reduced (Ignatiuk et al., 2006). Co-immunofluorescence 
experiments show co-localization between Ank105, p85, and PDGFR during endocytosis 
(Ignatiuk et al., 2006). Furthermore, HA-Ank105 co-localized with the lysosomal marker protein 
LAMP-1, but not with the early endosomal marker protein EEA1 (Ignatiuk et al., 2006) and 
treatment of cells with chloroquine inhibited PDGFR degradation in response to ligand (Ignatiuk 
et al., 2006). These observations indicate that Ank105 enhances the lysosomal degradation of the 
PDGFR and attenuates signaling pathways downstream of the receptor. 
 To evaluate the effect of HA-Ank105 expression on PDGFR expression and signaling, 
several cell lines were selected showing increasing amounts of HA-Ank105 expression (Figure 
4.1). Each Ank105-expressing cell line had reduced PDGFR levels as compared to untransfected 
controls (Figure 4.1). Additionally, activation of the receptor itself as well as downstream AKT 
and MAPK signaling pathways was also attenuated in HA-Ank105-expressing cells in response 
to PDGF stimulation, as compared to untransfected NIH 3T3 cells (Figure 4.1). The extent of 
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reduction in constitutive PDGFR levels and signaling activation in response to ligand tended to 
increase as HA-Ank105 expression increased. The expression levels of constitutive PDGFR is 
slightly higher in the high HA-Ank105-expressing cell line than in the medium HA-Ank105-
expressing cell line; however PDGFR phosphorylation and phosphorylation of both AKT and 
MAPK are increasingly attenuated as HA-Ank105 expression increases (Figure 4.1). It may be 
possible that at very high expression levels of Ank105, the endocytic cellular machinery became 
over saturated with Ank105 and excess Ank105 could sequester its binding partners, thereby 
impairing Ank105 function. Importantly expression of HA-Ank105 does not affect the 
expression levels of the MAPK and AKT proteins themselves (Figure 4.1). Both MAPK and 
AKT signaling are increasingly attenuated in HA-Ank105-expressing cells however reduction of 
MAPK activation is much more pronounced. Activation of AKT signaling primary occurs at the 
plasma membrane (Cantley, 2002) whereas MAPK activation and signaling is thought to occur 
on endosomes (von Zastrow and Sorkin, 2007). Alterations in endosomal trafficking of PDGFR 
in HA-Ank105-expressing cells could explain the difference observed in differential sensitivity 
of AKT and MAPK activation to HA-Ank105 expression. An alternative explanation is that since 
AKT activation depends on the production of lipid second messengers AKT signaling would be 
less dependent on total receptor levels for efficacy than the MAPK pathway. The production of 
second messengers amplifies the original signal, rendering downstream signaling less sensitive to 
the intensity of the original signal.    
 The degradation of both transmembrane cargo (Hicke, 2001) and intracellular proteins 
(Ravid and Hochstrasser, 2008) requires ubiquitination. The PDGFR was immunoprecipitated 
from untransfected NIH 3T3 cells and HA-Ank105-expressing cells in order to examine 
activation and ubiquitination of the PDGFR in response to ligand stimulation. PDGFR 
immunoprecipitated from NIH 3T3 cells showed a more intense overall ubiquitination signal 
than PDGFR from HA-Ank105-expressing cells (Figure 4.3A). The increased signal intensity in 
NIH 3T3 cells is expected due the significant decrease in constitutive PDGFR levels in HA-
Ank105-expressing cells, as more receptor was expressed and available for activation, 
phosphorylation and ubiquitination (Figure 4.3A). Despite HA-Ank105-expressing cells 
demonstrating less overall PDGFR ubiquitination, the ubiquitin moieties on the PDGFR appear 
to be at the same molecular weight as in NIH 3T3 cells, suggesting PDGFR is ubiquitinated 
similarly in NIH 3T3 and HA-Ank105-expressing cells in response to stimulation (Figure 4.3A). 
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This hypothesis would need to be confirmed by mass spectrometry of PDGFR 
immunoprecipitated from stimulated cells to identify ubiquitination sites on the PDGFR. 
 Interestingly, the PDGFR appears to be differentially phosphorylated upon ligand 
stimulation in NIH 3T3 cells and HA-Ank105-expressing cells (Figure 4.3A). Phosphorylation 
of the PDGFR, as indicated by Western blotting with antibody specifically detecting 
phosphorylated tyrosine residues, significantly increases the molecular weight of 
immunoprecipitated PDGFR in HA-Ank105-expressing cells as compared to NIH 3T3 cells 
(Figure 4.3A). Additional phosphorylation of the PDGFR in HA-Ank105-expressing cells could 
provide docking sites not present in NIH 3T3 cells for endocytic adaptor proteins to promote 
degradation of the PDGFR. To confirm this speculation, PDGFR could be immunoprecipitated 
from ligand stimulated, untransfected NIH 3T3 cells and HA-Ank105-expressing cells and 
examined via mass spectrometry to determine which intracellular tyrosine residues of the 
PDGFR are indeed phosphorylated. 
 The classical pathway of degradation of receptor tyrosine kinases upon growth factor 
stimulation is lysosomal degradation. Treatment of untransfected NIH 3T3 cells with chloroquine 
for 4 hours prior to PDGF stimulation inhibits receptor degradation (Figure 4.3B). The PDGFR 
phosphorylation profile in response to PDGFR stimulation in chloroquine treated NIH 3T3 cells 
was the same as untreated cells, indicating the PDGFR is still activated and de-activated 
normally even though the lysosomal degradation pathway is perturbed (Figure 4.3B). In HA-
Ank105-expressing cells treatment with chloroquine for 4 hours prior to PDGF stimulation only 
partially inhibited receptor degradation (Figure 4.3C). The constitutive PDGFR levels in 
chloroquine treated HA-Ank105-expressing cells were slightly higher than the constitutive 
PDGFR levels in untreated HA-Ank105-expressing cells and this increased receptor is degraded 
in response to PDGF stimulation (Figure 4.3C). Like untransfected NIH 3T3 cells, the activation 
profile of the PDGFR in HA-Ank105-expressing cells is similar with and without chloroquine 
treatment (Figure 4.3B,C). Possible explanations for only a slight increase in constitutive 
PDGFR levels is that PDGFR in this cell model is under control of an endogenous promoter and 
4 hours of chloroquine treatment may  not be sufficient to increase PDGFR levels to those 
observed constitutively in untransfected NIH 3T3 cells. Treatment times longer than 4 hours 
have proved toxic. An alternative explanation is that Ank105 mediates the majority of its effect 
on PDGFR levels via a mechanism other than lysosomal degradation. Indeed PDGFR present 
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after chloroquine treatment was degraded in response to PDGF stimulation. 
 Determining the receptor target range of Ank105 could provide a mechanism to attenuate 
pro-oncogenic RTK signaling in multiple cancers. Given that Ank105 promotes the degradation 
of PDGFR, the effect of HA-Ank105 expression on the degradation of EGFR was also 
determined. HA-Ank105 was transiently expressed in HEK293 cells and HeLa cells, both of 
which endogenously express EGFR. In HEK293 cells transfected with pHA3-Ank105, the level 
of constitutive EGFR expression decreased as HA-Ank105 expression increased in a dose-
dependent manner (Figure 4.2A). Expression of HA-Ank105 also attenuated phosphorylation of 
the EGFR even though phosphorylation of EGFR in this particular cell line appears to be 
independent of growth factor stimulation (Figure 4.2A). Transfection of the spectrin binding 
domain of Ank105 alone was sufficient to induce EGFR degradation; whereas, transfection of 
the regulatory domain of Ank105 alone did not induce EGFR degradation (data not shown). 
Expression of HA-Ank105 in HeLa cells did not affect EGFR expression levels. EGFR levels 
were similar in untransfected HeLa cells and cells transiently transfected increasing amounts of 
HA-Ank105 (Figure 4.2B). Indeed, EGFR activation and degradation profiles in response to 
EGF stimulation was consistent between untransfected HeLa cells and cells expressing HA-
Ank105 (Figure 4.2B). Interestingly, HeLa cells also express PDGFR at low levels and PDGFR 
levels are decreased upon HA-Ank105 expression.  Thus, HA-Ank105 expression differentially 
affects constitutive EGFR levels in HEK293 cells and HeLa cells. It may be that HEK293 cells 
express some additional factor specific to the EGFR such as an endocytic adaptor protein that 
sensitizes EGFR to Ank105-mediated degradation that is not expressed in HeLa cells; however 
this possibility was not explored further. It may prove interesting to immunoprecipitate EGFR 
from these two cell lines and compare the compliment of co-immunoprecipitating proteins. 
Differences in proteins interacting with the EGFR may provide insight into the mechanism of 
Ank105 function. Additionally it would be of value to determine the effects of HA-Ank105 
expression on the degradation of other RTKs, such as VEGFR or FGFR  
 
5.2 Ubiquitin binding function of Ank105 
 A common theme in the sorting of ubiquitinated cargo for lysosomal degradation is the 
ability of the sorting machinery to recognize monoubiquitinated cargo by interacting with the 
ubiquitin tag itself. Since Ank105 promotes degradation of the PDGFR, the ability of Ank105 to 
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interact with ubiquitin and ubiquitinated proteins was investigated. HA-Ank105 co-
immunprecipitated with several ubiquitinated proteins, particularly after ten minutes of ligand 
stimulation (Figure 4.4C), and interacted with monoubiquitin via an in vitro pulldown assay 
(Figure 4.4B). The ability of Ank105 to interact with polyubiquitin chains was not determined. It 
would prove interesting to determine if Ank105 could interact with lysine63-linked chains, as 
lysine63-linked chains are thought to provide a more efficient lysosomal degradation signal 
compared to monoubiquitin. Additionally, it would prove interesting to determine if Ank105 
interacts with lysine48-linked ubiquitin chains, as lysine48-linked ubiquitin chains target 
substrates for proteasomal degradation. Indeed, disruption of either lysosomal or proteasomal 
degradation with small molecule inhibitors dramatically impaired constitutive PDGFR 
degradation in HA-Ank105-expressing cells (Figure 4.13). 
 In order to determine if the ubiquitin binding function of Ank105 was required to mediate 
the effect of Ank105 expression on PDGFR degradation, point mutations and deletion mutations 
were employed to abrogate ubiquitin binding. Neither point mutation (HA-Ank105-S827D) nor 
deletion of the potential ubiquitin interaction motif (HA-Ank105-CΔ50, HA-Ank105-CΔ100) 
within the C-terminal regulatory domain disrupted ubiquitin binding (Figure 4.5A,B). The 
spectrin binding domain of Ank105 was shown to interact with ubiquitin while the regulatory 
domain itself did not bind ubiquitin (Figure 4.5C). 
To determine the region of the spectrin binding domain responsible for ubiquitin binding 
a series of deletion mutations were generated in regions of disorder in the spectrin domain of full 
length HA-Ank105 (Figure 4.8A). The region of the spectrin binding domain mediating ubiquitin 
binding remains elusive. Ubiquitin-GST pulldown experiments indicate that the HA-Ank105-
NΔ169 and HA-Ank105-NΔ359 proteins did not possess the ability to interact with ubiquitin 
while and HA-Ank105-NΔ385 deletion mutant retained ubiquitin binding (Figure 4.8B). The 
HA-Ank105-NΔ169 and HA-Ank105-NΔ359 proteins not binding ubiquitin while the HA-
Ank105-NΔ385 proteins retained ubiquitin binding is unexpected as the HA-Ank105-NΔ385 
protein has the same N-terminal amino acid residues deleted. The absence of observable 
ubiquitin binding with the HA-Ank105-NΔ169 and HA-Ank105-NΔ359 proteins could be due to 
the low overall signal intensity or complications in protein expression and folding, as the HA-
Ank105-NΔ169 protein is expressed as a doublet. One method to determine whether the HA-
Ank105-NΔ169 was properly folder or not would be to express this protein in NIH 3T3 or HEK 
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293 cells and determine whether if expression of this protein promotes degradation of the 
PDGFR or EGFR, respectively. Addition replicate experiments are required to improve signal 
intensity and determine the efficacy of HA-Ank105- NΔ169 ubiquitin binding, possibly by using 
more input lysate to increase signal intensity. Assuming the HA-Ank105-NΔ385 protein is able 
to interact with ubiquitin, the region of Ank105 mediating ubiquitin binding may be located 
between amino acids 360 and 588, which is the remainder of the spectrin binding domain. 
Deletion mutagenesis in this region could generate proteins to more closely pinpoint the region 
of Ank105 mediating ubiquitin interaction. The primary amino acid sequence of the spectrin 
binding domain does not correspond to the consensus sequences of any common ubiquitin 
binding domains, therefore Ank105 may bind ubiquitin by a novel mechanism. Identification and 
mutation of the amino acid residues in the spectrin binding domain which confer ubiquitin 
binding is required to determine if the ability of Ank105 to bind ubiquitin is linked to the 
observed phenotype of constitutive receptor tyrosine kinase degradation upon Ank105 
overexpression. If indeed the ability of Ank105 to recognize ubiquitin and ubiquitinated cargo is 
required for Ank105-mediated constitutive PDGFR and EGFR degradation then abrogation of 
ubiquitin binding via site directed mutagenesis would increase constitutive PDGFR and EGFR 
expression. 
 
5.3 Analysis of PDGFR endocytosis and degradation in the context of HA-Ank105 
expression 
 HA-Ank105-expressing cells were treated with a panel of small molecule endocytosis 
and protein degradation inhibitors to gain insight into the mechanism of Ank105-mediated 
constitutive PDGFR degradation. One challenge of studying Ank105-mediated constitutive 
receptor degradation is that Ank105 function is constitutive. Using small molecule inhibitors in a 
constitutively active system like Ank105 raises potential concerns. The PDGFR in HA-Ank105-
expressing cells is under the control of an endogenous promoter. Long inhibitor treatment times, 
potentially overnight, may be required to observe significant changes in PDGFR expression. 
Such long treatment times raise the possibility that changes observed in PDGFR expression may 
be due to off-target effects of the inhibitor. Thus a system permitting acute inhibitor treatment is 
desirable. Constitutive PDGFR levels in HA-Ank105-expressing cells are sensitive to the amount 
of serum used in the culture media. Culture of HA-Ank105-expressing cells in low levels of 
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serum increased constitutive PDGFR levels approximately 2 fold (Figure 4.9A). Incubation of 
low serum cultured cells in media containing normal serum levels induced degradation of the 
PDGFR and incubation in normal serum levels for 4 hours reduced PDGFR levels to those 
observed prior to serum restriction (Figure 4.9B,C). This system of inducible constitutive 
PDGFR degradation was used to study the effects of acute treatment of HA-Ank105-expressing 
cells with various small molecule inhibitors of endocytosis and protein degradation. Inhibition of 
endocytic and degradation pathways required for Ank105-mediated constitutive PDGFR 
degradation would result inhibition of PDGFR degradation (observed as increased levels of 
PDGFR protein) in serum restricted HA-Ank105-expressing cells when re-introduced to media 
containing normal serum levels. The small molecule inhibitors used were validated via 
comparison of the effects of these inhibitors on ligand induced PDGFR degradation and LDL 
uptake. 
 Cellular uptake of LDL is known to proceed via a clathrin and dynamin dependent 
mechanism of endocytosis. LDL uptake is impaired in HA-Ank105-expressing cells treated with 
inhibitors targeting clathrin or dynamin. Treatment with pitstop and chlorpromazine inhibited 
clathrin mediated uptake of LDL by 75% and 40%, respectively, whereas inhibition of dynamin 
activity with dynasore blocked 90% of LDL uptake (Figure 4.15). Extraction of plasma 
membrane cholesterol with MβCD slightly impaired LDL uptake. Inhibitors targeting clathrin 
independent mechanisms of internalization (Table 4.1, Figure 4.10, Figure 4.11) such as 
macropinocytosis (NCS 27366, EIPA), membrane ruffling (cytoskeleton inhibitors) and 
CLIC/GEEC (ML141) did not affect LDL uptake in HA-Ank105-expressing cells (Figure 4.15). 
The remainder of the inhibitors targeting broad endocytosis (monensin, wortmannin, nocodazole, 
latrunculin A and jasplakinolide) or protein degradation (chloroquine and MG132) also did not 
impact LDL uptake (Figure 4.15). Taken together, the small molecule endocytosis inhibitor panel 
confirmed the clathrin and dynamin dependent endocytosis of LDL. One caveat is the lack of 
effect of inhibitors targeting cytoskeleton dynamics. Indeed most mechanisms of endocytosis, 
including CME, are thought to require actin dynamics to function (Figure 4.11). Perhaps the 
involvement of actin in clathrin dependent uptake varies in different cell types. 
 The effects of the small molecule endocytosis inhibitor panel were examined for ligand 
induced degradation of the PDGFR in HA-Ank105-expressing cells. Stimulation of HA-Ank105-
expressing cells with PDGF for 240 minutes was sufficient to induce degradation of the PDGFR, 
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where PDGFR expression levels were reduced greater than 2 fold compared to unstimulated cells 
(Figure 4.17). Treatment with pitstop or dynasore inhibited 69% and 90% of PDGFR 
degradation, respectively (Figure 4.17), indicating that ligand induced PDGFR degradation 
occurs via a clathrin and dynamin dependent mechanism similar to LDL uptake. However there 
were differences between LDL uptake and ligand induced PDGFR degradation. Chlorpromazine 
treatment did not affect ligand induced PDGFR degradation (Figure 4.17), whereas 
chlorpromazine treatment reduced LDL uptake by 40% (Figure 4.15). Ligand induced PDGFR 
degradation is more sensitive to the level of cholesterol present in the plasma membrane. 
PDGFR expression levels in MβCD treated cells were 2 fold higher than in non-treated cells 
after PDGF stimulation (Figure 4.17), whereas MβCD treatment only slightly impaired LDL 
uptake (Figure 4.15). Additionally, treatment with the Src kinase inhibitor PP2 partially inhibited 
ligand induced PDGFR degradation (Figure 4.17) while having no effect on LDL uptake (Figure 
4.15). Similar to LDL uptake, inhibitors targeting clathrin independent pathways of endocytosis 
such as macropinocytosis (NCS 27366, EIPA), membrane ruffling (cytoskeleton inhibitors) and 
CLIC/GEEC (ML141), as well as broad endocytosis inhibitors (monensin, wortmannin, 
nocodazole, latrunculin A and jasplakinolide) did not impact ligand induced PDGFR degradation 
(Figure 4.15; Figure 4.17). Treatment with the lysosomal degradation inhibitor chloroquine and 
the proteasomal degradation inhibitor MG132 both partially inhibited ligand induced PDGFR 
degradation (Figure 4.17). Interestingly, ligand induced PDGFR degradation in untransfected 
NIH 3T3 cells was more sensitive to lysosomal degradation inhibitors than HA-Ank105-
expressing cells. Treatment of untransfected NIH 3T3 cells with chloroquine prior to ligand 
stimulation completely inhibits PDGFR degradation (Figure 4.3B), whereas the effect is much 
less pronounced in HA-Ank105-expressing cells (Figure 4.3C; Figure 4.17). It may be possible 
that the lower sensitivity of HA-Ank105-expressing cells to protein degradation inhibitors prior 
to PDGF stimulation may reflect the ability of Ank105 to interact with ubiquitinated proteins 
upon ligand stimulation. Alterations in trafficking of ubiquitinated PDGFR could result in 
differences in sorting of ubiquitinated cargo through the endosomal system for degradation in 
HA-Ank105-expressing cells as compared to untransfected NIH 3T3 cells. Taken together, 
results from the small molecule endocytosis inhibitors indicate that both ligand induced PDGFR 
degradation and LDL uptake occur by a clathrin and dynamin dependent mechanism in HA-
Ank105-expressing cells, and ligand induced PDGFR degradation is sensitive to the level of 
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cholesterol present in the plasma membrane and partially sensitive to both lysosomal and 
proteasomal degradation inhibitors. 
 Culturing HA-Ank105-expressing cells in low serum overnight increases PDGFR 
expression levels 2 fold and incubation of serum restricted cells in media containing normal 
serum levels for 240 minutes induces degradation of PDGFR, decreasing PDGFR expression 
levels to those prior to serum restriction (Figure 4.9). The effects of the small molecule 
endocytosis inhibitor panel were markedly different for constitutive PDGFR degradation than for 
ligand induced PDGFR degradation and LDL uptake. Inhibitors of CME (pitstop and 
chlorpromazine) did not significantly impair constitutive PDGFR degradation (Figure 4.13), 
whereas treatment of cells with pitstop dramatically impaired both ligand induced PDGFR 
degradation (Figure 4.17) and LDL uptake (Figure 4.15). Additionally, constitutive PDGFR 
degradation was insensitive to the level of cholesterol present in the plasma membrane (Figure 
4.13) whereas treatment with MβCB impaired ligand induced PDGFR degradation (Figure 4.17).  
Inhibitors targeting macropinocytosis and other endocytosis pathways relying on a 
dynamic cytoskeleton slightly increased constitutive PDGFR degradation (Figure 4.13). 
Treatment with the macropinocytosis inhibitor EIPA did not affect constitutive degradation 
(Figure 4.13), indicating that inhibition of alternative clathrin independent mechanisms of 
endocytosis, such as membrane ruffling, may increase constitutive PDGFR degradation. 
Inhibition of those clathrin independent pathways, sensitive to Rac-1 and PI3K activity as well as 
cytoskeletal dynamics, may increase the efficiency of constitutive PDGFR degradation, possibly 
by directing a greater proportion of the PDGFR population to an Ank105-mediated degradation 
pathway.  
Lysosomal and proteasomal degradation inhibitors demonstrate a more pronounced effect 
on constitutive PDGFR endocytosis, resulting in almost complete inhibition (Figure 4.13), as 
compared to ligand induced PDGFR degradation where the effects of these protein degradation 
inhibitors was much less pronounced (Figure 4.17; Figure 4.3C) Indeed, treatment of 
untransfected NIH 3T3 cells with the same concentration of chloroquine is sufficient to inhibit 
ligand induced PDGFR degradation. It is unclear whether constitutive PDGFR degradation is 
mediated by the lysosome, the proteasome or some combination of the two. Indeed, inhibition of 
either pathway was sufficient to significantly impair constitutive PDGFR degradation. Some 
research has suggested that the PDGFR is polyubiquitinated and degraded by the proteasome 
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(Ettenberg et al., 2001; Levkowitz et al., 1998; Lipkowitz, 2003). It remains possible that 
treatment of HA-Ank105-expressing cells with MG132 depletes the pool of free ubiquitin in the 
cell, thus impeding sorting and delivery of the PDGFR to the lysosome for degradation 
(Swaminathan et al., 1999). Other lines of evidence suggest proteasomal activity is required for 
sorting receptors into MVEs (Longva et al., 2002). Perhaps co-localization studies between 
PDGFR and endocytic marker protein with both lysosomal and proteasomal marker proteins in 
MG132 and chloroquine treated HA-Ank105-expressing cells would concretely identify the 
mechanism of constitutive PDGFR degradation. Interestingly inhibition of dynamin activity 
affected constitutive PDGFR degradation (Figure 4.13), ligand induced degradation (Figure 4.17) 
and LDL uptake (Figure 4.15) indicating that these different examples of endocytosis share a 
common feature required for internalization. Similar to ligand induced PDGFR degradation 
(Figure 4.17), inhibition of SRC kinase activity with PP2 partially impaired constitutive PDGFR 
degradation (Figure 4.13). 
It is certainly unusual for a mechanism of endocytosis to be independent of both clathrin 
and plasma membrane cholesterol, yet still be sensitive inhibition of dynamin activity. Indeed 
lipid clustering mechanisms of endocytosis which are independent of clathrin and plasma 
membrane cholesterol, yet still dependent upon dynamin activity, have been identified and are 
responsible for the endocytosis of the IgGE receptor (Figure 4.11) (von Kleist and Haucke, 
2012). It is possible that the observed clathrin independence of constitutive PDGFR degradation 
is an artifact of the inhibitors used. The pitstop inhibitor functions by competitively binding the 
region of clathrin responsible for interacting with adaptor proteins thereby preventing 
recruitment of clathrin to its adaptors (von Kleist et al., 2011). If constitutive PDGFR 
degradation relies on a different subset of adaptor proteins for endocytosis than ligand induced 
PDGFR degradation, these adaptor proteins may interact with clathrin in a manner which is not 
inhibited by pitstop. Indeed the clathrin-adaptor protein network is known to be extensive, 
complex and adaptive (Doherty and McMahon, 2009a).  
In order to confirm the observations made with small molecule inhibitors, expression of 
clathrin and dynamin and were targeted for knockdown via shRNA. Unfortunately, knockdown 
of the clathrin heavy chain proved to be detrimental to cell physiology. Only two stable cell lines 
were obtained after puromycin selection and neither of these clones demonstrated reduction of 
clathrin heavy chain expression via qRT-PCR. To evaluate the role of CME in Ank105-mediated 
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constitutive PDGFR degradation it would be prudent to transfect HA-Ank105-expressing cells 
with the clathrin binding domain of AP180. Overexpression of the clathrin binding domain of 
AP180 was sufficient to inhibit CME by impairing the ability of the clathrin lattice to interact 
with the plasma membrane (Ford et al., 2001).   
Dynamin-II was then targeted for shRNA-mediated knockdown and two stable cell lines 
were obtained, each showing approximately 50% reduction in dynamin-II expression via RT-
PCR (Figure 4.21A). Knockdown of dynamin-II was also confirmed via Western blot (Figure 
4.21B,C). One caveat with the Western blot data is that the scrambled shRNA control cell line 
also showed reduced dynamin-II protein expression levels (Figure 4.21B,C), but did not differ 
from HA-Ank105-expressing cells in dynamin-II mRNA levels (Figure 4.21A). Interestingly, 
PDGFR protein expression levels were similar in dynamin-II knockdown cell lines compared to 
HA-Ank105-expressing cells, as well as control scrambled shRNA cells (Figure 4.21B,C). 
Constitutive PDGFR endocytosis studies in dynasore treated HA-Ank105-expressing cells 
showed strong inhibition of PDGFR degradation (Figure 4.13), indicating a requirement of 
dynamin activity in Ank105-mediated constitutive PDGFR degradation. Since only a 50% 
reduction in dynamin mRNA levels was observed, it remains possible that dynamin was still 
expressed at a sufficient level for proper endocytosis to occur. Another possibility is that 
dynamin expression is sufficiently repressed to abrogate dynamin activity, and the cells have 
adjusted their endocytic machinery to bypass the requirement of dynamin function for receptor 
internalization and undergo endocytosis by an alternative mechanism (such as macropinocytosis 
or caveolar endocytosis). It may prove beneficial to evaluate both LDL uptake and ligand 
induced PDGFR degradation in dynamin knockdown cell lines using the small molecule 
inhibitors to determine differences between HA-Ank105-expressing cells and dynamin 
knockdown cell lines. Both LDL uptake and ligand induced PDGFR degradation were 
exquisitely sensitive to inhibition of dynamin activity. If LDL uptake and/or ligand induced 
PDGFR degradation are impaired in dynamin knockdown cells and constitutive degradation is 
not, it would suggest that constitutive degradation is proceeding via an alternative mechanism in 
the context of dynamin knockdown. Additionally, transfection of the dominant negative dynamin 
K44A mutant in HA-Ank105-expressing cells would be prudent to evaluate the role of dynamin 
in Ank105-mediated constitutive degradation. Dynamin K44A impairs endocytosis at the vesicle 
scission step, resulting in accumulation of committed “U-shaped” pits in the plasma membrane 
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(Macia et al., 2006a; Nankoe and Sever, 2006). Knockdown of the dynamin protein itself may 
produce a different phenotype where receptor cargo is not committed to dynamin-dependent 
endocytosis and can enter the cell via alternate mechanisms. 
 To further evaluate the role of lysosomal degradation in Ank105-mediated constitutive 
PDGFR degradation, tsg101 and rab7 were targeted for knockdown via shRNA. tsg101 is a 
critical component of the ESCRT machinery, required for sorting ubiquitinated cargo into MVEs 
which are subsequently trafficked to the lysosome and degraded (Raiborg and Stenmark, 2009). 
Knockdown of tsg101 was sufficient to impair EGFR degradation and results in accumulation of 
EGFR in late endosomal structures (Saksena et al., 2007). Indeed tsg101 is an interesting 
candidate for knockdown studies in HA-Ank105-expressing cells as HA-Ank105 binds ubiquitin 
and several ubiquitinated proteins, suggesting a role for Ank105 in sorting of ubiquitinated cargo 
for degradation. Several stable tsg101 knockdown cell lines demonstrated significant attenuation 
of tsg101 mRNA expression (Figure 4.22), yet had similar PDGFR protein expression levels as 
compared to HA-Ank105-expressing cells (Figure 4.22B,C). This could suggest that constitutive 
PDGFR degradation in HA-Ank105-expressing cells is independent of tsg101 and ESCRT 
sorting. Indeed ESCRT independent sorting of EGFR to the lysosome has been reported (Stuffers 
et al., 2009). Alternatively, the level of tsg101 knockdown in these cell lines may not be 
sufficient to adequately disrupt tsg101 function. As mRNA expressions and protein expression 
levels do not always directly correlate, tsg101 protein expression levels must be examined to 
determine the full extent of tsg101 knockdown. Development of in-house polyclonal rabbit 
antibodies would allow evaluation of tsg101 protein expression.  
The requirement of rab7 for constitutive PDGFR degradation in HA-Ank105-expressing 
cells was then determined as rab7 is the regulator of late endosome to lysosome trafficking 
(Zerial and McBride, 2001). The majority of rab7 knockdown cell lines showed a least an 80% 
reduction in rab7 mRNA expression as compared to control cells (Figure 4.23A) and a number of 
the rab7 knockdown cell lines showed decreased PDGFR levels as compared to HA-Ank105-
expressing cells (Figure 4.23B,C). It is expected that if lysosomal trafficking is the mechanism 
mediating PDGFR degradation then knockdown of rab7 would increase constitutive PDGFR 
levels. Acute treatment with the lysosomal degradation inhibitor chloroquine impairs constitutive 
PDGF degradation in serum restricted HA-Ank105-expressing cells (Figure 4.13). It would be of 
interest to study the effects of chloroquine and MG132 on constitutive PDGFR degradation in 
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rab7 knockdown cells to determine whether receptor degradation is still sensitive to inhibition of 
lysosomal degradation or if there is a greater sensitivity to proteasomal degradation inhibitors. 
Alternatively, HA-Ank105-expressing cells could be transfected with dominant negative mutants 
of rab7 and evaluated for constitutive PDGFR levels. Transfection of Rab7N125I in HeLa cells 
impairs EGFR degradation and promotes accumulation of EGFR in late endosomal structures 
(Ceresa and Bahr, 2006). 
 
5.4 Knockdown of known Ank105 binding partners does not rescue constitutive PDGFR 
protein expression levels 
 Previously identified Ank105 binding partners βII-spectrin and p85 were targeted for 
knockdown via shRNA. Interaction of the large isoforms of Ank3, which possess the N-terminal 
integral membrane protein binding domain, with βII-spectrin is required for Ank3 function. As 
abrogation of spectrin binding disrupts lateral membrane formation in epithelial cells (Kizhatil et 
al., 2007a; Kizhatil et al., 2007b), βII-spectrin was a candidate protein regulating Ank105-
mediated constitutive PDGFR degradation. Two cell lines showing significant reduction in βII-
spectrin mRNA expression via RT-PCR were obtained (Figure 4.24A). These cell lines were then 
screened by Western blot for βII-spectrin and PDGFR protein expression levels. Unfortunately, a 
suitable commercial antibody for the detection of endogenous βII-spectrin expression could not 
be obtained, and it is possible that βII-spectrin mRNA expression levels do not correlate to βII-
spectrin protein expression levels. To evaluate the effect of βII-spectrin knockdown, it could 
prove interesting to measure the rate of proliferation between HA-Ank105-expressing cells and 
βII-spectrin knockdown cells as knockdown of βII-spectrin has been previously shown to reduce 
thymidine incorporation in proliferation assays (Tang et al., 2003). Interestingly, PDGFR protein 
expression levels in βII-spectrin knockdown cell lines were dramatically reduced, suggesting 
potential roles for βII-spectrin in PDGFR biosynthesis or regulation of PDGFR turnover. If βII-
spectrin was required to mediate constitutive PDGFR degradation in HA-Ank105-expressing 
cells, then it is expected that knockdown of βII-spectrin would increase constitutive PDGFR 
expression levels. Since β-spectrin is expressed as several isoforms, it remains possible that other 
β-spectrin isoforms capable of interacting with Ank105 are still expressed. To further address the 
role Ank105-spectrin interaction, NIH 3T3 cells were stably transfected with GFP-tagged 
Ank105 containing mutations DAR999/1001 to alanine or A1024 to proline, that were previously 
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shown to abrogate spectrin binding (Kizhatil et al., 2007a; Kizhatil et al., 2007b). Unfortunately, 
these stable GFP-Ank105 mutant clones lost expression overtime, complicating analysis of the 
effects of these mutations on constitutive PDGFR expression (data not shown). The Ank105-
spectrin binding mutations were transferred to the HA vector, which has previously facilitated 
long term stable Ank105 expression, and stable clones in NIH 3T3 cells were generated. 
However, due to time constrains these cell lines were not evaluated. 
 The requirement of p85α for constitutive PDGFR degradation in HA-Ank105-expressing 
cells was then determined as p85α is binding partner of Ank105 (Ignatiuk et al., 2006). The p85α 
protein is an excellent candidate for regulation of Ank105-mediated constitutive PDGFR 
degradation as p85α directly binds the PDGFR and mediates downstream signaling of the 
PI3K/PTEN pathway (Chagpar et al., 2010; Mellor et al., 2012), as well as modulates PDGFR 
endocytosis via regulation of Rab5 activity (Chamberlain et al., 2008; Chamberlain et al., 2010; 
Mellor et al., 2012). HA-Ank105-expressing cells were transduced with shRNA targeting p85α 
to generate a mixed population and evaluated for PDGFR and p85α protein expression. 
Additionally, a mixed population of HA-Ank105-expressing cells transduced with scrambled 
control shRNA was also generated and screened. In the p85α knockdown mixed population cell 
line, p85α protein expression levels were reduced by 81% compared to the scrambled shRNA 
control mixed population cell line and HA-Ank105-expressing cells (Figure 4.24). Knockdown 
of p85α did not increase PDGFR expression levels as compared to control cell lines (Figure 
4.24), indicating p85α is not required for Ank105-mediated constitutive PDGFR degradation. 
The interaction between Ank105 and p85α may serve some purpose other than facilitating 
constitutive PDGFR degradation. 
 Given that knockdown of known Ank105 binding proteins βII-spectrin and p85α did not 
result in increased constitutive PDGFR expression, the identification of novel Ank105 binding 
partners could provide mechanistic insight into Ank105-mediated constitutive PDGFR 
degradation. To isolate potential binding partners, HA-Ank105 was immunoprecipitated from 
HA-Ank105-expressing cells and immunoprecipitants were analyzed via syproruby staining for 
proteins which co-immunoprecipitate with HA-Ank105. Indeed a number of high molecular 
weight (Figure 4.25A) and low molecular weight (Figure 4.25B) proteins were observed to co-
immunoprecipitate with HA-Ank105 and not from control samples. The Anderson laboratory is 
participating in an active collaboration with the laboratory of Dr. Mohan Babu (University of 
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Regina) to determine the identities of proteins which co-immunoprecipitate with HA-Ank105 via 
mass spectrometry. An additional complimentary experiment would be to immunoprecipitate 
PDGFR under constitutive and stimulated conditions in HA-Ank105-expressing cells, as well as 
untransfected NIH 3T3 cells, to determine the compliment of endocytic adaptor proteins, 
scaffold proteins and signaling molecules that interact with the PDGFR. These cell lines could 
potentially be cultured in low serum or treated with protein degradation inhibitors, as needed, to 
increase the relative abundance of proteins interacting with PDGFR. In this manner, proteins that 
specifically interact with the PDGFR in the context of HA-Ank105 expression could be 
identified. Indeed this may provide mechanistic insight into the regulation of constitutive and 
ligand induced PDGFR degradation in HA-Ank105 expressing cells. 
 
5.5 Summary of Ank105 function and relevance to PDGFR biology 
 Stable expression of HA-Ank105 in NIH 3T3 cells reduced constitutive PDGFR protein 
expression levels and attenuated pro-proliferative AKT and MAPK signaling pathways in 
response to ligand stimulation. Ank105 also promoted constitutive degradation of the EGFR; 
however this observation was cell type dependent. Expression of HA-Ank105 in NIH 3T3 cells 
alters the phosphorylation profile of intracellular tyrosine residues on the PDGFR in response to 
ligand stimulation and alters sensitivity of PDGFR degradation to chloroquine. NIH 3T3 cells are 
exquisitely sensitive to chloroquine, as chloroquine treatment drastically inhibited ligand induced 
PDGFR degradation, whereas chloroquine treatment of HA-Ank105-expressing cells has little 
effect on ligand induced PDGFR degradation. The greatest effect of HA-Ank105 expression on 
the PDGFR appears to be constitutive degradation as PDGFR expression levels in HA-Ank105-
expressing cells are significantly reduced compared to NIH 3T3 cells in the absence of PDGF 
ligand.  
PDGFR protein expression levels in HA-Ank105-expressing cells are sensitive to serum 
levels in the growth media. Overnight culture of HA-Ank105-expressing cells in media 
containing low levels of serum increased PDGFR protein expression levels by 2 fold and 
incubation of serum restricted cells in media containing standard levels of serum induced 
PDGFR degradation, with levels returning to those observed in non-serum restricted cells after 2 
hours, providing an inducible assay to study constitutive PDGFR degradation. Both LDL uptake 
and ligand induced PDGFR degradation in HA-Ank105-expressing cells are dependent upon 
140 
proper function of CME and dynamin activity, and are not greatly affected by protein 
degradation inhibitors (Figure 5.1B). Ligand induced PDGFR degradation is also dependent on 
the presence of cholesterol in the plasma membrane (Figure 5.1B). In contrast, constitutive 
PDGFR degradation in HA-Ank105-expressing cells is not dependent upon CME or cholesterol 
levels in the plasma membrane for function; however acute inhibition of dynamin activity 
impairs constitutive PDGFR degradation (Figure 5.1A). Expression of HA-Ank105 may promote 
the clathrin-independent, but dynamin dependent, constitutive endocytosis of the PDGFR. Of 
note, stable knockdown of dynamin-II in HA-Ank105-expressing cells does not increase 
constitutive PDGFR protein expression levels, however the extent of knockdown of dynamin-II 
may not have been sufficient to fully impair dynamin function or alternative mechanisms of 
internalization were up-regulated to compensate for long term attenuation of dynamin activity. 
Additional experiments with dominant negative mutants affecting dynamin activity and CME are 
required to explore the mechanism of internalization utilized for constitutive PDGFR 
degradation in HA-Ank105-expressing cells.  
Acute inhibition of either lysosomal or proteasomal degradation impairs constitutive 
PDGFR degradation (Figure 5.1A). It not clear if PDGFR is degraded in the proteasome or if the 
proteasome is involved in sorting of PDGFR to the lysosome for degradation (Figure 5.1A). The 
independence of ligand-induced PDGFR degradation to protein degradation inhibitors is 
surprising as PDGFR is effectively degraded post PDGF stimulation (Figure 5.1B), yet 
untransfected NIH 3T3 cells are exquisitely sensitive to inhibition of lysosomal degradation. 
These results could signify that, in the context of HA-Ank105 expression, degradation of the 
PDGFR in the absence of ligand proceeds by a novel mechanism compared to ligand induced 
degradation of the receptor (Figure 5.1A,B). The role of the proteasome in Ank105-mediated 
constitutive PDGFR degradation may share similarities to the mechanism of action of the 
benzoquinone ansamycins class drugs. Benzoquinone ansamycins class drugs induce ligand-
independent proteasomal degradation of a number of trans-membrane proteins including EGFR 
and ErbB2 (Blagosklonny, 2002; Lipkowitz, 2003; Mimnaugh et al., 1996; Neckers, 2002; Sepp-
Lorenzino et al., 1995; Tikhomirov and Carpenter, 2000). Proteasomal degradation induced by 
benzoquinone ansamycins is independent of the kinase activity of the receptor (Citri et al., 2002; 
Xu et al., 2001), whereas lysosomal degradation requires kinase activity to generate phospho-
tyrosine residues on the receptor to facilitate Cbl E3 ubiquitin ligase binding, ubiquitination and  
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Figure 5.1: Constitutive and ligand-induced PDGFR degradation in HA-Ank105-
expressing cells. 
A. Diagram of the effects of small molecule inhibitors on constitutive PDGFR degradation in 
Ank105-expressing cells. Cellular pathways that impair constitutive PDGFR degradation when 
inhibited are boxed in red and pathways that only slightly impair constitutive degradation when 
inhibited are boxed red dashed lines. Cellular pathways that do not affect constitutive PDGFR 
degradation when inhibited are boxed in green. B. Diagram of the effects of small molecule 
inhibitors on ligand induced PDGFR degradation in Ank105-expressing cells. Cellular pathways 
that impair ligand induced PDGFR degradation when inhibited are boxed in red and pathways 
which only slightly impair ligand induced degradation when inhibited are boxed red dashed 
lines. Cellular pathways which do not affect ligand induced PDGFR degradation when inhibited 
are boxed in green. 
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subsequent trafficking through the endosomal system (Levkowitz et al., 1999). Benzoquinone 
ansamycins target chaperone proteins including Hsp90 and Grp94 which stabilize RTKs 
(Blagosklonny, 2002; Neckers, 2002), causing the chaperone to adopt an alternate conformation 
which is indicative of protein instability (Blagosklonny, 2002; Neckers, 2002). The proteins 
interacting with the chaperone are ubiquitinated and degraded by the proteasome (Blagosklonny, 
2002; Lipkowitz, 2003; Mimnaugh et al., 1996; Neckers, 2002; Tikhomirov and Carpenter, 
2000; Xu et al., 2001). Ankyrin2 was previously shown to interact with the molecular co-
chaperone Hsp40 via the regulatory domain (Mohler et al., 2004a). Perhaps ankyrin3 and its 
isoforms are also capable of binding heat shock proteins, and the interaction between Ank105, 
PDGFR and a heat shock protein targets the PDGFR for ubiquitination and proteasomal 
degradation. Determining the identity of Ank105 binding partners via mass spectrometry could 
determine if Ank105 does indeed interact with heat shock proteins and provide an interesting 
avenue for further investigation. 
Tsg101 and rab7 were targeted for knockdown to address the role of the lysosome for 
constitutive PDGFR degradation, as constitutive degradation but not ligand induced PDGFR 
degradation. Knockdown of either tsg101 or rab7 did not increase constitutive PDGFR protein 
expression levels, indicating that Ank105-mediated PDGFR degradation may proceed 
independently of ESCRT mediated sorting of ubiquitinated cargo to MVEs and rab7-mediated 
trafficking of MVEs to the lysosome (Figure 5.1A). Again, similar to dynamin-II knockdown cell 
lines, knockdown of tsg101 and rab7 may not have been sufficient to fully impair their respective 
functions. Further compounding this issue is that lack of robust commercial reagents for the 
detection of endogenous tsg101 and rab7 protein. If knockdown is sufficient in these cell lines, 
the data suggests that Ank105-mediated degradation promotes the sorting and degradation of 
PDGF independently of the canonical ESCRT/rab7 dependent lysosomal trafficking pathway 
(Figure 5.1A).  
Interestingly, HA-Ank105 binds ubiquitin in vitro via the spectrin binding domain and 
co-immunoprecipitated with several ubiquitinated proteins in response to short term PDGF 
stimulation, suggesting a role for Ank105 in the sorting of ubiquitinated proteins for degradation. 
This hypothesis must be confirmed by studying the effects of Ank105 mutants that cannot bind 
ubiquitin on constitutive and ligand induced PDGFR degradation. Furthermore, HA-Ank105 co-
immunoprecipitated with a number of high and low molecular weight proteins in the absence of 
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PDGF stimulation. Identifying and validating these potential Ank105 binding partners could 
provide insight into the mechanism of Ank105-mediated PDGFR degradation, and for example, 
identify proteins which are required for constitutive PDGFR degradation in the context of HA-
Ank105 expression. 
 Aberrant expression and signaling of the PDGFRα is implicated as a driving event in 
several malignant diseases including glioblastomas, gastrointestinal stromal tumors, skin tumors 
and myeloproliferative disorders (Figure 1.3). In the case of glioblastomas where amplification 
and overexpression of the PDGFR or its ligand is common, as well as gastrointestinal tumors 
where activating point mutations in the juxtamembrane regions of the PDGFR (Chompret et al., 
2004; Heinrich et al., 2003) promote ligand independent activity (Jones and Cross, 2004), 
Ank105-mediated down-regulation of constitutive PDGFR expression could alleviate excess 
proliferative autocrine signaling, thereby reducing tumorigenesis. Indeed PDGFR hyperactivity 
has been reported in 30% of glial tumors (Brennan et al., 2009) and PDGFR expression 
positively correlates to tumor grade and aggressiveness (Hermanson et al., 1996). In the case of 
myeloproliferative disorders harboring constitutively active fusion mutations, the effectiveness 
of Ank105 expression on constitutive degradation on each of the fusion mutants would need to 
be individually investigated as regions interacting with Ank105 may be disrupted or the fusion 
mutant may not be available to Ank105 if the fusion mutation alters the endocytosis or cellular 
localization of the mutant receptor.  
Several types of epithelial tumors, including breast carcinoma, hepatocellular carcinoma, 
prostate and colon cancers, are initially unresponsive to PDGF stimulation (Heldin and 
Lennartsson, 2013); however these tumors acquire PDGFR expression while undergoing 
epithelial-to-mesenchymal transition (Jechlinger et al., 2003) and PDGFR signaling is thought to 
promote maintenance of the mesenchymal phenotype (Barr et al., 2008). Indeed PDGFR 
expression positively correlates with tumor grade, invasiveness and metastasis in breast 
carcinoma (Carvalho et al., 2005; Jechlinger et al., 2006). In the case of hepatocellular 
carcinoma and prostate cancer, attenuation of PDGFR signaling inhibited metastasis (Dolloff et 
al., 2005; Gotzmann et al., 2006; Russell et al., 2009). Thus, targeting PDGFR for Ank105-
mediated constitutive PDGFR degradation could attenuate PDGFR signaling and promote 
transition to an epithelial-like phenotype, thereby reducing tumorigenesis and metastasis in 
epithelial-based cancers with acquired PDGFR expression. 
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PDGFR signaling can also have extensive paracrine effects in the tumor micro-
environment, promoting remodeling of the stroma to facilitate invasiveness, angiogenesis and 
metastasis as the tumor itself often expresses PDGF and the cells of the stroma express the 
receptor (Bremnes et al., 2011; Heldin and Westermark, 1999; Zigrino et al., 2005). Tumor based 
production of PDGF promotes the recruitment and proliferation of CAFs, which in turn secrete 
extracellular matrix, cytokines, matric metalloproteinases and VEGF to remodel the tumor 
stroma and promote angiogenesis (Figure 1.4) (Bremnes et al., 2011). Additionally, PDGFR 
signaling recruits pericytes to newly formed blood vessels promoting their stabilization and 
maturation (Figure 1.4) (Gerhardt and Semb, 2008). Pharmacological inhibitors targeting the 
VEGFR in pancreatic cancer models show greater efficacy when combined with the PDGFR 
inhibitor imatinib, causing blood vessel destabilization via removal of pericytes and reducing 
tumor viability by the ensuing hypoxic phenotype (Figure 1.4) (Bergers et al., 2003). Additional 
experiments in the same model system indicate that hypoxia induced by this leaky vasculature 
can drive tumor progression to a more invasive and metastatic phenotype (Figure 1.4) (Xian et 
al., 2006). In the case of paracrine PDGFR signaling in the tumor microenvironment, induction 
of Ank105-mediated constitutive PDGFR degradation could have the most benefit in low grade 
tumors that do not have an established vasculature by reduction of CAF recruitment and 
proliferation. In this manner up-regulation of Ank105-mediated constitutive PDGFR degradation 
in the tumor stroma could attenuate CAF-mediated stromal remodeling, deposition of 
extracellular matrix, VEGF secretion and angiogenesis. Additionally, CAF recruitment and 
deposition of extracellular matrix increases tumor IFP, which in turns impairs tumor uptake of 
chemotherapeutics (Figure 1.4). Indeed tumors with stromal expression of PDGFR such as lung, 
breast and colon carcinoma frequently demonstrate high IFP (Ostman and Heldin, 2001). In a 
thyroid cancer model system, uptake and efficacy of both taxol and 5-fluorouricil was increased 
when treated in combination with imatinib to reduce IFP, while imatinib treatment alone did not 
affect tumor growth (Pietras et al., 2002). Imatinib treatment was also demonstrated to decrease 
IFP and increase tumor uptake and efficacy of cyclophosphamide in both lung and pancreatic 
carcinomas (Falcon et al., 2011). Attenuation of stromal PDGFR signaling via Ank105-mediated 
PDGFR degradation and reduction of CAF recruitment could lower tumor IFP, thereby allowing 
increased tumor uptake and efficacy of chemotherapeutics. 
The ANK3 gene, as part of an 11 gene signature, was previously demonstrated by micro-
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array analysis to be down-regulated in multiple human cancers (Glinsky et al., 2005). Indeed 
down-regulation of the ANK3 gene was a prognostic indicator of metastasis and poor clinical 
outcome (Glinsky et al., 2005), suggesting ANK3 has a potential tumor suppressive role. Perhaps 
down-regulation of Ank105 expression in these cancers elevates constitutive RTK levels and 
increases pro-oncogenic autocrine and paracrine RTK signaling, thereby contributing to tumor 
progression. Analysis of mRNA expression of multiple cancer cell lines from distinct lineages 
demonstrated that ANK3 expression is frequently attenuated and is often accompanied by 
increased expression of pro-oncogenic RTKs. Studying the mechanism of Ank105-mediated 
PDGFR degradation by determining the specific pathway of PDGFR endocytosis in Ank105-
expressing cells and by identifying Ank105 binding partners could lead to the identification of 
novel therapeutic targets to promote Ank105 function and re-expression of Ank105 in cancer cell 
lines with elevated RTK levels could provide an avenue of future study to determine the effects 
of Ank105 expression on tumorigenicity. Indeed, expression studies in cell lines with reduced 
ANK3 expression will allow for the determination of the effect of each ankyrin3 isoform, 
independently of each other. Reduction of constitutive PDGFR levels in cancers with PDGFR 
driver mutations, acquired PDGF responsiveness and stromal expression of PDGFR could 
significantly reduce tumor proliferation, tumorigenesis and increase effectiveness of 
chemotherapeutics.  
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